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General introduction 
 
1.1 Aim of this study 
 Transfection of malaria parasites is a technology that provides modern genetic tools for 
investigating the regulation of gene expression, expressing transgenes as well as elucidating the 
function of proteins by disrupting, modifying or replacing the genes encoding them. The technology 
now permits the experimental evaluation of molecular techniques for developing attenuated malaria 
parasite vaccines.  
 The difficulty of working with human malaria parasites has meant that a significant amount of 
research has been performed on different animal models of malaria. Furthermore, these models 
offer the only means to experimentally investigate natural host-parasite interactions in vivo. 
Plasmodium knowlesi, a natural parasite of macaques, is a comparative model for understanding 
many of the important aspects of human malaria. The entire life cycle of the parasite is accessible to 
experimentation suggesting that all aspects of malaria, from biology to host-parasite interaction can 
be studied under controlled conditions. In addition, an in vivo transfection technique has been 
developed for the parasite and the entire genome has been sequenced. This enables investigation of 
the parasite at a mechanistic level and identification of new targets for chemotherapeutic or 
immunological intervention. In order to fully benefit from the advantages offered by malaria 
transfection technology, the protocols for transient, stable episomal and integration dependent 
transfection of P. knowlesi are required.  
 The goal of the studies described in this thesis was to develop transient, stable episomal and 
integration dependent transfection protocols for P. knowlesi and to use the system to evaluate 
transgenic expression of an immunomodulatory host cytokine as a strategy for generating 
immunopotentiated malaria parasites. In addition, the current procedures for in vitro culture of P. 
knowlesi do not allow long term culturing and are insufficient for generating sufficient amounts of 
parasites for analysis. It was important that long term culture procedures are optimised in order to 
develop a versatile in vitro transfection system for P. knowlesi. Finally, a new baboon model was 
developed for in vivo determination of host-parasite interaction of the genetically modified 
parasites. 
 
1.2.1 Malaria: the problem 
 Malaria is caused by protozoan parasites of the subphylum Apicomplexa belonging to the genus 
Plasmodium.  The disease is transmitted by female mosquitoes of the genus Anopheles. Human 
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malaria is caused by four parasite species namely Plasmodium falciparum, P. vivax, P. malariae 
and P. ovale. P. falciparum is the most lethal accounting for over 90% of malaria associated deaths. 
Malaria is a major disease of mankind. It is estimated that there are 300-500 million cases world 
wide and up to 2.7 million deaths occur annually. Africa accounts for over 90% of the deaths, 
mainly children aged below five. Of all the parasitic diseases, malaria is not only the greatest killer 
but is also the most widely spread. It is a threat to approximately 40% of the human population in 
over 90 countries in the tropics and sub-tropics [1]. 
 Efforts to control malaria are made through treatment of infected people and by physical and 
chemical strategies to control the mosquito vector. However, it is to be expected that, due to the 
rapid increase in multi-drug resistant parasites and reduced investment in developing new drugs, the 
number of malaria cases and casualties will rise in the coming years. These factors necessitate the 
development of new and alternative approaches to resolve the current malaria crisis.  
 The development of new and alternative strategies for malaria control is hampered by the 
complex life cycle of the parasites and their interactions with human hosts and insect vectors. 
Therefore, a more rational approach to resolving the malaria crisis requires a deeper understanding 
of the biology of malaria parasites. 
 
1.2.2 Malaria vaccine development 
 To complement existing means of controlling malaria, effort is being put into the development of 
a vaccine. Vaccine development against human malaria currently focuses on three types based upon 
aspects of the parasites life cycle. Transmission blocking vaccines are directed against sexual 
stages. They target to interrupt transmission to the mosquito. Vaccines directed at sporozoite and/or 
liver stages (pre-erythrocytic stages) are aimed at protecting against onset of blood stage infection 
and blood stage vaccines are to prevent malaria related pathology and erythrocyte invasion [2].  
 Current vaccine efforts largely focus on the development of single parasite molecules and on 
combinations of parasite molecules either delivered as recombinant proteins or through DNA/live 
vector approaches. So far the protection induced in volunteers from endemic and non-endemic areas 
have not been optimum for manufacturing a vaccine (reviewed in [2]). This partly results from the 
polymorphic nature of many malaria vaccine candidates. It seems likely that any ultimate malaria 
vaccine will comprise multiple components directed against different parasite stages.  
 Two observations suggest that an attenuated malaria vaccine may be achievable. First for people 
that survive malaria infection, immunity develops slowly as a consequence of exposure. As few as 
one or two infections may be sufficient to protect against severe non-cerebral malaria [3] although 
clinical immunity may not be fully developed until adolescence. Second, immunisation with 
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attenuated sporozoites induces sterile protection in mice and humans [4, 5] mediated via IFN-γ 
dependent mechanisms and recently published data [6] shows that chimpanzees can be protected. 
Hence there is justification for development of a vaccine based upon attenuated malaria parasites.  
 
1.2.2.1 Attenuated malaria vaccines 
 An attenuated vaccine is a weaker, related or modified version or lower inoculum of a pathogen 
that stimulates protection against serious illness. Attenuated vaccines are possibly the oldest 
vaccines. Ancient Chinese protected against small pox in the process of variolation. In 1796, 
Edward Jenner used cowpox virus to protect against small pox. In the 1880’s, Louis Pasteur 
protected chickens from cholera and sheep from anthrax using attenuated forms of the pathogens 
and in 1921, protection was achieved against tuberculosis using BCG. To date, use of attenuated 
vaccines has been the most successful vaccination procedure, protecting against measles, mumps, 
rubella, varicella, polio etc.  
 Several studies have shown that attenuated malaria vaccines are feasible. Immunisation with 
irradiated sporozoites protects or partially protects rodents [5], monkeys [7] and humans [8-10] 
against sporozoite induced infection. These studies showed that attenuated sporozoites vaccination 
has the capacity to prevent induction of blood stage infection and induce sterile protection against 
liver stage infection. To immunise large numbers of people with attenuated sporozoites vaccines, 
they must be delivered either by bite of infected mosquitoes or by intravenous injection. Although 
this is likely to be clinically and logistically difficult, effectiveness of attenuated sporozoites 
vaccines indicates that a multi-valent pre-erythrocytic stage vaccine might induce sterile immunity. 
This type of vaccine would prevent all manifestations of disease and may have an important role in 
limiting malaria related morbidity and mortality. 
 Many scientists have focused on understanding the mechanisms of attenuated sporozoite induced 
immunity, their antigenic targets and on developing vaccine delivery systems that can mimic the 
protection. Much of this work has been done using P. berghei and P. yoelii and has led to a number 
of candidate vaccines [11-13]. 
 Attenuated malaria parasite vaccines  are expected to mimic natural protective responses induced 
in endemic areas by presenting a larger antigen repertoire to the host thereby evoking protective 
immune responses that will be boosted by a natural infection. Attenuated vaccines are administered 
without adjuvants and the natural infection boosts the immune responses. However, because 
sporozoites can not yet be cultured in mass, this does not yet form the basis of an effective vaccine. 
 Transfection of malaria parasites now permits the experimental evaluation of molecular 
techniques for developing live-attenuated blood stage parasite vaccines that could induce full 
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protection. Malaria blood stage infection is the cause of malaria associated morbidity and mortality, 
making it a major focus of malaria vaccine development.  
 
1.2.2.2 Cytokine mediated immunomodulation of pathogens 
 Studies using viruses, and protozoan parasites have shown that pathogens expressing host 
cytokines in vivo can be immunopotentiated and/or attenuated, subsequently manipulating host-
pathogen interaction and stimulating protective host responses. In addition, non pathogenic micro-
organisms expressing host cytokine have been shown to immunomodulate unrelated diseases. 
 Vaccinia  viruses expressing host IL-2  and IL-12 separately became attenuated and enhanced 
immune responses [14, 15]. In another experiment, recombinant vaccinia viruses expressing either 
IL-2 or IL-15 were  attenuated in athymic nude mice leading to increased peripheral NK-cell 
mediated immune responses [16]. These studies indicated that localised expression of host 
immunomodulatory cytokines by intracellular pathogens could lead to immunopotentiation of the 
pathogens. Expression of host IFN-γ in another type of virus, simian immunodeficiency virus, was 
shown to be safe and immunogenic in rhesus monkeys [17].  
 A recent study by Steidler et al., [10] showed that cytokine expressing bacteria can be used to 
immunomodulate a chronic disease leading to cure. Murine colitis was effectively treated using the 
bacteria Lactococcus lactis expressing host interleukin-10. This study indicated that cytokine 
expressing micro-organisms also have the potential for therapeutic use.  
 The protozoan parasite Leishmania major expressing host IFN-γ was significantly attenuated in 
nude mice, indicating that localised expression of host immunomodulatory cytokines by an 
intracellular protozoan parasite enhances protective immune responses [19]. 
 Thus far, expression of host cytokines by malaria parasites has not been examined. The 
development of transfection technology for malaria parasites (see section 2.3) now enables 
expression of recombinant host proteins such as cytokines in Plasmodium. It is tempting to 
speculate that genetically modified malaria parasites that express immunomodulatory cytokines can 
induce effective immune responses in vivo. 
 
1.3 Transfection of malaria parasites 
 Transfection is a mechanism for mutating eukaryotic cells by introducing exogenous genetic 
material [20]. The introduced genetic material is expressed and retained either temporarily 
(transient transfection) or functionally maintained for longer periods (stable transfection) resulting 
in a genetically modified organism [21]. In transfection, a particular gene is modified followed by 
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assessing the phenotype of the mutant cell. Consequently, transfection is useful for determining the 
precise relationship between the structure of a gene and its expression and function.  
 Earlier attempts to develop transfection constructs and introduce DNA into malaria parasites 
were unsuccessful. Cloning Plasmodium DNA in Escherichia coli proved to be difficult as a result 
of high AT content of Plasmodium DNA [22]. Furthermore, successful transfection required DNA 
to cross four membranes to reach the nucleus of the predominantly intracellular Plasmodium 
parasite. Finally, in 1993, the extracellular gametocytes of P. gallinaceum were transfected by 
electroporation [23]. Since then P. falciparum [24], P. berghei [25], P. knowlesi [26], P. cynomolgi 
[27] and P. yoelii [28] have been successfully transfected. 
 
1.3.1 Transient transfection of malaria parasites 
 Transient transfection is a procedure by which DNA is introduced into a eukaryotic recipient 
cell, retained and expressed temporarily. Developing the procedure has facilitated analysis of how 
gene expression is developmentally controlled in malaria parasites. Transient transfection provides 
the opportunity to identify genetic elements that control gene expression in malaria parasites [26, 
27]. These studies showed that different regions of Plasmodium promoters were associated with 
controlling varying levels of expression, reminiscent of regulatory elements in other eukaryotes.  
 Transient transfection has been reported for P. gallinaceum [23], P. berghei [29] and P. 
falciparum [30]. In each of the systems, either luciferace or chloramphenical acetyl transferase 
(CAT) were used as reporter genes to study regulation of Plasmodium genes [31, 24]. Information 
resulting from these studies has been useful for further development of transfection technologies 
including identification of suitable promoters to drive transgene expression and in gaining insight 
into the basic processes that direct gene expression in malaria parasites. 
 
1.3.2 Stable transfection of malaria parasites 
 During stable transfection, DNA is introduced into a eukaryotic recipient cell and maintained in 
a functional state for extended periods of time. This results into a heritable change of the transfected 
cell.  Selectable markers are used to grow transfected parasites under drug pressure. This is required 
for selection and maintenance of foreign genes in transfected parasites. 
 Stable transfection technology is used when analysis of the transfected cell is required over 
several generations. Stable transfection can be categorised as episomally based when the introduced 
DNA is maintained as an extrachromosomal replicating plasmid. Alternatively, transfected DNA 
can integrate into the genome of the host cell. This is referred to as integration dependent 
transfection. Integration dependent transfection relies on the recombination between two copies of a 
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sequence, one present in the genome (target DNA sequence) and the other in the incoming DNA 
(targeting construct) [32]. 
 Stable transfection of malaria parasites is therefore a versatile genetic tool for expressing foreign 
genes and for disrupting, modifying or replacing genes to analyse protein function. Currently, stable 
transfection is possible in P. falciparum [33], P. berghei [25], P. knowlesi [26], P. cynomolgi [27] 
and P. yoelii [28].  
 
1.3.3 Parameters for transfection of malaria parasites 
 Transfection of malaria parasites requires a careful choice of the target gene for integration 
dependent transfection. The gene should be non-essential in the parasite developmental stage you 
are selecting in. Genetic alteration of an essential gene could be lethal to the mutant parasite 
consequently failing to generate transfected parasites. 
 Introduction and integration of DNA into Plasmodium genome is a low frequency combination 
of events, estimated to vary but could be as low as 10-7. Thus drug selection is required for selecting 
the transformed events [34].  
 Integration of DNA into the Plasmodium genome occurs almost exclusively by site specific 
homologous recombination mechanisms. However, there are species specific differences in the 
mechanisms involved [34]. P. falciparum will only accept integration of circular DNA either by 
single [35] or double [33] crossover mechanisms. In the rodent malaria parasite P. berghei, 
integration occurs via linear DNA [36, 37]. The transfection construct for integration by double 
crossover mechanisms is usually linearised at two positions. This is usually at the ends defining the 
vector backbone DNA sequence. Integration by single crossover mechanisms in P. berghei only 
occurs when the transfection construct is linearised in the target DNA sequence region thereby 
defining the exact point of integration [37].  
 There are a number of regulatory DNA sequences available for controlling gene expression in 
Plasmodium (Table 1). Promoters currently in use, vary in strength and stage specificity, enabling 
gene expression at different levels and at distinct stages of the parasite [38-39]. Control of 
(trans)gene expression depends on promoter stage specificity. For example, expression of P. 
falciparum apical membrane-1 antigen (AMA-1) was restricted to mature schizont stages when 
expressed under the ama-1 promoter but the stage specificity was lost when the gene was expressed 
under a constitutive promoter [40].  Certain promoters can also drive gene expression in more than 
one Plasmodium species (heterologous promoter activity). The 5’ untranslated region (UTR) from 
the P. chabaudi dihydrofolate reductase thymidylate synthase (dhfr-ts) gene is transcriptionally 
active in P. falciparum [30], while the P. falciparum calmodulin (CAM) promoter region is active 
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in P. berghei [31]. This offers the possibility of developing shuttle vectors for transfection of 
Plasmodium. A detailed list of heterologous regulatory DNA sequences is shown in Table 1. 
 Four types of transfection constructs exist for transfection of Plasmodium [41]. First are 
constructs for transient transfection. In these constructs, the gene to be expressed is flanked by 5’ 
and 3’ UTR sequences. Together these three elements make up the expression cassette. Second, 
plasmids for stable episomal transfection.  These constructs contain two expression cassettes, one 
for expressing the selectable marker (selection cassette) and the other for expressing the gene of 
interest (expression cassette). Plasmids are maintained in transfected parasites under conditions 
where the plasmid provides a selective advantage such as drug resistance. Removal of drug pressure 
results in plasmid loss over time due to incomplete daughter cell segregation. This leads to plasmid 
copy number variability and/or inefficient replication [42, 43]. Third, constructs for integration by 
single crossover mechanisms. These are referred to as insertion constructs. The constructs contain 
an expression cassette(s) and a single gene targeting sequence. A segment of the target gene is used 
as the gene targeting sequence. Finally, constructs for integration by double crossover mechanism. 
These are also known as replacement constructs. They contain two target gene sequences disrupted 
by a selection cassette and/or an expression cassette of the gene under study. Transfection of P. 
falciparum using insertion or replacement constructs requires circular constructs [41, 33]. However, 
in integrating DNA into P. berghei genome, the insertion construct is linearised within the target 
sequence, while the replacement construct is regularly linearised by removing bacterial plasmid 
sequences [41].  
 Because Plasmodium developmental stages are haploid (only the zygote is diploid), a single 
selectable maker is sufficient for knockout and gene expression by site directed integration. This 
has so far relied on using mutant forms of the dhfr-ts gene. Two types of selectable markers are 
commonly used for transfection of malaria parasites. Positive selectable markers donate a drug 
resistant trait to transfected parasites [34], allowing growth under drug pressure. Alternatively, 
applying drug pressure to parasites transfected with negative selectable markers [33, 44] confers 
survival disadvantage. Selectable markers currently used for transfection of Plasmodium are shown 
in Table 1. 
 Transfection and selection of mutants in malaria parasites is a slow process. In P. berghei, 
transfected parasites can be selected within a period of 3 weeks after transfection [45]. In contrast, it 
takes about 3 months to select for P. falciparum integrants [42]. 
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Table 1. Parameters for transfection of malaria parasites 
 
Event Transfection system Refe-
rences 
 P. gallinaceum P. falciparum P. berghei P. knowlesi P. yoelii P. cynomolgi  
Electroporator 
settings 
 
 
1.5, 2.5 and 3 
kV, 25µF, 
200Ω in 0.4 
cm cuvettes 
2.5 kV, 25µF, 
200Ω in 0.4 
cm cuvettes ; 
0.31 kV, 
960µF, in 0.2 
cm cuvettes 
800V, 25µF, 
in 0.4 cm 
cuvettes 
1.5, 2 and 
2.5 kV, 
25µF, 200Ω 
in 0.4 cm 
cuvettes 
800V, 
25µF, in 
0.4 cm 
cuvettes 
1.5, 2 and 
2.5 kV, 
25µF, 200Ω 
in 0.4 cm 
cuvettes 
[24,25,
46,47] 
Transfected 
parasite 
stage 
Extracellular 
gametocytes 
Merozoites 
Intra- 
erthrocytic 
Merozoites 
Intra- 
erythrocytic 
Merozoites Merozoites Merozoites [23,24,
26,28, 
47] 
Positive 
selectable 
markers 
 
- T. gondii  
dhfr-ts 
Human  
dhfr-ts 
Puromycin N 
-acetyl 
transferase, 
BSD, NEO 
 
T. gondii  
dhfr-ts 
Human  
dhfr-ts 
P. berghei 
dhfr-ts 
T. gondii 
dhfr-ts 
P. berghei 
dhfr-ts 
T. gondii 
dhfr-ts 
T. gondii 
dhfr-ts 
[41,48,
38,49-
50] 
Negative 
selectable 
markers 
- Cytosine 
deaminase, 
Thymidine 
kinase 
 
- - - - [33] 
Integration 
transfection 
and selection 
- 6 weeks to 3 
months 
Less than 3 
weeks 
- Less than 
3 weeks 
- [28,51,
45,46] 
Promoters pgs28 P. falciparum 
hsp 86, cam, 
hrp3 and 
dhfr-ts; P. 
chabaudi  
dhfr-ts,  
P. berghei 
dhfr-ts  
ama-1,  
ef-1α  trap,  
and cs; P. 
chabaudi 
dhfr-ts, P. 
falciparum 
pfs25 
 
P. berghei 
dhfr-ts and 
pbs21; P. 
falciparum 
hrp3,  
P. berghei 
dhfr-ts, 
P. berghei 
dhfr-ts, 
[25,28,
29,33, 
38,39, 
52,50] 
Transfection 
culture 
In vitro In vitro In vivo In vivo In vivo In vivo [23,24,
26,28, 
47] 
Current 
transfection 
mechanisms 
Transient Transient, 
stable 
episomal, 
integration by 
single and 
double cross-
over 
Transient, 
stable 
episomal, 
integration 
by single 
and double 
cross-over 
 
Stable 
episomal, 
Stable 
episomal, 
integration 
by double 
cross-over 
Stable 
episomal  
[23,24,
26,28, 
47] 
Transfection 
constructs 
Circular Circular Circular, 
linear 
Circular Circular, 
linear 
Circular [23,24,
26,28, 
47] 
 
 
BSD, Blasticidin s deaminase; NEO, Neomycin phosphotransferase II; HSP 86, heat shock protein 86; CAM, 
calmodulin; TRAP, Thrombosponding related anonymous protein; CS, circumsporozoite protein; HRP3, histidine 
rich protein 3; pfs25, P. falciparum Pfs25; pgs28, P. gallinaceum antigen Pgs28; pbs21, P. berghei antigen 
Pbs21  
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1.3.4 Application of transfection 
 Transient expression of plasmids in Plasmodium has allowed for promoter mapping in order to 
define regions controlling gene expression. Functional analysis has been performed on the P. 
falciparum hsp86 and hrp3, cam, dhfr-ts and gp130 promoters and promoter regions and on the P. 
chabaudi dhfr-ts promoter (reviewed in [38]). 
 Transient transfection is also useful for rapid analysis of promoter activity. Stage specific 
promoter activity and heterologous promoter activity in Plasmodium was also shown using the 
procedure [29, 41, 26, 53]. 
 Transfection techniques can be used to study the expression of genes that are uniquely processed 
by Plasmodium in a particular stage of the life cycle, for example expression of mosquito stage 
proteins in blood stage parasites [54]. This was clearly demonstrated for Pbs21. In this study, it was 
shown that stage specific expression is dependent on the promoter and not post-transcriptional 
modification. As deletions were made towards the transcriptional start site sites, stage specificity 
was lost and genes were expressed constitutively [55].  
 A major application of gene knockout studies is to analyse protein function in vivo. Gene 
knockout studies have shed useful information into the function of leading vaccine candidates. 
Menard et al., [45] reported that knocking out P. berghei csp gene resulted in the failure of 
sporozoites to infect hepatocytes, salivary glands and to undergo later stages of sporogony in the 
oocyst. Another knockout involving P. berghei TRAP, showed that the molecule was necessary for 
sporozoite gliding motility [37]. In a study involving knob associated histidine-rich protein [56], the 
knockout parasites bound weakly to CD36 and lost knob formation showing that the protein is 
important for knob assembly and for sequestration. 
 Through integration dependent transfection in P. berghei, it was shown that genetic 
complementation following gene knockout studies can confirm if a gene knockout is lethal. The 
knockout parasite can be complemented by a similar or modified version of the gene to restore gene 
function [52, 50]. This procedure is useful in confirming gene function. 
 The ability to transfect and express transgenes in P. falciparum has been an important 
technological breakthrough in determining the role of different malaria proteins in phenotypes such 
as drug resistance [57]. The direct role of particular mutations in the DHFR-TS enzyme was 
confirmed by transfection of the mutant dhfr-ts gene into P. falciparum to obtain parasite lines that 
were resistant to the expected levels of pyrimethamine [42]. Furthermore, transfection of the 
different mutant alleles of the gene for the bi-directional enzyme PPPK-DHPS has determined the 
mutations in dhps that confers sulphadoxine resistance [58]. Gene knockout and replacement with a 
modified version of the cg2 gene has shown that it is not involved in chloroquine resistance and 
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instead a closely linked pfcrt gene is responsible [59, 60]. More recently, polymorphisms in the 
pfmdr1 gene were determined through gene replacement strategies to affect resistance and 
sensitivity to mefloquine, halofantrine and quinine [61]. 
 A number of genes from higher eukaryotes and other protozoan parasites have successfully been 
expressed in Plasmodium as transgenes. Reporter molecules from the jellyfish Aequorea victoria 
(GFP) [62, 63] and Luciferase [23, 24, 29] from the firefly were the first proteins from higher 
eukaryotes to be expressed in Plasmodium. A leading malaria vaccine candidate AMA-1 molecule 
from P. falciparum and P. knowlesi were successfully expressed in P. berghei [40, 47]. This 
provides wide possibilities to express P. falciparum proteins in animal malaria parasites and to 
study their function(s) using animal models. In another study, O'Donell et al., [64] successfully 
transfected P. chabaudi MSP-119 in P. falciparum and concluded from the experiments that 
antibodies against MSP-119 are a major component of the invasion-inhibitory response in 
individuals and mice immune to malaria. 
 Additional selectable markers are required for genetic complementation and for modification of 
essential genes. Current transfection of P. berghei and P. knowlesi has relied on dhfr-ts as the 
selectable marker of choice. Transfection has been used to develop new selectable markers based on 
blasticidin, geneticin and puromycin for use in P. falciparum [48, 49] and experiments are 
underway to adapt them to other Plasmodium systems. In the P. berghei transfection system, a new 
marker based on the drug WR92210 and the human dihydrofolate reductase gene is currently in use 
[52, 65].  
 Three exogenous reporters (GFP, luciferase and CAT)  have been expressed in transfected 
Plasmodium [38]. These reporters are useful as molecular indicators of gene expression and in the 
study of intracellular molecular trafficking. In P. falciparum, expression of GFP was also used to 
determine signal peptide activity [66]. Fluorescence activated sorting of GFP expressing parasites 
was used to harvest pure parasite developmental stages for specific analysis, hence facilitating the 
characterisation of their phenotypes [62, 67]. Another reporter gene, the firefly luciferase has been 
used to develop the transfection systems for P. gallinaceum and P. falciparum and to determine 
promoter activity in P. berghei [23-25]. 
 Transfection of malaria parasites can be applied to generate genetically engineered attenuated 
malaria parasites for possible inclusion into an attenuated malaria parasite vaccine. Nonhuman 
malaria parasites such as P. knowlesi offer the added advantage of testing host-parasite interaction 
of the attenuated parasites under natural host-parasite setting. Therefore, it is necessary to develop 
transfection systems for these parasites. The subsequent sections describe the P. knowlesi system. 
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1.4 The parasite P. knowlesi  
 The life cycle of P. knowlesi (Fig. 1) begins when an infected mosquito transmits sporozoites 
into a susceptible vertebrate host via blood sucking. The sporozoites migrate to the liver cells, 
where, in a process termed exo-erythrocytic schizogony (liver stage development), they undergo 
many rounds of replication and transform into liver schizonts. The infected hepatocytes rupture 
releasing merozoites which infect circulating erythrocytes immediately. In the cyclical pattern of 
development termed intra-erythrocytic schizogony (blood stage development) that follows, the 
parasites develop to rings, trophozoites and schizonts releasing more merozoites that continue to 
invade, colonise and replicate within erythrocytes. Schizont infected erythrocytes rupture releasing 
an average of 10 merozoites that continue the cycle of infection. The asexual cycle in blood is 
quotidian lasting 24 hours. During the blood stage development, P. knowlesi invades both mature 
erythrocytes and reticulocytes [68]. Ring forms appear in blood and appliqué forms are frequently 
seen. Band forms are common in the trophozoite stage. Mature schizonts have 10 merozoites on 
average, but the number can go as high as 16. Regular rings have one or more accessory chromatin 
dots. The factors which signal sexual development are poorly understood, but at some signal, a 
proportion of re-invading merozoites start to differentiate into male and female forms (micro- and 
macrogametocytes respectively). Mature gametocytes are seen in 3 days post-inoculation if the 
infection is heavy. Mature microgametocytes (8.5 µm) are smaller than the macrogametocytes (7 
µm) and stain brick red with Giemsa, compared to the light blue colour of macrogametocytes. 
Gametocytes are taken up by a mosquito in a subsequent blood meal.  In the mosquito midgut, 
gametocytes differentiate into mature micro- and macrogametes that mate to produce a zygote. The 
zygote differentiates into a motile ookinete that crosses the mosquito midgut and develops into a 
multi-nuclear oocyst. A mature oocyst, filled with sporozoites, ruptures releasing sporozoites into 
the heamocoel, from where they migrate to the salivary gland, ready to infect a vertebrate host 
during the next blood meal [69, 67, 71]. 
 The mosquito hosts for P. knowlesi include A. dirus, A. balabacensis and A. hackeri [69, 70], all 
of which are found in Asia. Other possible vectors include A. freeboni, A. maculatus, and A. 
quadrimaculatus [70]. Development in the mosquito (sporogony) takes 10-12 days at  a temperature 
of 26 to 28°C while the exo-erythrocytic phase lasts 5.5 days.  
 
1.4.1 Animal models of P. knowlesi 
 The natural vertebrate hosts for P. knowlesi are Macaca fascicularis and M. nemestrina. 
Experimental infection can also be induced in a number of monkeys such as M. mulatta, M. radiata, 
M. assamensis, Presbytis entellus, Callithrix jacchus, Aotus trivigatus, Saimiri sciureus and 
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Figure 1. The life cycle of the simian malaria, Plasmodium knowlesi. Malaria infection of the monkey 
begins when an infected mosquito injects sporozoites into the blood circulation. The sporozoites circulate in 
the blood for less than 1 hour before invading liver cells, and develop into tissue schizonts in less than one 
week. The liver schizonts release thousands of merozoites into the blood stream, where they invade 
erythrocytes in less than 30 minutes. The newly invaded merozoites quickly develop into ring forms. The ring 
forms grow and differentiate into actively feeding forms known as trophozoites. A number of the ring forms 
differentiate into male and female sexual forms referred to as gametocytes. As the trophozoites feed and 
develop, the nucleus undergoes between 8 and 16 rounds of division (schizogony), without subsequent cell 
division. The multi-nucleate trophozoite (schizont) starts to divide its cytoplasm producing a similar number of 
haploid merozoites. The fully mature schizont (segmenter) ruptures the erythrocyte, releasing free 
merozoites that invade other erythrocytes, thereby completing the blood stage cycle. When a mosquito 
ingests blood with mature gametocytes, they emerge from the erythrocyte and differentiate into gametes. 
The male gametocyte (microgametocyte) undergoes three rounds of nuclear division, producing 8 flagellated 
microgametes (exflagellation), while the female gametocyte differentiates into a single gamete celled 
macrogamete. In the mosquito midgut, the microgamete immediately fertilises the macrogamete  to form a 
diploid (2N) zygote. The diploid zygote undergoes one more round of genome division into a polyploid (4N) 
zygote. The zygote then undergoes meiotic division and transforms into a motile ookinete, which penetrates 
the midgut wall, and rounds up below the midgut epithelium as an oocyst. The oocyst enlarges and the 
nucleus divides frequently, followed by multiple cell fission to form thousands of midgut sporozoites. The 
sporozoites are released into the haemocoel where they migrate to the salivary glands, waiting for being 
injected into a new vertebrate host [69,70]. 
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baboons [69, 70, 72-76]. In baboons, the infection has been induced in P. cynocepahalus, P. 
doguera, P. jubileaus and P. papio [70]. The parasite does also infect humans [77-80]. In humans, 
P. knowlesi causes mild infection seldom exceeding 1% parasitaemia. However, infection could get 
virulent on repeated passages in humans [81].  In the natural hosts, the infection is chronic with 
several relapsing peaks. The highest parasitaemia is usually in the first peak and rarely passes 5%. 
In the rhesus monkey (and most experimental models), the infection is acute and usually fatal, 
killing the animals in 7 to 14 days post-infection [69]. It requires several infections and cure in 
order for M. mulatta to develop immunity against P. knowlesi [82-84]. 
 The availability of natural and experimental hosts for P. knowlesi offers the possibility to 
study the biology of malaria parasite and its antigens in a natural host-parasite combination and in 
hosts whose systems are predictable of the human situation [85]. In addition, the dichotomous 
disease profile of P. knowlesi (a chronic infection in natural hosts and an acute disease in artificial 
hosts) provides opportunities for understanding the mechanisms of immunity to malaria [86]. 
Experimental P. knowlesi infection has not been characterised in P. anubis, the most commonly 
used baboon for biomedical research. 
 
1.4.2 In vitro culture of P. knowlesi 
 In 1912 Bass and Johns [87] were the first to report in vitro development of malaria parasites. 
Defibrinated patient blood containing P. falciparum and P. vivax was cultured for two cycles in 
glass vials to which small amount of glucose had been added. Nearly 25 years later [88], short-term 
cultures of P. knowlesi in rhesus monkey erythrocytes were achieved. The medium used in these 
cultures was known as Harvard growth medium. It was based on a chemical analysis of monkey 
plasma. Improved growth and multiplication was obtained with subsequent modifications of this 
medium, but only a few erythrocytic cycles were achieved in vitro [89]. In these early experiments, 
blood from infected rhesus was mixed with uninfected erythrocytes to give an initial parasitaemia 
of 1%. The blood was washed and suspended in Harvard medium or one of the modifications of it, 
in a culture vessel of considerable surface area such as a 50 ml conical flask. The cultures were 
gently agitated on a rocking platform to maintain the cells in suspension. The parasites would 
mature through the first in vitro cycle and often would invade into new erythrocytes, with little or 
no increase in parasite numbers. At best the parasites developed for a few days but with decreasing 
numbers, after an initial increase, until the cultures no longer contained viable parasites. 
 These earliest in vitro experiments revealed specific in vitro nutritional requirement by P. 
knowlesi for para-aminobenzoic acid. Other specific nutritional requirements demonstrated by 
General introduction 
 15
short-time cultures included biotin, methionine and purines [90]. In addition the cultures were used 
to study certain aspects of parasite metabolism [91] and action of anti-malaria drugs [92]. 
 During later years, attempts for long term culture of P. knowlesi were made based on the 
assumption that cultured erythrocytes rapidly became unsuitable as host-cells for the parasites. To 
that effect, fresh erythrocytes were frequently added with increments of as high as 40% packed cell 
volume. However, the rate of parasite multiplication could not keep ahead of the rate of erythrocyte 
dilution and the cultures died out within 7 days [93]. Later experiments [94] further demonstrated 
that less multiplication was progressively achieved with successive cycles of development in vitro. 
These experiments not only achieved low parasitaemia, for example, in the range of 0.92% and 
3.6% [95] but also generated morphologically abnormal parasites [96]. Culturing was done using 
the petri-dish candle jar method [95] and a sophisticated semi-automated tipping culture apparatus 
[96]. These culturing conditions were insufficient for generating large amounts of parasites for 
analysis. Furthermore, cloning was not achieved. These studies show that long term in vitro culture 
of P. knowlesi has remained elusive. 
 
1.4.3 P. knowlesi as a model parasite for malaria research 
 Although human malaria parasites are seen as a major priority for research because of the 
mortality associated with this infection, they are not always the optimal system in which to study 
the biology and immunology of Plasmodium. The host specificity of human malaria parasites 
represents a major constraint on in vivo studies. The parasites can not be maintained in convenient 
small laboratory animals. As a result, numerous species of rodent (e.g. P. berghei) and avian (e.g. 
P. gallinaceum) malaria parasites have been widely used as laboratory models to study the biology 
of Plasmodia [97]. Although there is proximal phylogenetic relationship between P. falciparum and 
avian Plasmodia such as P. gallinaceum [98], differences  in their life cycles, insect hosts and in  
the immune systems of their vertebrate hosts [4] limit their usefulness as models for human malaria.  
A good laboratory model should be relevant to human malaria and offer the ability to study the 
biology of the parasite at the cellular and molecular level. Biological, chemotherapeutic and 
immunological studies have made use of the fact that a number of Plasmodium species found 
naturally in monkeys are very similar biologically and antigenically and have similar host-parasite 
relationships to the human Plasmodia in man. This is in part due to the close phylogenetic 
relationships between the nonhuman primate and human malaria parasites [99]. 
 P. knowlesi is an attractive experimental system for malaria research. Firstly, it is a parasite of 
monkeys that have immune and metabolic systems very similar to those of humans [85].  Secondly, 
P. knowlesi is phylogenetically close to P. vivax, sharing many vaccine candidate molecules [100]. 
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Thirdly, the entire genome has recently been sequenced to 5-fold coverage [101], availing more 
gene sequences for analysing parasite biology and discovering vaccine candidate genes.  Finally, 
tools for genetic manipulation in P. knowlesi are available. Because P. knowlesi has a 24 hour life 
cycle, this allows rapid generation and analysis of transfected parasites. 
 
1.5 Outline of this thesis 
 Transfection of malaria parasites now permits the experimental evaluation of molecular 
techniques for developing live-attenuated blood stage parasite vaccines that could induce strong 
protection comparable to attenuated sporozoite vaccines. In the studies described in this thesis, an in 
vitro transfection system of the primate malaria parasite P. knowlesi has been developed and used to 
investigate molecular ways of immunopotentiating malaria parasites, as a potential component of an 
attenuated blood stage vaccine. This is because 1) there is no suitable animal model for the 
evaluation of attenuated P. falciparum (New World monkeys become rapidly immune to further 
infection or require splenectomy) 2) as a natural parasite of old world monkeys P. knowlesi will 
infect animals on multiple occasions before immunity develops, and interactions can be evaluated 
in an immunological and metabolic environment similar to humans. 
 The content of this thesis is grouped into three categories. Chapters 2, 3 and 5 focus on 
development of tools required for in vitro transfection of P. knowlesi and in vivo analysis of 
transfected parasites. In chapters 4 and 6, the in vitro transfection system of P. knowlesi is applied 
to analyse expression of a host cytokine, IFN-γ as an approach for immunopotentiating malaria 
parasites. Finally, chapter 7 is devoted to development of a new model for in vivo analysis of 
transfected parasites. 
 In order to transfect and select malaria parasites in vitro, long term in vitro culture techniques, 
similar to the P. falciparum system [102] are required. In chapter 2, a long term in vitro culture 
system was developed for P. knowlesi blood stages. Culture adapted parasites were continuously 
cultured in vitro for over 12 months in order to determine their long term culture characteristics. In 
addition, in vitro cloning by limiting dilution was tested. In vivo characteristics of culture adapted 
parasites were also characterised in rhesus monkeys (Macaca mulatta). P. knowlesi was 
successfully adapted to long term in vitro culture. In vitro adapted parasites regained wild type 
characteristics after a single passage through an intact rhesus monkey. Cloning by limiting dilution, 
and in vitro transfection were successfully achieved using culture adapted parasites. In addition, 
integration into the CSP locus was done. Microscopic evaluation of developing oocyst from 
mosquitoes that had fed on CSP knockout parasites showed impairment of sporozoite formation. 
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 In studies described in chapter 3, a transient transfection system was developed for P. knowlesi 
using luciferase as a reporter molecule. Expression of luciferase was tested under the control of the 
stage specific P. berghei apical membrane antigen-1 (pbama-1), the constitutive P. berghei 
elongation factor-1 alpha (pbef-1α) and pbdhfr-ts promoter regions. In addition stable episomal 
transfection technology was used to analyse in vitro stage specific expression of GFP under the 
pbama-1 promoter. The P. berghei pbama-1, pbef-1α and pbdhfr-ts promoter regions successfully 
drove expression of luciferase in P. knowlesi using transient transfection technology. This study 
identified the pbef-1α promoter as a strong heterologous promoter ideal for over-expression  of 
transgenes in P. knowlesi blood stages. Stable episomal transfection was successfully applied to 
express GFP in P. knowlesi. These experiments showed that the pbama-1 promoter maintained a 
tight stage-specific expression of GFP in P. knowlesi.  
 Expression of host cytokines in malaria parasites offers the opportunity to investigate the 
potential of an immunomodulatory approach by generating immunopotentiated parasites. Chapter 
4 of this study analysed the capacity of malaria parasites to express host IFN-γ. The in vitro 
transfection protocol for P. knowlesi was applied to explore the conditions for expressing host 
cytokines in malaria parasites. In vitro culture adapted P. knowlesi blood stage parasites were 
transfected with DNA constructs for expressing rhesus monkey IFN-γ under control of the pbama-1 
promoter. P. knowlesi blood stage parasites were shown to produce IFN-γ into the culture medium. 
In vitro analysis through inhibition of virus cytopathic effects and activation of M. mulatta 
peripheral blood cells showed that the parasite produced IFN-γ was bioactive.  
 The vast majority of antibodies available for characterisation of host responses in primates are 
anti-human. The molecules recognise the same epitopes in the primate under study [103]. These 
antibodies were selected through their optimal cross-reactivity with similar primate antigens. In 
order to generate cross-reactive antibodies for use in characterisation of host responses to malaria 
parasites, a large number monoclonal antibodies were characterised for their cross-reactivity with 
the chimpanzee, the squirrel monkey, and the  rhesus monkey cell surface antigens. These monkeys 
are common nonhuman primate hosts of malaria. Several antibodies that reacted with T-cell 
antigens and cytokine receptors were identified for in vivo immunological studies. The list of cross-
reactive antibodies and their levels of activity is tabulated in chapter 5. Suitable antibodies will be 
used to characterise host-parasite interaction between IFN-γ expressing P. knowlesi and the rhesus 
monkey. 
 In chapter 6, rhesus monkeys were infected with cytokine expressing parasites and clinical and 
immune response parameters measured to determine the efficacy and safety of IFN-γ expressing 
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parasites. This would also determine in vivo bioactivity of parasite produced IFN-γ and the vaccine 
potential of IFN-γ producing parasites. Animals infected with IFN-γ producing P. knowlesi 
developed a non-fulminating parasitaemia. Their liver and kidney functions were within normal 
ranges. There was a 2.5 to 5 fold increase in γδ T-cells compared to a 1 to 2 fold increase in the 
controls. After challenge infection, there was a 5 to 6 day longer pre-patent period compared to the 
controls. Control monkeys also developed a fulminating infection averaging 5 days earlier. 
 In order to determine the suitability of olive baboons (Papio anubis) as experimental hosts for P. 
knowlesi, 10 baboons were experimentally inoculated with P. knowlesi blood stages. The animals 
were observed for parasitaemia profiles, clinical and pathological parameters. Historical data was 
collected from rhesus monkeys infected with a similar P. knowlesi strain and used for comparative 
purposes. The results of this study are reported in chapter 7. All baboons infected with blood stage 
P. knowlesi developed either a severe moribund disease accompanied by multiple system organ 
dysfunction and cerebral malaria, or a mild infection characterised by low level parasitaemia and 
splenomegaly. These studies demonstrated for the first time that P. anubis is a suitable P. knowlesi 
host for studying clinical symptoms and pathology. 
 Chapter 8 is the general discussion. This chapter discusses the current status of P. knowlesi 
transfection. Long term in vitro culture protocol was established thus expanding experimental 
possibilities for transfection. In vitro and in vivo transfection  protocols currently in place will 
minimise the use of resourceful monkeys for the simple process of generating parasites, while 
retaining the possibility of in vivo experimentation as need arises. Expression of host cytokines such 
as IFN-γ offers new approaches for developing attenuated and immunopotentiated malaria vaccines. 
The genome of P. knowlesi has been sequenced, indicating that genes for all possible drug and 
vaccine candidates are accessible. Transfection should play a role in deciphering the function of 
these molecules and by analogy, similar molecules could be isolated from human malaria parasites 
and expressed in P. knowlesi. Subsequently, the drug and/or vaccine potential of selected candidates 
can be determined using in vitro and in vivo systems.  As a parasite of primates that also infects 
humans, P. knowlesi currently is the only malaria transfection system that combines the benefits of 
a simple long term in vitro culture system and analysis of host-parasite interaction in natural and 
experimental host systems similar to human. 
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ABSTRACT 
 Transfection technology for malaria parasites provides a valuable tool for analysing gene 
function and correlating genotype with phenotype. Transfection models are even more 
valuable when appropriate animal models are available in addition to complete in vitro 
systems to be able to fully analyse parasite-host interactions. Here we describe the 
development of such a model by using the nonhuman primate malaria Plasmodium knowlesi. 
Bloodstage parasites were adapted to long-term in vitro culture. In vitro-adapted parasites 
could readapt to in vivo growth and regain wild-type characteristics after a single passage 
through an intact rhesus monkey. P. knowlesi parasites, either in vitro adapted or in vivo 
derived, were successfully transfected to generate circumsporozoite protein (CSP) knockout 
parasites by double-crossover mechanisms. In vitro-transfected and cloned CSP knockout 
parasites were derived in a time span of only 18 days. Microscopic evaluation of developing 
oocysts from mosquitoes that had fed on CSP knockout parasites confirmed the impairment 
of sporozoite formation observed in P. berghei CSP knockout parasites. The P. knowlesi 
model currently is the only malaria system that combines rapid and precise double-crossover 
genetic manipulation procedures with complete in vitro as well as in vivo possibilities. This 
allows for full analysis of P. knowlesi genotype-phenotype relationships and host-parasite 
interactions in a system closely related to humans. 
 
INTRODUCTION 
 The development of transfection technology for blood-stage malaria parasites [1-6] is of 
great importance in the postgenomic era. It provides a direct way in which to correlate 
genotype with phenotype, and this enhances the further understanding of parasite biology. 
This will facilitate rational design of new vaccines and drugs, which are urgently needed to 
fight the malaria epidemic that kills annually between 1.5 and 2.7 million people, mainly 
young children, in Sub-Saharan Africa alone [7].  
 Four species of Plasmodium are natural to humans [8], and two of them, Plasmodium 
falciparum and P. vivax, are the most prevalent and important in terms of disease. 
Phylogenetically, P. falciparum, the more deadly form of the two, forms a separate clade with 
P. reichenowi, which causes chimpanzee malaria, and P. vivax clusters with simian malarias 
[9]. The nonhuman primate malaria, caused by P. knowlesi, a natural parasite of Macaca 
fascicularis, has a relatively broad host range extending to humans, where it causes a mild 
disease [10]. The parasite is closely related to P. vivax [9], and many genes identified in P. 
vivax have homologues in P. knowlesi. To date, transfection techniques developed for malaria 
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parasite bloodstages [11] include episomal transfection and targeted integration with linear 
constructs for the rodent parasite P. berghei [3, 4], episomal transfection and targeted 
integration with circular DNA for the human parasite P. falciparum [6, 8], and episomal 
transfection for the nonhuman primate malaria parasites P. knowlesi [2] and P. cynomolgi [1]. 
Targeted integration experiments in P. falciparum, exploiting the results from the genome 
project [12, 13], are time-consuming, requiring several cycles of drug pressure to select for 
integration events based on a single crossover [5]. In addition, this system offers only 
restricted in vivo possibilities in scarce New World  primate systems. The P. berghei system 
offers a rapid targeted integration regime through double crossover [3]. It has, however, only 
limited in vitro possibilities for bloodstage parasites due to reticulocyte restriction, precluding 
in vitro transfection and selection procedures and thus, for example, the use of selectable 
markers that are toxic to the host.  
 P. knowlesi offers an especially powerful experimental system, since both the natural host, 
M. fascicularis, and an experimental host, Macaca mulatta, are phylogenetically close to 
humans. Genetic manipulation of this parasite species [2] offers the unique possibility to 
study parasite-host interactions in a system that is highly predictive for the human situation 
[14, 15]. A complete in vitro transfection and selection system for this parasite would greatly 
enhance the experimental possibilities, since some analyses could be carried out without any 
requirement for primates. Furthermore, where host-parasite interactions are being studied, in 
vitro selection of the cloned parasite of the correct genotype can be assured before primate 
use is required. Publications on in vitro cultivation of P. knowlesi bloodstage parasites are 
scarce, and the reported technology is cumbersome [16-18]. Culture medium was refreshed at 
least twice daily [16], red blood cells were added five times per week leading to up to 40% 
erythrocyte concentrations, and multiplication rates of <2.5 per 24-h lifecycle were reported 
[16, 18]. These labour-intensive culture conditions do not allow the generation of enough 
parasites of good quality to perform transfection experiments.  
 We set out to develop a complete in vitro system for P. knowlesi to allow long-term in 
vitro culture and an extremely rapid procedure for in vitro transfection, selection, and cloning 
of transfected parasites. In addition, we further developed the in vivo and in vitro transfection 
technology for P. knowlesi to include targeted integration with linear constructs. This was 
demonstrated by targeting the circumsporozoite protein (CSP) locus and phenotypical 
analysis of the CSP knockout. The P. knowlesi system now is the only malaria system that 
combines rapid genetic manipulation procedures with complete in vitro as well as in vivo 
possibilities, allowing full analysis of genotype-phenotype and parasite-host relationships in a 
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host closely related to humans. 
 
MATERIALS AND METHODS 
 Parasites and animals. P. knowlesi Nuri [19] and H strain [8] cryopreserved stocks were 
used to initiate blood-stage infection in rhesus monkeys by intravenous inoculation of 105 
parasites. In vitro cultures were started with the same parasite strains. 
 Adult rhesus monkeys (M. mulatta) of either sex, each weighing over 4 kg, were used in 
these studies. They were infected with cryopreserved stocks of P. knowlesi, in vitro-adapted 
blood-stage P. knowlesi parasites, or blood from another rhesus monkey. All experimental 
animal work in these studies was carried out under protocols approved by the independent 
Institutional Animal Care and Use Committee and performed according to Dutch and 
European laws. 
 Long-term in vitro culture of P. knowlesi. In vitro cultures were initiated with either 
cryopreserved or fresh P. knowlesi parasites isolated from an infected rhesus monkey. Rhesus 
red blood cells were used to culture P. knowlesi. White blood cells were removed by 
Plasmodipur filtration (Eurodiagnostica, Apeldoorn, The Netherlands), and red cells were 
stored for up to 2 weeks in RPMI at 4°C. Parasites were grown in static cultures at 36.5°C 
under reduced oxygen conditions (5% CO2, 5% O2, 90% N2) in RPMI 1640, supplemented 
with 20% pooled, heat-inactivated rhesus serum and rhesus erythrocytes at a 2.5% 
haematocrit. During the adaptation period medium was changed every 24 h, and fresh 
erythrocytes were added every 4 days to a maximum haematocrit of 5%. Once they had been 
established in culture, parasites were maintained under the same conditions except for 
medium changes every 48 h and subculturing when parasitaemias exceeded 5%. Parasitaemia 
was determined by microscopic examination of Giemsa-stained thick and thin films prepared 
from the cultured material at regular intervals. The culture-adapted parasites were 
subsequently adapted to growth in RPMI 1640 supplemented with 20% pooled, heat-
inactivated human A or AB serum, by using a similar strategy. Parasites were cryopreserved 
at the young ring stage of development by standard protocols [20]. Cloning of culture adapted 
P. knowlesi was performed by limiting dilution. 
 Transfection constructs. All transfection constructs contained a heterologous selection 
cassette based on mutagenised Toxoplasma gondii dihydrofolate reductase/thymidine 
synthase gene (dhfr/ts) conferring pyrimethamine resistance, flanked by P. berghei dhfr/ts 
flanking sequences [21]. 
 Sequences for P. knowlesi CSP locus were retrieved from GenBank entries (accession 
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numbers K00822 and M19749). To prepare a CSP knockout construct, 5’ and 3’ regions from 
csp were amplified by PCR. These regions were as follows: 5’ nucleotides (nt) -1495 to -560 
and 3’ nt 1 to 1089 (for numbering, nt 1 is the start of open reading frame [ORF]). Through a 
series of cloning steps plasmid pDB.DTm.DB/CSPko was derived (Fig. 1A). After purification 
on Plasmid Maxi columns (Qiagen), the vector backbone was excised from the construct by 
EcoRI digestion, and the linear DNA was used for transfection of P. knowlesi. Recombinant 
DNA manipulations and analyses were performed according to standard procedures [22]. 
 Transfection procedures and selection of transfected parasites. Transfection of mature 
blood-stage schizonts of P. knowlesi H-strain derived from a donor rhesus monkey and in 
vivo selection of transfected parasites by using oral dosing of pyrimethamine were performed 
as described previously [2], except that pyrimethamine was given at 1 mg/kg of body weight 
daily for five consecutive days and thereafter every other day until the end of the experiment. 
For transfection of culture-adapted parasites, up to 2 ml (packed cell volume) of red cells 
containing between 0.5 × 109 and 1 × 109 mature schizont-infected red cells was washed with 
incomplete Cytomix [6], mixed with 100 µl of transfection construct containing 50 µg of 
DNA, and electroporated (Bio-Rad GenePulser) in three 700 µl aliquots at a pulse of either 
1.5, 2, or 2.5 kV, with 25-µF capacitance  and 200 Ω resistance (the time constant ranged 
from 0.7 to 1.1 ms). Samples electroporated under the same conditions were pooled, 
incubated on ice for 5 min, and used to initiate 20 ml in vitro cultures at a 10% haematocrit. 
Culture medium was refreshed daily for 3 days to remove parasite material resulting from 
dead parasites and lysed erythrocytes. After that, the medium was replenished every other 
day. Pyrimethamine selection (25 ng/ml [final concentration] from a stock solution in 0.5% 
lactic acid in phosphate-buffered saline) was started 24 h after culture inoculation and 
maintained throughout the culture period. 
 DNA analysis. Total parasite DNA was isolated (Gentra Systems, Inc., Minneapolis, 
Minn.) directly from in vitro cultures or after Plasmodipur filtration of P. knowlesi-infected 
rhesus monkey blood according to the manufacturer’s instructions. Parasite DNA was 
analysed through plasmid rescue by electroporation into E. coli, PCR, and Southern blotting 
according to standard procedures [19]. The PCR primers used for confirming integration into 
the CSP locus were A (5’-GTGTCTATATTACCAACTC-3’) and B (5’-
GTCAAAAAAGGGTCAGTCAAAAAGGG-3’) (Fig. 1A). 
 Transmission studies. Rhesus monkeys were infected as described above, and Anopheles 
stephensi mosquitoes were allowed to feed for 10 min on the shaven chests of sedated 
monkeys 6 to 8 days after infection, when the parasitaemia was between 0.5 and 3%. Unfed 
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mosquitoes were removed, and engorged mosquitoes were maintained at 26°C and 80% 
relative humidity. From day 6 onward, midguts were dissected and examined by light 
microscopy (400× magnification) to monitor oocyst development and sporozoite formation 
within oocysts. 
 
RESULTS 
 Long-term in vitro culture of P. knowlesi. To improve the versatility of the P. knowlesi 
transfection system [2], in vitro protocols are required to allow the generation of genetically 
transformed parasites without the need for primates. Transformed parasites of the desired 
genotype can then be used in vivo to study biological questions at the parasite-host interface. 
Development of an in vitro transfection and selection protocol required establishment of 
stable, long-term in vitro culture of parasites. In vivo we have observed different growth 
characteristics between the H strain and the Nuri strain. Nuri strain reproducibly gives 
fulminating parasitaemias with an average 15-fold multiplication rate that rises to >20% ca. 1 
week after infection. Some rhesus monkeys infected with H strain showed similar parasite 
development but with a four- to fivefold multiplication rate. Others showed a rapid rise to ca. 
5% parasitaemia that subsequently developed into a chronic infection. P. knowlesi H strain 
and Nuri strain, originating from cryopreserved stocks or directly from an infected rhesus 
monkey, were both successfully adapted to in vitro culture by using RPMI 1640 
supplemented with 20% rhesus serum and an incubation temperature of 36 to 37°C. After an 
initial lag phase of at least 3 weeks in which parasites were hardly detectable in the cultures, 
adapted parasites emerged that now had been in continuous culture for >18 months (Fig. 2). 
Routinely, three- to fourfold multiplication rates per 24 h were obtained for the H strain and 
slightly higher (four- to fivefold) for the Nuri strain parasites in static cultures, and 
parasitaemias of up to 20% could easily be obtained. Culture adapted H-strain parasites were 
subsequently adapted to growth in medium containing 20% human serum, in which similar 
growth rates were observed. The use of temperatures of 39°C (the normal temperature of 
rhesus monkeys) during cultivation slowed down the parasite growth, and temperatures of 36 
to 37°C appeared to be the optimal growth temperature. Culturing parasites under shaking 
conditions or in a roller bottle system did not dramatically improve growth rates, but roller 
bottles now routinely supplied 1010 parasites from a 200 ml culture in a 2-liter flask. Finally, 
culture-adapted parasites were cloned by limiting dilution (Table 1), demonstrating the 
feasibility of the procedure required to obtain clonal parasite populations after transfection.  
The P. knowlesi H strain (either wild type or culture adapted) was used in subsequent  
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Figure 1. DNA constructs and analysis of integration into P. knowlesi CSP locus after 
transfection. (A) Linear DNA construct designed for integration into the P. knowlesi CSP locus. The 
5-kb selectable marker cassette (TgDHFR cassette) contains P. berghei dhfr/ts flanking regions 
controlling expression of mutagenised T. gondii dhfr/ts. Relevant restriction sites are indicated: R, 
EcoRI; P, PstI; H, HindIII; B, BamHI. (C) The location of the PCR primers A and B and the specific 
probe used for Southern blotting are shown. ORF-containing sequences are marked with an open 
arrow, and sequences used for targeted integration are indicated. (B) PCR analysis of transfected 
parasites. Lanes 1 to 3 show PCR with CSP integration-specific primers A and B. Lanes: 1, P. 
knowlesi H-strain DNA; 2, PkCSPko clone DNA; 3, pDB.DTm.DB/CSPko vector DNA. PkCSPko and the 
transfection construct were all positive for PCR with the two T. gondii dhfr/ts-specific primers (not 
shown). (C) Southern blot analysis of transfected parasites. PstI-digested DNA from P. knowlesi H 
strain (lane 2), PkCSPko clone (lane 3), and the transfection vector pDB.DTm.DB/CSPko (lane 1) was 
used to prepare a Southern blot. The blot was probed with a P. knowlesi CSP-specific probe (see 
panel A). 
 
 
transfection experiments. 
 Culture-adapted parasites can be readily readapted to in vivo growth. To determine 
whether P. knowlesi H strain that had been maintained in culture for 11 months was still able 
to grow in rhesus monkeys, a rhesus monkey was infected with 105 parasites. Patent 
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parasitaemia was observed after 12 days, and a chronic low-level parasitaemia developed 
with a peak parasitaemia of 0.2%. On day 17, 1 ml of blood from this monkey was 
transferred to a second rhesus monkey, and this monkey developed a fulminating 
parasitaemia from day 6 onward, reaching 19% parasitaemia on day 10. Two further 
infections were initiated by using stocks from the first passage, resulting in peak 
parasitaemias of 5% on day 8 and 1.2% on day 10, respectively. After the peak, the 
parasitaemias declined in both rhesus. Two rhesus monkeys were infected with a stock from 
the second passage, and patency started on day 4, resulting in 4.2% parasitaemia on day 7 and 
6.3% parasitaemia on day 9, respectively. At that time, the animals were bled to provide 
parasites for further transfection experiments. These results indicate that the in vivo H-strain 
phenotype of either a fulminant infection or a chronic infection after a ca. 5% peak 
parasitaemia is obtained after one passage through an immunologically intact rhesus monkey. 
When these parasites were cultured in vitro again they immediately developed like in vitro-
adapted parasites, without any adaptation period. 
Transfected P. knowlesi can be readily selected in vitro. By using previously determined 
transfection conditions [2], P. knowlesi schizonts, derived either from an infected rhesus 
monkey or from an in vitro culture, were transfected with plasmids containing the T. gondii 
dhfr/ts selection cassette. After transfection, parasites were maintained in 20 ml cultures, and 
pyrimethamine selection was applied from day 1 onward. The only transfection condition that 
consistently resulted in selection of transfected parasites was at 2.5 kV, 200 Ω, and 25 µF.  
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Figure 2. In vitro growth characteristics of P. knowlesi H strain. Parasitaemia development over a 
15-day period. Parasites were cultured as described in Materials and Methods, and after 3 months the 
parasitaemia level was determined daily and expressed as a percentage of infected red blood cells. 
Arrows indicate the days on which the culture was diluted. 
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Pyrimethamine-resistant parasites emerged in culture after 21 days for parasites derived from 
the monkey and after 8 days for in vitro-adapted parasites. Plasmid rescue from the resistant 
pools of parasites demonstrated the presence of plasmid DNA in an unrearranged form (not 
shown). 
 Targeted integration through double crossover can be obtained in vivo as well as 
entirely in vitro. Previously, we reported transfection of P. knowlesi with plasmids that were 
maintained as episomes [2]. To determine whether targeted integration in this system is 
feasible with linear constructs, as has been reported for P. berghei [3], an integration 
construct for the P. knowlesi CSP locus was prepared. The construct had 0.93 kb of P. 
knowlesi CSP 5’-untranslated region (UTR) sequence located 5’ of the selection cassette and 
1.0 kb of P. knowlesi CSP ORF sequence located 3’ of the selection cassette (Fig. 1A). 
Parasites derived from a rhesus monkey were transfected with linearised constructs and 
selected in vivo as described above. In parallel, the CSP knockout construct was used to 
transfect in vitro cultured schizonts, and selection was performed in vitro. As with the 
episomal transfections, 2.5 kV consistently resulted in selection of pyrimethamine-resistant 
parasites. In vivo and in vitro, pyrimethamine-resistant parasites were detected on day 8. 
Plasmid rescue experiments from these parasites consistently failed to produce ampicillin-
resistant E. coli, suggesting the absence of (recircularised) episomes within the transfected 
parasite populations. Cloning by limiting dilution of in vitro-selected transfectants was 
started on day 8, and clones were observed in thin films by day 18. Multiplication rates for 
these transfected parasites were about four times per 24 h in vivo and about three times per 24 
h in vitro. PCR on in vitro-selected and cloned PkCSPko genomic DNA with primers A and 
B (Fig. 1 A) (amplifying a 1.7 kb P. berghei dhfr/ts 5’-UTR–CSP ORF region only present 
when targeted integration has occurred) showed integration into the CSP locus (Fig. 1B, lanes 
1 to 3). This was also confirmed by Southern blotting with a 0.89 kb HindIII fragment (Fig. 
1A) of the CSP ORF as a probe. As shown in Fig. 1C, lanes 1 to 3, the 10 kb wild-type PstI 
fragment from the CSP locus (lane 2) is converted to a 2.5 kb fragment in PkCSPko (lane 3) 
due to the introduction of PstI sites contained in the transfection construct. 
 CSP knockout P. knowlesi does not produce sporozoites in oocysts. To examine the 
phenotype of CSP knockout P. knowlesi, rhesus monkeys were infected with either P. 
knowlesi H strain or the PkCSPko blood-stage parasites. The development of parasitaemia in 
both monkeys was similar, showing a rapid rise to ca. 10% parasitaemia on days 8 and 9 
postinfection. A. stephensi mosquitoes were allowed to feed on day 8 on the wild-type 
infected monkey (0.9% parasitaemia) and on days 6 and 7 on the PkCSPko-infected monkey 
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(0.5 and 3% parasitaemias, respectively). Fed mosquitoes were isolated and kept at 26°C to 
allow oocyst and sporozoite development. From day 6 postfeeding onward, mosquitoes were 
dissected and midguts were examined for the presence of oocysts and sporozoites. Day 7 
feeding of the PkCSPko resulted in the highest transmission rates (100%), with ca. 50 oocysts 
per midgut. The wild-type feeding resulted in 83% infection and ca. 26 oocysts per midgut. 
Wild-type oocysts produced sporozoites in the heamocoel from day 8 postfeeding onward, as 
determined by light microscopic examination of midguts (Fig. 3A and C). Spontaneously 
ruptured oocysts showed release of sporozoites, and rupture by applying gentle force to the 
coverslip also released sporozoites from the oocysts. As expected, due to rupture and release 
of sporozoites, the number of oocysts dramatically declined from days 8 to 11 postfeeding. 
Salivary gland sporozoites were not detected, since P. knowlesi sporozoites are not able to 
invade the salivary glands of A. stephensi [23]. In contrast, in the PkCSPko oocysts no 
sporozoites developed, and this remained so until the experiment was stopped at a point when 
the great majority of the wild-type oocysts had matured and ruptured (Fig. 3B and D). The 
number of oocysts did not decline from days 8 to 12 as observed with wild-type oocysts. 
PkCSPko oocyst development otherwise appeared to be similar to that of wild-type oocysts, 
as observed by light microscopy (Fig. 3A and B), resulting in similar-sized oocysts at day 11. 
 
Table 1. Cloning of in vitro culture adapted P. knowlesi 
Seeding density* Percentage of positive 
wells‡ 
Probability of clones§ Number of clones 
obtained 
100 100 0 0 
20 100 0 0 
4 100 0 0 
0.8 75 46.2 0 
0.16 21 91.7 5 
0.032 4 98.4 1 
 
*Average number of parasites used to start cultures in 24 wells of a 96 well plate. 
‡ Cultures were maintained for 30 days before scoring as negative 
§Probability that parasites are derived from a single infected erythrocyte is calculated according to 
Gritzmacher and Reese [24] 
 
 
DISCUSSION 
 The postgenomic analysis of the sequences now being obtained for a range of malaria-
causing species will require versatile tools for genetic manipulation. Transfection permits 
targeted genomic manipulation of malaria parasites to characterise structural and functional 
relationships. Analysis of transfected parasites in a natural host-parasite setting is not possible 
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with transfected human malaria parasites. In this respect P. knowlesi, a natural parasite of M. 
fascicularis [8], is a system with great potential because (i) the parasite is phylogenetically 
closely related to human malarial parasites, such as P. vivax [9] (in fact, the parasite can also 
infect humans [10]); (ii) animal hosts are available for experimentation [14, 25]; (iii) animal 
hosts are primates, enabling analysis of transfectant phenotypes in systems closely related to 
humans [15]; and (iv) we have developed in vivo transfection systems [2], allowing 
functional genome analysis.  
 We have now further improved and extended the P. knowlesi system in several ways to 
provide more widely available access to genetic manipulation of this parasite species. First, 
two P. knowlesi strains, Nuri and H, were adapted to long-term in vitro growth by using 
simple protocols. This is important since it obviates the need for primates as parasite donors 
to provide parasites for genetic manipulation. Second, by using protocols developed for in 
vivo selection of transfected parasites, transfected parasites were selected in vitro based on 
the T. gondii dhfr/ts gene providing resistance to pyrimethamine.  
 
 
 
 
 
 
Figure 3. Microscopic evaluation of wild-type and CSP knockout P. knowlesi oocyst 
development in A. stephensi midguts. (A) Intact wild type oocyst 9 days postfeeding. (B) Intact 
CSP knockout oocyst 11 days postfeeding. (C) Wild-type oocyst releasing sporozoites (marked with 
arrows) 8 days postfeeding. (D) Force-induced rupture of CSP knockout oocyst 11 days postfeeding. 
Sporozoite release was never observed in CSP knockout oocysts. 
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This also obviates the need for primates as transfected parasite recipients during the initial 
selection for transfectants and allows development of new selectable markers, including those 
that would otherwise be toxic to the host, exploiting the benefits of complete in vitro 
selection. Third, to determine whether gene targeting through double crossover was possible 
in P. knowlesi or whether the lengthy P. falciparum procedures needed to be adopted, 
transfection experiments with linear DNA constructs designed to target the CSP locus were 
performed. These experiments, performed in vivo as well as in vitro, showed that targeted 
integration could be obtained with linear constructs and entirely in vitro. Recently, by using 
similarly designed constructs, the P. knowlesi thrombospondin-related adhesive protein gene 
was also efficiently disrupted (H. Ozwara et al., unpublished results). The in vitro procedure 
allows for deriving cloned parasites within 18 days of transfection, demonstrating the relative 
speed of this procedure compared to in vitro P. falciparum procedures, and allowing high-
throughput analysis of gene functions. 
 Recently, the P. knowlesi genome sequence to a threefold coverage has become available 
(http://www.sanger.ac.uk/Projects/P_knowlesi/). This greatly expands the possibilities for 
transfection studies since homologues from P. falciparum genes and from genes available 
from the expanding P. vivax gene sequence tag database 
(http://www.ncbi.nlm.nih.gov/Malaria/plasmodiumblcus.html) can now easily be identified in 
P. knowlesi. 
 Finally, we have shown that parasites that have been growing in vitro for a long period of 
time can readily readapt to in vivo growth, displaying wild-type H-strain growth 
characteristics after single passage through an intact rhesus monkey. This observation is 
extremely important since in vitro-selected transfected parasites will be vital tools for 
studying host-parasite interactions. In vitro culture might lead to alteration of expression of 
SICAvar genes [26-28] and thus to loss of avoiding splenic clearance by sequestration, which 
can influence infectivity in nonsplenectomized rhesus monkeys. One passage through an 
intact rhesus is apparently sufficient to select for parasites that are readily able to infect 
rhesus monkeys and that can still be cultured in vitro.  
 In this study in a nonhuman primate malaria of the P. vivax type, we confirmed the earlier 
observations in a rodent malaria of the essential nature of CSP in sporozoite development 
[29]. In P. knowlesi CSP is also critical for sporozoite formation in developing oocysts in 
mosquito midguts, and the lack of CSP expression results in absence of sporozoite formation. 
Unlike the situation in P. berghei, oocysts of the CSP knockout have similar morphology to 
wild-type oocysts, and the phenotype only becomes clear at the time of sporozoite release. 
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This difference is mainly due to the fact that in P. knowlesi H-strain oocysts sporozoites are 
not visible “like rays from the sun” as described for P. berghei [18], and thus both wild-type 
and CSP knockout oocysts show an undefined morphology. 
 The P. knowlesi system now provides a unique malaria transfection system that allows for 
fast and simple in vitro genetic manipulations and combines this with the opportunity to 
perform in vivo studies in a nonhuman primate that is closely related to humans. It is the only 
malaria system described to date that is amenable to genetic manipulation that combines 
complete in vitro possibilities with studies in vivo in an animal model that is closely related to 
humans. This fact makes P. knowlesi highly suitable for the development of new antimalarial 
drugs and vaccines, as well as for studying basic biological questions in the postgenomic era 
at the parasite-host interface. 
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 A more rational approach to vaccine development and drug design requires a deeper 
understanding of the biology of malaria parasites. Transfection of malaria parasites [1–6] 
provides a broad range of tools to study malaria parasite biology. Transient transfection for 
malaria parasites provides the opportunity to precisely and rapidly examine control of gene 
expression in malaria parasites [7–9], an approach that is critical in understanding how gene 
expression is developmentally controlled in Plasmodium parasites. Luciferase and green 
fluorescent protein (GFP) are reporter molecules that have proven to be useful as markers for 
gene expression during transient and stable transfection in the avian parasite Plasmodium 
gallinaceum [1], the human parasite Plasmodium falciparum [10] and the rodent parasite 
Plasmodium berghei [11]. The use of heterologous promoters in transfection of Plasmodium 
[4, 6] is advantageous, especially in gene targeting experiments where it could reduce 
integration of the construct into loci different from that of interest. It is important to analyse 
regulation of expression under heterologous promoters to determine that they work in the 
same way as in the homologous system. Furthermore, promoters influence the timing of 
expression and eventual distribution of expressed transgenes [12]. The aim of this study was 
to characterise heterologous promoter activity upon transient and stable transfection in the 
simian malaria parasite Plasmodium knowlesi. 
 In order to rapidly characterise heterologous promoter activity in P. knowlesi, transient 
transfection was evaluated using luciferase as the reporter gene. The heterologous stage 
specific P. berghei apical membrane antigen-1 (pbama-1) promoter [13], and the 
heterologous constitutive P. berghei elongation factor-1 alpha (pbef-1α) promoter [13], were 
used to drive luciferase expression in P. knowlesi. To test these heterologous promoters, P. 
berghei luciferase constructs pE(A)b.luc∧D and pAb.luc.∧Db were used [13]. As a positive 
control, the construct pDb.luc.∧Db [13] for expressing luciferase under the heterologous 
pbdhfr-ts promoter was tested along side since the pbdhfr-ts promoter is known to be 
functional in P. knowlesi [4, 14]. The constructs were transfected into asynchronous in vitro 
culture adapted blood stage parasites using conditions described previously [14]. Luciferase 
assays were performed either as described [13] or using the lucliteTM kit (Perkin-Elmer Life 
Sciences) according to the manufacturer’s instructions. Luciferase activity was measurable 
within 24 h post-electroporation using either of the two detection systems. The Top Count 
NXT Microplate Scintillation and Luminescence Counter (Perkin-Elmer, used with the luclite 
kit) has the capacity to rapidly measure luciferase activity either in a 96- or 384-well plate 
format. This is less labour intensive compared to the single tube procedure using the Lumat 
LB 9507 luminometer (EG & G Berthold), and has the potential for high throughput analysis.      
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The results (Fig. 1) show that luciferase activity was measurable using either of the three 
heterologous promoters and was consistently the highest using the construct with the pbef-1α 
promoter. The ef-1α promoter drives expression in all parasite blood stages of P. berghei and 
P. knowlesi except mature schizonts [15], while the dhfr-ts and the ama-1 promoters are 
active in late trophozoites/young schizonts [16] and mature schizont stages [17], respectively. 
Asynchronous parasite cultures were used for transfection and analysis of luciferase activity 
because they omit the time-consuming procedure of culture synchronisation. 
 Consequently, the pbdhfr-ts and pbama-1 promoters were active in only a proportion of 
the asynchronous parasites tested for luciferase activity.  
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 Figure 1. Transient transfection and heterologous promoter activity in P. knowlesi H strain. 
Asynchronous blood stage parasites were transfected with DNA constructs described in [13]. 
Parasites were electroporated in a gene pulser II (Biorad) as described previously [14]. 
Electroporations were done with 2 X 108 parasites and 50 µg of DNA resuspended in 800 µl of 
cytomix [19] in a 0.4-cm cuvette (Biorad). As controls for luciferase activity, parasites were 
electroporated without DNA. Electroporated parasites were cultured in 20 ml of complete medium as 
described previously [14]. Luciferase activity was measured 24 h later using a Lumat LB 9507 
luminometer (EG & G Berthold) or a Top Count NXT Microplate Scintillation and Luminescence 
Counter (Perkin-Elmer). Each culture was split into two equal parts before harvesting and measuring. 
Luciferase activity values from control cultures were subtracted from all readings. To transform 
readings to percentage relative luciferase activity, the average luciferase light units measured under 
the pbef1α promoter using a Lumat LB 9507 luminometer was scored as 100% [13]. The other 
readings were normalised against it. The luciferase activity shown is the average of two experiments 
per luminometer (±S.D.). pbama-1, parasites expressing luciferase under the pbama-1 promoter; 
pbdhfr-ts, parasites expressing luciferase under the pbdhfr-ts promoter; pbef-1α, parasites expressing 
luciferase under the pbef-1α promoter; Berthold, Lumat LB 9507 luminometer; Topcount NXT, 
Topcount NXT Microplate Scintillation and Luminescence counter. 
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This, as well as actual differences in promoter strength, can explain the lower luciferase 
activity observed under the pbdhfr-ts and the pbama-1 promoters as compared to the pbef-1α 
promoter if similar tight regulation is maintained in the heterologous parasite. Transient 
transfection protocols were used subsequently to determine the optimum electroporation 
conditions for mixed blood stage P. knowlesi transfection. We tested high voltage, low 
capacitance and low voltage high capacitance electroporation conditions, previously shown to 
transfect intracellular P. falciparum blood stages [3, 18] alongside previously published [14] 
P. knowlesi conditions, using plasmids for expression of luciferase under pbdhfr-ts and pbef-
1α promoters. Transfection using conditions of 2.5 kV, 25 µF, and 200 Ω consistently gave 
high and more reproducible luciferase activity (Table 1), indicating that these are the most 
optimal conditions for transfecting asynchronous and mature P. knowlesi blood stages [14]. 
Currently, both P. knowlesi episomal and integration types of transfection are routinely 
performed in our laboratory using electroporation conditions of 2.5 kV, 25 µF and 200 Ω, 
and 0.5 x109 to 1 x109 parasites resuspended with DNA in cytomix to 800 µl [19] in a 0.4 cm 
cuvette (Biorad). These conditions are suitable for transfecting as little as 20 µg plasmid 
DNA per electroporation (data not shown), but for uniformity of results, we use routinely at 
least 50 µg of DNA per electroporation.  
 
 
Table 1. Electroporation conditions for asynchronous P. knowlesi parasites 
 
Electroporation conditions Luciferase activity (%) a 
 Expt 1 Expt 2 Expt 3 Expt 4 
2 kV, 25 µF, 200 Ω 56.2b 100.0 21.0 29.9 
2.5 kV, 25 µF, 200 Ω 92.5 97.3 100.0 100.0 
0.37 kV, 975 µF 28.3 8.5 1.7 1.1 
0.4 kV, 975 µF 62.7 47.6 3.6 3.2 
0.45 kV, 975 µF 100.0 46.3 2.9 8.6 
 
a For each experiment, luciferase activity was normalised on electroporation conditions that yielded 
the highest activity. 
b Each culture was split into two equal parts prior to reading and measuring. Luciferase activity values 
are based on average of the readings. 
Expt. experiment. 
 
 
 The asynchronous nature of P. knowlesi parasite cultures used in transient transfections 
precluded precise determination of stage specific control of expression under the pbama-1 
promoter. Gene expression under the pbama-1 promoter in the homologous system is 
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restricted to mature schizonts [12] when six or more nuclei are present [17]. Using GFP as a 
reporter molecule [20], stable drug-selectable transfection experiments were done to analyse 
stage specific control of gene expression under the heterologous pbama-1 promoter in P. 
knowlesi. GFP is easily quantifiable [21, 22], non-toxic to cells [23] and allows analysis of 
stage specific expression in an asynchronous parasite culture by direct microscopic 
examination. 
Plasmid pDB.DTM.DB/AB.GAM3.DB was constructed for stable episomal expression of GFP 
in P. knowlesi. The gfp mutant 3 gene was isolated by BamHI digestion of plasmid 
pDB.DTM.DB/DB.GFP.DB [21] and gel purification. The insert was cloned into the BamHI 
digested pDB.DTM.DB/AB.DB [12] to generate the transfection plasmid 
pDB.DTM.DB/AB.GAM3.DB. P. knowlesi blood stage parasites (5 x 108) were transfected with 
this plasmid and selected in vitro using pyrimethamine. Drug resistant parasites were 
observed 8 days post-electroporation. Plasmid rescue experiments showed that the 
transfection plasmid was present in a stable form in P. knowlesi. Parasites expressing GFP 
were examined freshly for fluorescence after addition of 4,6-diamidino-2-phenylindole 
(DAPI) to stain parasite DNA, allowing precise determination of parasite developmental 
stage. Strong GFP fluorescence, diffused throughout the cytoplasm (Fig. 2), was observed in 
mature schizonts (Fig. 2D), indicating similar tight regulation of the heterologous pbama-1 
promoter in P. knowlesi as observed in the homologous parasite P. berghei [12]. 
Occasionally, GFP fluorescence was observed in young ring stages, possibly due to high 
levels of GFP expressed in schizonts from multiple plasmid copies [16]. Due to the apparent 
relatively short half life of GFP in this system, this only results in minor carry over to 
subsequent ring stages. These experiments also indicated that GFP was successfully 
expressed by P. knowlesi blood stages, and that it can be used as a reporter. 
 Episomally transfected parasites maintain several copies of plasmids leading to over-
expression of genes [16] and mutants of GFP may require up to 10,000 molecules for 
accurate detection inside a cell [24]. Whereas over-expression by episomal transfection 
readily achieves the threshold, we wanted to determine whether single copy gene expression 
was also sufficient. Experiments were performed to integrate a single copy of the gfp gene 
under control of the pbama-1 promoter into the non-essential P. knowlesi 140 kDa locus [25] 
by double cross-over mechanisms [14]. GFP fluorescence was readily detected in parasites 
that were confirmed by PCR and plasmid rescue to only contain a single copy of the gfp gene 
integrated in the 140 kDa locus (Fig. 2D). This demonstrates that single copy gene expression 
under control of the pbama-1 promoter is sufficient for detectable GFP expression in P. 
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knowlesi. These experiments indicate that GFP is a suitable reporter in P. knowlesi under 
over-expression and single gene copy expression conditions. In all the experiments, there 
were no indications that expression of GFP compromised parasite viability. 
 
 
 
Figure 2. Expression of green fluorescent protein (GFP) in Plasmodium knowlesi mature 
schizont stage. GFP fluorescence was observed under fluorescein isothiocyanate (FITC) filter 
settings using a Nikon Microphot-FXA fluorescence microscope (A). DAPI was added to culture 
smears at a final concentration of 1.9 µM to stain parasite nuclei and the smears were directly 
observed as described above for GFP except that the microscope filter was under UV settings (B). A 
bright field image of the parasitized erythrocyte is depicted in (C). The pictures were derived from 
parasites expressing GFP after integration into the 140 kDa locus. Characteristics of GFP expression 
in different blood stages are shown in (D). aCultures were followed through an entire blood stage cycle 
and 400 parasitised erythrocytes were evaluated for each developmental stage. bIn order to design 
the GFP expression construct for integration into the P. knowlesi 140 kDa locus [25], the ORF was 
isolated by BamHI digestion of plasmid pDB.DTM.DB/DB.GFP.DB [21], and gel purification. Through a 
series of cloning steps, plasmid p140K/DB.DTM.DB/AB.GAM3.DB/140K was generated. The plasmid was 
linearised by restriction digestion with Eco RI and Not I prior to transfection. Targeted integration of 
the GFP expression construct into the 140 kDa locus was determined by PCR analysis. 
cFluorescence was observed in young ring stages from some of the parasite culture smears 
examined. dSchizonts were classified either as immature if the number of nuclei were not more than 
four (N ≤  4) or mature if the number of nuclei was six and above (N ≥  6).  
(-) no fluorescence; 
(±) sparse fluorescence occasionally seen in some parasites; 
(+++) strong fluorescence diffused in the parasite cytoplasm. 
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GFP experiments reported here show that the heterologous pbama-1 promoter maintains tight 
stage-specific regulation of expression in P. knowlesi. Further studies will be required to 
show whether P. knowlesi uses the same transcription start site(s) as used in P. berghei, and 
whether other tightly regulated P. berghei promoters are also similarly active in P. knowlesi. 
Luciferase and GFP will be useful tools in addressing these questions. Expression of these 
reporters in P. knowlesi will now provide an effective means to study both gene expression 
and protein trafficking in tagging experiments [10, 11]. This study has further identified the 
pbef-1α promoter as a strong heterologous promoter ideal for targeted integration and over-
expression [13] of transgenes in P. knowlesi blood stages. The tools reported here will be 
used to further develop the P. knowlesi transfection system to enable full exploitation of the 
advantages offered by this versatile transfection system. 
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ABSTRACT 
 Transgenic pathogenic micro-organisms expressing host cytokines such as gamma 
interferon (IFN-γ) have been shown to manipulate host-pathogen interaction, leading to 
immunomodulation and enhanced protection. Expression of host cytokines in malaria 
parasites offers the opportunity to investigate the potential of an immunomodulatory 
approach by generating immunopotentiated parasites. Using the primate malaria parasite 
Plasmodium knowlesi, we explored the conditions for expressing host cytokines in malaria 
parasites. P. knowlesi parasites transfected with DNA constructs for expressing rhesus 
monkey (Macaca mulatta) IFN-γ under the control of the heterologous P. berghei apical 
membrane antigen 1 promoter, produced bioactive IFN-γ in a developmentally regulated 
manner. IFN-γ expression had no marked effect on in vitro parasite development. Bioactivity 
of the parasite-produced IFN-γ was shown through inhibition of virus cytopathic effect and 
confirmed by using M. mulatta peripheral blood cells in vitro. These data indicate for the first 
time that it is feasible to generate malaria parasites expressing bioactive host 
immunomodulatory cytokines. Furthermore, cytokine-expressing malaria parasites offer the 
opportunity to analyse cytokine-mediated modulation of malaria during the blood and liver 
stages of the infection. 
 
INTRODUCTION 
 Recombinant pathogenic microorganisms expressing host cytokines such as gamma 
interferon (IFN-γ) have been shown to modulate immune responses, leading to enhanced 
protection [1–7]. Vaccinia virus and simian immunodeficiency viruses expressing a range of 
host cytokines were attenuated in vivo, leading to enhanced immune responses [1–3], and 
Leishmania major expressing host IFN-γ was significantly attenuated in nude mice [7]. These 
data indicate that in vivo expression of host cytokines by pathogens can manipulate the host-
pathogen interaction and generate protective host responses. Thus far, expression of host 
cytokines by malaria parasites has not been examined. The development of transfection 
technology for malaria parasites [8–11] now enables expression of recombinant host proteins, 
such as cytokines in Plasmodium.  
 IFN-γ is one of the central effector cytokines in host response to malaria infection, 
especially during the liver stage [12 –17] and hence is attractive for expression in malaria 
parasites. In vitro and in vivo studies in rodent models of malaria have demonstrated that 
IFN-γ plays a central role in protection against malaria liver-stage infection, possibly by 
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inducing the infected hepatocyte to produce nitric oxide that kills parasites [14, 18]. In 
clinical vaccination studies with an attenuated sporozoite vaccine [reviewed in reference 19], 
vaccinated humans were protected from subsequent infection through IFN-γ-dependent 
responses. In separate studies in mice and monkeys, sterile protection was achieved through 
IFN-γ-dependent responses after exogenous treatment with interleukin-12 (IL-12) [13, 16]. 
Studies using rodent and human malaria models have demonstrated that IFN-γ also plays a 
role in protection against malaria blood stages when either endogenously produced [20 – 25] 
or exogenously administered [26 – 29]. 
 Although cytokines have been shown to mediate protection against malaria infection after 
exogenous delivery [13, 16, 27, 29], systemically delivered cytokines are short-lived and 
require repetitive administration (often in large doses that could be toxic to the host) [28, 30, 
31], and only a small portion reaches the site of infection [30, 32]. Alternatively, cytokine 
expression by the pathogen itself will ensure that the cytokine is released where its activity is 
required, as long as the infection persists and in proportion to the level of infection. In this 
report, Plasmodium knowlesi, a natural malaria parasite of macaque monkeys [33] and an 
experimental system for human malaria, was transfected in vitro to express Macaca mulatta 
IFN-γ. In vitro expression and bioactivity of P. knowlesi-expressed rhesus monkey IFN-γ 
(rhIFN-γ) was characterised, showing for the first time that malaria parasites can produce a 
bioactive recombinant host cytokine. 
 
MATERIALS AND METHODS 
Parasites. In vitro culture-adapted P. knowlesi H strain [34] wild type and transfected 
blood-stage parasites were maintained and cloned where necessary as described previously 
[35].  
Transfection constructs and procedures. All transfection constructs contained a 
heterologous selection cassette based on a mutagenised Toxoplasma gondii dihydrofolate 
reductase/thymidine synthase gene (dhfr/ts) conferring pyrimethamine resistance, flanked by 
P. berghei dhfr/ts flanking sequences [36]. To construct the rhIFN-γ expression vector, the 
open reading frame (ORF) of M. mulatta IFN-γ was isolated by XbaI and SpeI restriction 
digestion of the M. mulatta IFN-γ cloning vector (a gift from F. Villinger) [37], Klenow 
polymerase treatment, and purification with the Qiagen gel extraction kit (Qiagen, 
Chartsworth, Calif.). The IFN-γ gene was cloned into the blunted BamHI site of plasmid 
pDB.DTM.DB/AB.-.DB [36] to generate pDB.DTM.DB/AB.γMM.DB (Fig. 1A). The construct was 
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used for episomal transfection of P. knowlesi [35]. The 140-kDa merozoite surface antigen 
was shown to be nonessential during the bloodstage development of P. knowlesi [38]. 
Therefore, we designed the rhIFN-γ expression construct for integration into the P. knowlesi 
140- kDa locus. The M. mulatta IFN-γ ORF was isolated as described above, and through a 
series of cloning steps, plasmid p140K/DB.DTM.DB/AB.γMM.DB/140K was generated (Fig. 
1B). Given that integration into the P. knowlesi genome by a double crossover mechanism 
requires linear constructs [35], the construct for integration into the 140 kDa locus was 
linearised by restriction digestion with PvuI and NotI prior to transfection. As controls, 
parasites were transfected separately with pDB.DTM.DB/AB.-.DB and p140K/DB.DTM.DB/AB.-
.DB/140K constructs. Parasite cultivation and in vitro transfection and selection procedures 
were performed as described elsewhere [35].  
DNA analysis. Total parasite DNA was isolated (Gentra Systems, Inc., Minneapolis,  
Minn.) directly from in vitro cultures according to the manufacturer’s instructions. The DNA 
from episomally transfected parasites was analysed through plasmid rescue by 
electroporation into Escherichia coli and PCR according to standard procedures [39]. PCR 
was performed on total parasite DNA with primers A (5’GGCTTTTCAGCTCTGCATTG-3’) 
and B (5’-CCGCTCGAGGCTGGGATGCTCTTCGACC-3’) to detect rhIFN-γ (Fig. 1B). 
Primers A and B amplify the ORF of rhIFN-γ from nucleotide positions - 24 to - 478. In order 
to discount the presence of episomes following integration-dependent transfection, primers C 
(5’-GTCATAGCTGTTTCCTG-3’) and D (5’-GTGTCTATATTACCAACTC-3’) were used 
to amplify the plasmid backbone of the integration construct. Primers E (5’-
GAATTCCATTTATGAATATCC-3’) and D (Fig. 1B) were subsequently used to confirm 
integration into the 140-kDa locus, by amplifying the downstream region of the disrupted 
locus.  
In vitro analysis of rhIFN-γ expression. Transfected and control parasite cultures were 
expanded in vitro [35], and culture supernatants were harvested and frozen at -80°C. The 
culture supernatants were analysed for the presence of rhIFN-γ by enzyme-linked 
immunosorbent assay (ELISA, using a macaque IFN-γ ELISA kit (U-Cytech, Utrecht, The 
Netherlands) according to the manufacturer’s instructions.  
To monitor release of rhIFN-γ, control and rhIFN-γ-expressing P. knowlesi cultures were 
synchronised by alanine treatment [40]. Schizont-stage parasites (5×108) were inoculated into 
20 ml of culture medium with 0.1 µM pyrimethamine and 5% haematocrit and cultured in 
vitro [35]. Culture supernatants for determining release of IFN-γ over 6 h time spans during 
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the life cycle of the parasite were harvested by centrifugation of parasite cultures. 
Subsequently, fresh culture medium was added to the parasites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. DNA constructs and analysis of integration into the P. knowlesi 140 kD locus. (A) 
Plasmid pDB.DTM.DB/AB. γMm.DB for episomal expression of rIFN-γ. The selection cassette contains P. 
berghei dhfr/ts flanking regions controlling expression of mutagenized T. gondi dhfr-ts. Rhesus IFN γ 
cassette contains the rIFN γ gene under the expression control of the  P. berghei apical membrane 
antigen-1 5' UTR and the P. berghei dhfr/ts 3' flanking sequence. (B) Disruption of the P. knowlesi 
140 kD locus to express rIFN-γ. Restriction sites used for linearizing the 13.4 kb plasmid 
p140K/DB.DTM.DB/AB.  γ Mm.DB/140K to generate the integration construct are indicated: N, Not I; P, Pvu 
I. The location of PCR primers A, B, C, D and E are shown. (C) PCR analysis of transfected parasites 
with integration-specific primers  D and E. Lanes: 1, 1 kb DNA marker; 2, P. knowlesi H strain DNA; 3, 
DNA from transfected parasites; 4, p140K/DB.DTM.DB/AB.  γ Mm.DB/140K vector DNA. (D) Analysis of 
transfected parasites for circular DNA using plasmid-specific primer C and selection cassette-specific 
primer D. Lanes: 1, 1 kb DNA marker, 2, P. knowlesi H strain DNA; 3, 
p140K/DB.DTM.DB/AB.  γMm.DB/140K vector DNA and 4, DNA from transfected parasites. 
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All harvested supernatants were stored at -80°C until assayed. In order to determine the in 
vitro stability of rhIFN-γ, 500 µl of parasite culture supernatant containing parasite-produced 
rhesus IFN-γ was incubated for 30 h with wild-type P. knowlesi-infected erythrocytes or in 
culture medium only. Parasite-containing cultures had a haematocrit of 2.5% and a starting 
parasitaemia of 3% (90% rings, 4% schizonts, and 6% trophozoites). Aliquots of the culture 
supernatant were harvested at 6 h intervals and stored at -80°C.  To assay for rhIFN-γ present 
in the culture medium, supernatants were thawed on ice, and the rhIFN-γ concentration was 
determined by ELISA (UCytech). 
 Antiviral cytopathic effect assay. The bioactivity of rhIFN-γ was quantified by its ability 
to inhibit the cytopathic effect of vesicular stomatitis virus (VSV) in human HEp2 cell lines 
[41]. Human HEp2 cells [41] were plated in duplicate wells at a concentration of 2 ×104 per 
well and incubated at 37°C for 24 h in 1% foetal calf serum (FCS)–RPMI medium with 
culture supernatants of rhIFN-γ-expressing parasites. The cells were challenged with an 
appropriate dilution of VSV [41] and cultured for a further 24 h in 10% FCS–RPMI medium. 
As a control for IFN-γ specific activity, parasite culture supernatants containing rhIFN-γ were 
incubated with 15 µg of neutralising antibody per ml (U-Cytech) for 30 min at room 
temperature prior to incubation with the HEp2 cells. Supernatants from parasite-free culture 
medium and wild-type parasite cultures were also used as controls. Recombinant human IFN-
γ (U-Cytech) was used as a standard for calibration of antiviral cytopathic effect. One 
antiviral unit of rhIFN-γ was defined as the inverse of the dilution that conferred 50% 
protection to the monolayer. 
 In vitro whole-blood-cell activation assay. The bioactivity of rhIFN-γ was also 
determined by measuring release of tumour necrosis factor alpha (TNF-α) from whole-blood-
cell cultures incubated with parasite culture supernatants. Blood was obtained by 
venipuncture from a naïve rhesus monkey and used immediately. The blood was washed 
three times in RPMI 1640, diluted 1:1 in 10% FCS–RPMI medium, and plated at 1 ml per 
well in 24-well culture plates containing parasite culture supernatants and controls. Whole-
blood-cell culture supernatants were harvested 6 h later and stored at -80°C. Frozen culture 
supernatants were thawed on ice and assayed for TNF-α with a monkey TNF-α ELISA kit 
(U-Cytech) according to the manufacturer’s instructions. Controls included parasite culture 
supernatants that were preincubated with 15 µg of IFN-γ neutralising antibody per ml (U-
Cytech) for 30 min at room temperature prior to the activation assay, culture supernatants 
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from wild-type parasites, and bacterial lipopolysaccharide (LPS). 
 FACS analysis. IFN-γ stimulates monocytes to upregulate CD64 and major 
histocompatibility complex (MHC) class II DR expression in humans and rodents [42, 43, 44, 
45]. To determine whether parasite culture supernatants from rhIFN-γ-producing parasites 
could produce a similar effect on rhesus monkey whole blood cells, rhesus monkey venous 
blood was obtained, processed, and cultured as described above, except that the cultures were 
incubated for 48 h. The blood cells were harvested, lysed with fluorescence-activated cell 
sorter (FACS) lysis solution (BD, Heidelberg, Germany), and stained with antibodies against 
human CD14, CD64, and MHC class II DR (BD). These antibodies cross-react with rhesus 
homologues. The number of CD64+ MHC class II DR+ cells within the CD14+ cell 
population was analysed by FACS as previously described [46]. 
 
RESULTS 
 Transfection of P. knowlesi and analysis of rhIFN-γ production. P. knowlesi blood-
stage parasites were transfected with rhIFN-γ expression constructs pDB.DTM.DB/AB.γMM.DB 
and linearised p140K/ DB.DTM.DB/AB.γMM.DB /140K to determine the capacity of P. knowlesi 
to express host IFN-γ from episomal and integrated genes, respectively. Pyrimethamine-
resistant parasites were observed in transfected cultures at 8 days postelectroporation. 
Plasmid rescue experiments and PCR analysis using primers A and B amplifying the IFN-γ 
ORF showed that plasmid pDB.DTM.DB/AB.γMM.DB was intact and therefore stable in P. 
knowlesi and that the gene was also present in parasites transfected with the integration 
construct. Integration into the 140-kDa locus was confirmed by PCR using primers D and E 
(Fig. 1C), and analysis for circular plasmids following integration-dependent transfection 
using primers C and D was negative (Fig. 1D). This showed that gene targeting into the 140-
kDa locus in P. knowlesi by double-crossover mechanisms was feasible.  
 To determine rhIFN-γ production in transfected P. knowlesi, parasite cultures were 
expanded, and their supernatants were harvested and analysed for the presence of rhIFN-γ by 
ELISA with a macaque IFN-γ ELISA kit. rhIFN-γ was detected in culture supernatants from 
parasites transfected with plasmid pDB.DTM.DB/AB.γMM.DB, and the integration construct but 
not from control cultures (Table 1). The results further suggested that both episomal and 
chromosomal expression of IFN-γ produced similar amounts (Table 1) and that empty vector-
transfected parasites are equivalent to wild-type parasites. In all subsequent experiments, 
episomally transfected parasites were used.  
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 The time course of rhIFN-γ production was evaluated in order to define the kinetics of 
rhIFN-γ release into culture medium. Cultures of rhIFN-γ-producing parasites were initiated 
at the schizont stage; supernatants were harvested at 6 h intervals and assayed for rhIFN-γ by 
ELISA. Culture medium was completely replaced at each harvest time point. rhIFN-γ was 
detected in the culture supernatants only after the rupture of schizonts (Fig. 2A).  
 N-glycosylation of IFN-γ protects the protein from rapid degradation by proteases [47]. 
However, malaria parasites have severely reduced capacity for N-glycosylation of proteins 
[48], prompting us to determine the in vitro stability of P. knowlesi-produced IFN-γ. It would 
be expected that highly unstable rhIFN-γ would be detected only immediately following 
schizont rupture. Evaluation of the stability of rhIFN-γ showed that, in the presence or 
absence of infected erythrocytes, the concentration of rhIFN-γ in the supernatant did not 
change significantly over a 30 h period (Fig. 2B). 
 
 Table 1. IFN-γ release from P. knowlesi following integration dependent transfection 
 
Culture Transfection construct IFN-γ release 
(pg/ml)a 
Wild type parasites - 11.8 
Red blood cellsb - 11.8 
Transfected 
parasites: 
Integration 
 
p140K/DA.DTM.DB/AB.γMm.DB/140K 
 
         1853.5 
Integration control 
Episomal 
Episomal control 
p140K/DA.DTM.DB/AB..DB/140K 
pDB.DTM.DB/AB. γMm.DB 
pDB.DTM.DB/AB.-.DB 
10.0 
         1552.0 
11.0 
 
 
a Values show the IFNγ  concentration from 5 × 108 parasites cultured for 24 h and analyzed by 
ELISA. 
b Complete culture medium with culture erythrocytes but lacking parasites. 
This culture was incubated under the same conditions as the other cultures. 
 
 
P. knowlesi-produced rhIFN-γ is bioactive. The standard procedure for determining 
bioactivity of IFN-γ is to test the antiviral cytopathic effect [2, 41, 49, 50, 41]. To determine 
bioactivity of rhIFN-γ in P. knowlesi culture supernatants using an antiviral cytopathic effect 
assay, HEp2 cells [41] were incubated overnight with parasite culture supernatants. The cells 
were subsequently challenged with VSV and observed 24 h later for cytopathic effect. The 
HEp2 cells were protected from VSV cytopathic effect by culture supernatants from parasites 
transfected with the rhIFN-γ expression plasmid, but not by control supernatants (Fig. 3A). 
Protection from cytopathic effect was abrogated by preincubation with a neutralising anti- 
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IFN-γ antibody [41], demonstrating that the protection was mediated by rhIFN-γ.  
 
 
 
Figure 2. Characteristics of P. knowlesi produced rhIFN-γ. A., In vitro-transfected P. knowlesi H 
strain-produced rhIFN-γ coincides with schizont rupture. Schizont-stage P. knowlesi parasites were 
transfected in vitro to express rhIFN-γ under the stage-specific P. berghei apical membrane antigen 1 
promoter. The release of rhIFN-γ was assayed by ELISA . The graph shows the relationship between 
parasite developmental stage and release of rhIFN-γ over  a period of 30 h. The concentration of 
rhIFN-γ was analysed in culture supernatants harvested every 6 h. In order to assess rhIFN-γ 
production during each 6 h period, culture medium was completely replaced at each sampling time 
point. The developmental stage of the malaria parasites was determined at each time point and is 
expressed as a percentage of the total parasitaemia. The dotted lines show the accumulated 
concentration of rhIFN-γ in parasite culture supernatants during the 6 h sample windows. The bars 
represent the percentage of ring (    ), trophozoite (    ), and schizont (   ) stages at the time of harvest. 
B., In vitro stability of P. knowlesi-produced rhIFN-γ culture supernatants were harvested from rhIFN-
γ-producing parasites, diluted 1:1 with fresh culture medium, and incubated with (gray bars) or without 
(open bars) wild-type P. knowlesi-infected erythrocytes over a 30-h period. At various timepoints, the 
rhIFN-γ concentration was determined by ELISA. The results represent an average of three 
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experiments ± standard deviation 
 
The concentration of rhIFN-γ in parasite culture supernatants was calculated at 125 antiviral 
units per 5× 108 schizonts.  
  Bioactive IFN-γ activates blood cells to release TNF-α [42]. To determine whether 
culture supernatants from rhIFN-γ-producing P. knowlesi activate rhesus whole blood cells to 
release TNF-α, blood was obtained from a rhesus monkey and incubated with culture 
supernatants from rhIFN-γ-producing parasites. Whole-blood-cell culture supernatants were 
harvested and assayed for TNF-α release. Significant TNF-α was released by whole blood 
cells incubated with culture supernatants from rhIFN-γ-producing parasites (Table 2). The 
release was blocked when culture supernatants from rhIFN-γ-producing parasites were mixed 
with neutralising antibody against human IFN-γ prior to incubation with whole blood cells 
(Table 2), confirming that activation of rhesus whole blood cells to release TNF-α was 
mediated via rhIFN-γ. TNF-α release from whole blood cells incubated with culture 
supernatants from control cultures was below detection levels (Table 2).  
IFN-γ activates monocytes and macrophages to upregulate CD64 and MHC class II DR 
antigens [42– 45]. To determine the effect of culture supernatants from IFN-γ -producing P. 
knowlesi on the expression of CD64 and MHC class DR by monocytes from naïve rhesus 
monkeys, the whole blood was incubated with parasite culture supernatants, harvested, 
stained, and analysed by FACS for expression of CD14, CD64, and MHC class II DR 
antigens. Incubation of rhesus monkey blood cells with culture supernatant from rhIFN-γ-
expressing P.knowlesi resulted in an increased number of CD14+ cells expressing CD64 and 
MHC class II DR (Fig. 3B). Neutralisation of IFN-γ inhibited this effect. Supernatants from 
control parasites and cell culture medium had no effect on the number of CD14+ cells 
expressing CD64 and MHC class II DR.  
P. knowlesi-produced rhIFN-γ   had no marked effect on in vitro parasite 
multiplication. The in vitro growth rate of rhIFN-γ-producing parasites was comparable to 
that in wild type and control cultures (data not shown), indicating that the production of 
rhIFN-γ had no marked effect on parasite production.  
 
 
DISCUSSION 
In this paper, we show that P. knowlesi parasites, transfected with an rhIFN-γ gene under 
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control of the heterologous P. berghei apical membrane antigen 1 promoter, express bioactive 
IFN-γ. This is the first example of a host molecule being produced by a malaria parasite. It 
demonstrates that the malaria parasite transcription and translation machinery can effectively 
express a bioactive host cytokine.  
Secreted malaria parasite proteins have to be transported across three bilayer membranes 
before getting out of the infected erythrocyte [51]. In order to determine the release 
characteristics of rhIFN-γ, time course experiments were done in vitro. The data shows that 
rhIFN-γ is released into culture medium after schizont rupture. Since the heterologous 
pbama-1 promoter restricts expression to late-stage schizonts in P. knowlesi (Ozwara et al., 
unpublished data), it is not possible to determine from these experiments whether rhIFN-γ is 
actively secreted into the culture medium or whether it is released from parasitised cells 
during schizont rupture. However, rhIFN-γ minimally has to be secreted across one set of 
membranes to reach the parasitophorous vacuole, suggesting that the parasite effectively 
recognises higher eukaryotic secretion signals.  
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Figure 3A. Antiviral cytopathic effects of P. knowlesi released rhIFN-γ. The bioactivity of rhIFN- γ 
in parasite culture supernatants was determined by an antiviral cytopathic effect assay. Strong 
antiviral activity, as measured by the inhibition of the cytopathic effect, was observed in culture 
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supernatant from rhIFN- γ -expressing parasites (V) but not from wild-type parasites ({) and parasite 
culture medium (Ì). The antiviral activity was abrogated when culture supernatants from rhIFN-γ-
producing parasites were preincubated with neutralising antibodies ().   
 
 
Figure 3B. FACS analysis. Rhesus monkey whole blood cells were incubated with culture 
supernatants from IFN-γ-producing P. knowlesi parasites and controls for 48 h and subsequently 
analysed for CD14+ cells. Within the CD14+ cell population, the expression of CD64 and MHC class 
DR was analysed without anti- IFN-γ antibody (   ) or with anti- IFN-γ antibody (   ). 
 
  
Developmentally regulated promoters that restrict expression to the ring and trophozoite 
stages would be required to analyse the secretion process in more detail [52]. It is noteworthy 
that the rhIFN-γ produced by the parasites has no marked effect on parasite growth in vitro. 
This indicates that the cytokine itself, either present in the culture supernatant or accumulated 
in the infected cell, has no direct effect on parasite viability. 
 Arakawa et al. [53] showed that bioactivity of IFN-γ depends on protease processing of 
the carboxyl end of the protein. Furthermore, stable and bioactive IFN-γ exists as a 
noncovalent homodimer [54]. The fact that bioactive rhIFN-γis produced in P. knowlesi 
suggests that the molecule is properly processed and present in the homodimeric form. 
Interestingly, at in vitro culture concentrations, rhIFN-γwas stable for at least 30 h. This 
duration is likely to be sufficient for in vivo activity.  
 For example, despite clearance from rhesus monkey circulation within 6 h of exogenous 
administration [30], IFN-γ was protective in Plasmodium cynomolgi-infected rhesus monkeys 
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[22], suggesting that stability of IFN-γ for 6 h could be sufficient for mediating in vivo 
bioactivity in the monkeys. 
 We expressed IFN-γ because it is a key effector cytokine in protection against malaria, 
especially during the liver stages [13, 15–17, 19]. Studies in humans and animal models 
looking at endogenously produced and exogenously administered IFN-γ have shown that the 
cytokine is also required for protection against blood-stage infection [21, 22, 24, 25, 27, 29]. 
In order to determine the immunomodulatory effect of rhIFN-γ-expressing parasites during 
the malaria liver-stage infection, the host must be inoculated with sporozoites. Integration 
into the genome of the cytokine expression construct is required to express rhIFN-γ in the 
liver stages, since episomally transfected parasites undergo random segregation of plasmids 
[55], and in the absence of drug pressure during development in the mosquito, the plasmids 
could be lost. Therefore, we generated parasites expressing rhIFN-γ after integration-
dependent transfection. The levels of rhIFN-γ produced were similar to those of episomally 
transfected parasites. 
 
Table 2. TNFα release from rhesus monkey whole blood cells  
 
Activation Sample TNF-α release (pg/ml) 
in 6 hours 
Culture supernatant from wild type parasites <<a 
Cell culture medium from control cells << 
Commercial human IFN-γ (250 pg)b 168 
Culture supernatant from IFN-γ producing parasites (400 pg/litre)c 265 
Culture supernatant from IFN-γ producing parasites (400 pg/litre) b  
Pre-incubated with neutralizing antibody d 
 
 
<< 
Bacterial lipopolysaccharide (100 pg) 808 
 
a <<, below detectable levels. 
b Commercial human IFN-γ was purchased from U-Cytec. 
c Concentration of IFN-γ in the culture supernatants as estimated by ELISA. 
d Neutralizing antibody was antimacaque IFN γ antibody from U-Cytech. 
 
 It is now feasible to generate malaria parasites expressing bioactive host cytokines, to 
characterise the capacity of the parasites to immunomodulate the infection, and to 
characterise the role of the expressed cytokine in host responses to malaria. It is important 
that the safety of cytokine-expressing parasites in vivo be determined prior to such 
experiments. A preliminary safety study with a small number of rhesus monkeys showed that 
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the levels of rhIFN-γ released by transfected malaria parasites were well tolerated by rhesus 
monkeys (data not shown). During this safety study, aspects of the immune responses of 
animals exposed to the rhIFN-γ parasites were compared with those of animals that had 
received parasites transfected with a control vector. All four animals exposed to rhIFN-
γ parasites had a marked expansion (2.5- to 5-fold) of the γδT-cell compartment within 2 
weeks of the start of infection compared with five controls (1- to 2-fold expansion). A more 
comprehensive analysis of host responses to rhIFN-γ-expressing P. knowlesi in M. mulatta is 
ongoing. However, this study already clearly demonstrates that the rhIFN-γ produced by the 
parasites is bioactive in vivo. In conclusion, the expression of host cytokines by malaria 
parasites, as demonstrated in our study, offers a new approach to explore the development of 
attenuated and immunopotentiated malaria vaccines. 
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ABSTRACT 
 There are relatively few monoclonal antibodies (mAb) that have been characterised for 
their applicability in studies on the immune system of various nonhuman primates. In the 
present study, we identified a large number of mAb that can be used in future immunological 
studies in three different nonhuman primates, i.e., chimpanzees, rhesus macaques, and 
squirrel monkeys. The reactivity of 161 anti-human mAb to T-cell antigens and cytokine 
receptors were tested on peripheral blood mononuclear cells (PBMC) from the three primate 
species by flow cytometric analysis. A total of 105 (65%), 73 (45%), and 68 (42%) antibodies 
reacted with PBMC from chimpanzees, rhesus macaques, and squirrel monkeys, respectively. 
Out of the 161 mAb, 38 reacted with all three species and 112 reacted with one or two of the 
species. No specific reaction was observed with mAb to receptors to GM-CSF, 4-1BB, FLT3, 
FLX2, common β-chain, IL-l (type I receptor), and IL-8. 
 
INTRODUCTION 
 Nonhuman primates are frequently used as animal models for a broad range of disciplines, 
including immunological, drug, and vaccine development studies against human diseases [1, 
2, 3, 4]. Optimal results from such studies require a thorough knowledge of the immune 
response in the nonhuman primate but the availability of characterised monoclonal antibodies 
(mAb) against various nonhuman primate immune systems is limited. However, due to the 
close phylogenetic relationship between nonhuman primates and man, their immune systems 
have many similarities [5, 6] and several studies have previously reported on the reactivity of 
mAb defined against human haematopoietic cells to cross-react with similar, if not identical, 
molecules expressed by cells from a variety of nonhuman primate species [5-12]. The ever-
growing list of anti-human mAb, together with the identification of novel structures on 
human cells that play an important role in immune functions, e.g., co-stimulatory activity, 
prompted us to examine the reactivity of these new reagents to cross-react with cells from 
chimpanzees (Pan troglodytes), rhesus macaques (Macaca mulatta), and squirrel monkeys 
(Saimiri sciureus). In the present study, a large panel of mAb against human T-cell markers 
and cytokine receptors were investigated for their reactivity with peripheral blood 
mononuclear cells (PBMC) from these three nonhuman primate species. 
 
 
MATERIALS AND METHODS 
 Animals. From each of the three nonhuman primate species, three adult animals of either 
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sex were used. The animals were housed at the Biomedical Primate Research Centre 
(Rijswijk, The Netherlands) (BPRC) primate facilities. The squirrel monkeys were naturally 
infected with Trypanosoma cruzi, one chimpanzee was infected with HIV, and the rhesus 
macaque was infected with SlV. 
 Isolation and preservation of PBMC. Heparinised blood was drawn from each animal 
by either venipuncture (chimpanzees and rhesus macaques) or cardiac puncture (squirrel 
monkeys) and used as a source of PBMC. PBMC were isolated from peripheral blood by 
density gradient centrifugation using lymphocyte separation medium (Organon Teknika, 
Durham, NC). Interface cells were collected, washed twice with RPMI 1640 (Gibco, Paisly, 
Scotland), adjusted to 1 x 107 cells/ml, and either used immediately or cryopreserved for later 
use. To cryopreserve cells, 1 x 107 cells were resuspended in 1 ml of RPMI 1640 containing 
10% dimethyl sulfoxide (DMSO) and 25% heat-inactivated foetal calf serum (FCSi), placed 
in cryocell freezing containers filled with cold isopropanol, and kept at -80°C overnight. The 
cells were stored at -135°C in a cryostar ultralow freezer (New Brunswick Scientific, USA) 
until use. 
 Prior to use, cryopreserved cells were thawed rapidly in a water bath at 37°C and 
immediately diluted 1:1 with RPMI 1640 medium containing 20% FCSi, 2 mM L-glutamine, 
100 µg/ml gentamycin followed by two washes in the same medium. Cells were adjusted 
again to 1 x 107/ml after the last wash. 
 Monoclonal antibodies. Antibodies against T-cell surface antigens and cytokine receptors 
were part of the panel presented during the VI International Workshop and Conference on 
Human Leukocyte Differentiation Antigens. The mAb names and specificities are included in 
the Results section. Further details on the mAb have been published elsewhere [13, 14]. 
 Flow cytometric analysis. Single-label indirect immunofluorescence was used to screen 
the mAb for their reactivity against nonhuman primate PBMC. In short, 5 ×105 cells were 
dispensed into each FACS tube on ice and washed in PBS pH 7.3 containing 2% FCSi and 
0.1 % azide (FACS buffer). After centrifugation, the supernatant was aspirated, the cells 
mixed with 10 µl of antihuman mAb diluted 1:50 in FACS buffer, and incubated on ice for 
30 min. After washing with cold PBS, the cells were resuspended in 15 µl of goat antimouse-
PE conjugated antibody (Dako, Glostrup, Denmark) diluted 1:20 in FACS buffer, and 
incubated for 30 min on ice. Free antibody was washed off with cold PBS and cells were 
immediately fixed for 1-12 hr in 1 % formalin. Prior to FACS analysis, the cells were washed 
and resuspended in PBS. Fluorescence was measured on a FACSort (Becton Dickinson, 
Mountain View CA). Cells were first analysed by forward and right-angle scatter and the 
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lymphocyte population was gated to assess reactivity of the mAb with PBMC. In each 
sample, 5,000 events in the lymphocyte gate were measured. Data analysis was performed 
using CellquestTM software (Becton Dickinson) to determine frequencies and mean 
fluorescence intensities. 
 The reactivity of the mAb with PBMC was scored as type 0, 1, 2, or 3, depending on 
histogram patterns that emerged during FACS analysis (Fig. 1). In short, basal levels were set 
between fluorescence intensity 100 and 101. Type 1 reactivity was characterised by a slight 
shift of the basal peak toward a fluorescence intensity between 101 and 2-5 x 101.  
Type 2 and type 3 reactivity were characterised by a peak at basal level with a second peak 
between fluorescence intensity 101 and 103 for type 2 and between 103 to 104 for type 3 
reactivity. 
 
 
 
 
 
  
 
 
 
Figure 1. Histogram patterns observed during FACS analysis of PBMC from chimpanzees, 
rhesus macaques, and squirrel monkeys stained with antihuman mAb. 
 
 
RESULTS 
From the total of 161 anti-human mAb analysed, 58 antibodies were directed against T-
cell surface antigens, 99 against various cytokine receptors, and 4 were directed against 
unknown antigens (Table 1). Of the antibodies against T-cell surface antigens, 81 %, 68%, 
and 63% reacted with PBMC from chimpanzees, rhesus macaques, and squirrel monkeys, 
respectively. For the cytokine receptors, 58%, 34%, and 32% of the mAb reacted with PBMC 
from chimpanzees, rhesus macaques, and squirrel monkeys, respectively. 
There was no individual variation observed in the reactive mAb against T-cell antigens in  
PE-  
control 
Type 3Type 2Type 1
10410
3
PE-intensity 
100 101 
102
Chapter 5 
 66
Table 1. Summary of antigens tested and number of reactive antibodies that emerged 
  Number of positive antibodies 
Reactivity Number tested Chimpanzees Rhesus macaques Squirrel monkeys 
C02 4 4 4 2 
C03 4 4 1 3 
C04 13 12 7 8 
C05 5 5 1 5 
C07 3 3 3 1 
C08 12 11 10 8 
C027 3 3 3 2 
C028 4 4 4 2 
COW109 3 0 1 1 
C030L 2 0 2 2 
C040L 5 0 3 2 
MSPR 2 0 1 1 
GM-CSFR 3 0 0 0 
IL-4R 2 0 0 1 
IL-7R 2 2 2 1 
SCFR 11 1 1 2 
4-1 BB 1 0 0 0 
gp130 28 24 22 9 
IL-2Ra 5 3 0 3 
C071 1 1 1 1 
FLT3 2 0 0 0 
OX40 2 1 1 0 
IL-6R 11 11 8 7 
FLT3/FLX2 2 0 0 0 
FAS 10 10 5 1 
common 1 0 0 0 
IL-1R type 1 2 0 0 0 
IL-3Ra 1 1 0 0 
IL-2R 2 2 1 1 
IL-8R 1 0 0 0 
IL-1R type II 1 0 1 1 
TNFR/75kO 2 2 0 1 
IL-2Ry 6 1 0 1 
TNFR/55kO 1 0 0 1 
UNKNOWN 4 0 0 1 
TOTAL 161 105 73 68 
% 100 65 45 42 
 
 
 
 
Table 2. Reactivity of mAbs specific for human T cell surface antigens with PBMC from
chimpanzees, rhesus macaques, and squirrel monkeys 
CD number mAb name Chimpanzees Rhesus macaques Squirrel monkeys
2 LT2 3* 3 3 
2 MEM-65 3 3 0 
2 L303 3 3 0 
2 RPA-2.10 3 3 3 
3 LT3 3 3 3 
3 IP30 3 0 or 1 ** 1 
3 Wu948 3 0 or 1 2 or 3 
3 131F26 3 0 0 
4 HIT4a 3 3 2 or 3 
4 HIT4b 3 3 2 or 3 
    (continued)
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Table 2. Reactivity of mAbs specific for human T cell surface antigens with PBMC from
chimpanzees, rhesus macaques, and squirrel monkeys (continued) 
CD number mAb name Chimpanzees Rhesus macaques Squirrel monkeys
4 LT4 3 0 0 
4 MEM-16 0 3 0 
4 IP34 3 0 0, 1, or 2 
4 193-19 3 0 0 
4 anti-C04 3 0 or 1 2 
4 L3 3 3 3 
4 RPA-T4 3 0 or 2 2 
4 OKT4A 3 3 2 or 3 
4 R2B7 3 0 or 2 0 
4 8F4 3 3 3 
4 LT4(UHKT) 3 3 2 
5 HI211 3 0 1 
5 HISM2 3 0 1, 2 or 3 
5 SM3 3 1 1 or 3 
5 MEM-128 3 0 1 or 2 
5 7.8 3 0 1 or 2 
7 LT7 3 3 3 
7 MEM-186 3 3 0 
7 BE57 3 3 0 
8 HI212 3 3 0 
8 HITBd 3 3 3 
8 IP48 3 3 3 
8 L2 3 2or3 3 
8 BU88 3 3 3 
8 ITI-5C2 3 3 3 
8 5F2 0 0 0 
8 RPA-T8 3 3 3 
8 OKTBf 3 3 3 
8 7B12/1G11 3 3 3 
8 VIT8b 3 3 0 
8 MC08 3 0 or 3 0 
27 203-6 3 1 or 3 3 
27 L128 3 1 or 3 3 
27 1M 3 1 or 3 0 
28 204-12 3 3 2 or 3 
28 B-T3 3 3 3 
28 B-L8 3 3 0 
28 4B10 3 3 0 
w109 701 0 0 0 
w109 8A3 0 0 2 or 3 
w109 02 0 0 0 
30L M81 0 1 2 or 3 
30L M82 0 1 0 or 2 
40L TRAP-1 0 1 0 
40L M79 0 1 0 
40L M90 0 0 or 2 0 or 2 
40L M92 0 2 2 or 3 
40L 39-106 0 0 or 2 0 
*0, 1, 2, and 3 are reactivity patterns that emerged during FACS analysis of PBMC from chimpanzees,
rhesus macaques, and squirrel monkeys stained with anti-human mAbs. For details see Figure 1. 
**The presence of more than one type of reactivity reflects intraspecies variation of binding.    
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the chimpanzees. However, there was intraspecies variation with some mAb against T-cell 
antigens in rhesus macaques (20%) and squirrel monkeys (26%). Intraspecies variation in 
reactivity of mAb against cytokine receptors was observed in all three species. The most 
variation was observed in rhesus macaques (31%); chimpanzees and squirrel monkeys 
showed 13% and 11% intraspecies variation, respectively. 
 T-cell surface antigens. Antibodies against 11 T-cell surface antigens were tested for 
reactivity with PBMC from chimpanzees, rhesus macaques, and squirrel monkeys. Most of 
the tested mAb reacted with chimpanzee cells and showed type 3 reactivity (Table 2). Of the 
mAb reactive with rhesus PBMC, most were type 3 while there was more variety in the type 
of reaction against markers of PBMC derived from squirrel monkeys (Table 2). In total, 22 
mAb directed against T cell surface antigens reacted with PBMC from all three species 
(Table 2). 
 Cytokine receptors. A panel of mAb against 23 different cytokine receptors on PBMC 
was tested. Four antibodies whose reactivities in the human had not been fully characterised 
were also included (Table 3). Of the antibodies tested, several reacted with antigens on cells 
from all three species, i.e., with IL-7R, gp130, CD71, FAS, IL-2R/3, and IL6R (Table 3). 
Some antibodies only reacted with PBMC from one or two of the three species, whereas no 
mAb reactive with GM-CSFR, 4-lBB, FLT3, FLX2, common β, IL-IR type I, and IL-8R 
were found (Table 1). 
 
DISCUSSION 
 
 In this study, we describe the reactivity of 161 antihuman mAb with PBMC from three 
different non human primate species, i.e., chimpanzees, rhesus macaques, and squirrel 
monkeys. We show that of this panel, 38 mAb reacted with PBMC from all three species 
tested and 112 mAb reacted with PBMC of one or two of the three species tested. These 
reactive antibodies most likely recognise antigens similar to those on human PBMC, as has 
been demonstrated in earlier studies [5, 6, 8, 10, 11]. Since these mAb have not been tested 
before in these three species, this increases the number of mAb that can be used in 
biomedical studies with these primate species. 
 Our results show that 65% of the tested mAb reacted with chimpanzee PBMC, whereas 
only 45% reacted with rhesus macaques and 42% with squirrel monkeys. This agrees with the 
assumption that reactivity between anti-human mAb and nonhuman primate systems 
increases with a decrease in phylogenetic distance [6, 8, 15]. The data from the present study 
also show that within the same species, several mAb reacted with one individual but not with  
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Table 3. Reactivity of mAbs specific for human cytokine receptors with PBMC from
chimpanzees, rhesus macaques, and squirrel monkeys* 
Reactivity mAb name Chimpanzees Rhesus macaques Squirrel monkeys 
MSP-R 101 0* 0 or 2* 1 
MSP-R 102 0 0 0 
GM-CSF-R SCO6 0 0 0 
GM-CSF-R SCO4 0 0 0 
GM-CSFR hGMCSFR-M1 0 0 0 
SCFR A3C6E2 0 0 0 
SCFR 57A5 0 0 0 
SCFR 10402 0 0 0 
SCFR NU-C-KIT 0 0 0 
SCFR L15 0 0 0 
SCFR NU-SCF2 0 0 0 
SCFR NU-SCF1 0 0 0 
SCFR MTK1 0 0 1 
SCFR MTK2 3 0,2 or 3 1 
SCFR 17F11 0 0 0 
SCFR 95C3 0 0 0 
4-1 BB ANTI-4-1 BB/4B4 0 or 2 0 0 
gp130 B-K5 2 1 or 2 0 
gp130 B-K11 0 0 0 
gp130 B-L9 2 1 or 2 0 
gp130 B-N4 2 1 or 2 0 
gp130 B-N9 2 1 or 2 0 
gp130 B-R9 2 1 or 2 0 
gp130 B-S1 2 1 or 2 0 
gp130 B-T6 2 1 or 2 1 
gp130 B-T12 2 0 or 2 0 
gp130 B-T2 0 or 2 1 or 2 1 
gp130 B-T9 0 0 0 
gp130 B-P8 2 1 or 2 0 
gp130 B-P4 2 0 or 1 0 
gp130 B-S12 2 1 or 2 0 
gp130 B-R3 2 1 or 2 1 
gp130 B-S8 2 1 or 2 1 
gp130 A2 2 1 or 2 1 
gp130 B1 2 1 or 2 1 
gp130 C2 1 1 or 2 0 
gp130 04 0 0 0 
gp130 E1 2 0 or 1 0 
gp130 F2 2 1 or 2 1 
gp130 G1 0 0 0 
gp130 H1 2 0,1 or 2 0 
gp130 11 2 0,1 or 2 0 
gp130 J1 2 1 or 2 1 
gp130 GPX7 2 1 or 2 1 
gp130 AM64 2 1 or 2 1 
C071 BU56 1 3 1 
OX40 BER-ACT35 2 0 0 
OX40 L106 0 2 0 
IL-1 R type 1 6B5 0 0 0 
IL-1Rtype1 h1L-1 R-M1 0 0 0 or 2 
IL-1R type 2 h1L-1 R2-M22 0 2 3 
IL-2Rα 7G7B6 2 0 1 or 3 
IL-2Rα MEM-145 0 0 0 
   (continued)
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Table 3. Reactivity of mAbs specific for human cytokine receptors with PBMC from
chimpanzees, rhesus macaques, and squirrel monkeys* (continued) 
IL-2Rα MEM-140 0 0 1 
IL-2Rα Wu949 2 0 2 
IL-2Rα H-31 2 0 0 or 1 
IL-2Rα H-31 2 0 0 or 1 
IL-2Rβ 2R-B 0 or 2 0** 0 
IL-2Rβ CF1 2 1** 1 
IL-2Rγ TUGh4 0 0 1 
IL-2Rγ 3B5 0 0 0 
IL-2Rγ 3G11 0 0 0 
IL-2Rγ AG14C 0 0 or 1 0 or 1 
IL-2Rγ AG43C 0 or 1 0 or 1 0 
IL-2Rγ AG184 1 0 or 1 0 
IL-3Rα 9F5 2 0 0 
IL-4R hIL-4R-M57 0 0** 0, 1, or 2 
IL-4R S456C9 0 or 1 0 0 
IL-6R M11 0 or 1 0 3 
IL-6R M91 2 1 or 2*** 3 
IL-6R M164 2 1*** 0 
IL-6R M182 1 or 2 0 or 1 ** 3 
IL-6R M195 0 or 2 1 or 2*** 1 
IL-6R PM1 2 1*** 3 
IL-6R M5 2 2 0 or 2 
IL-7R hIL-7R-M20 3 2 or 3 0 
IL-7R R34.34 3 3 3 
FLT-3 4G8 0 0 0 
FLT-3 BV10 0 0 0 
FLT3/FLK2 SF1.340 0 0 0 
FLT3/FLK2 SF1.394 0 0 0 
FAS 7C11 2 0 0 
FAS OX2 3 3 3 
FAS Anti-Fas-(CH11) 2 0 0 or 2 
FAS B.029 3 3 0 
FAS B.E28 2 or 3 2 0 
FAS B.G27 3 0 0 or 1 
FAS B.G30 1 or 2 0 0 
FAS B.G34 1 2 0 
FAS B.K14 1 or 2 1 0 
FAS B.L25 1 0 0 
IL-3R common 307 0 0 0 
TNFR/55kO htr9 0 or 2 0 1 
TNFR/75kO hTNFR-M1 2 0 3 
TNFR/75kO utr1 2 0 0 or 2 
Unknown G42 0 0 0 
Unknown HIM62 0 0 1 
Unknown M6-12 0 or 1 0 0 
Unknown WH2 0 0 0 
 
 
*0, 1, 2, and 3 are reactivity patterns that emerged during FACS analysis of PBMC from chimpanzees, 
rhesus macaques, and squirrel monkeys stained with anti-human mAbs. For details see Figure 1. 
**Reactivity of mAb with rhesus PBMC also described in reference 5. 
***The presence of more than one type of reactivity reflects intraspecies variation of binding. 
Abbreviations: IL, Interleukin; MSP-R, macrophage stimulating protein receptor; GM-CSFR, 
granulocyte/monocyte colony stimulating factor receptor; SCFR, stem cell factor receptor, TNFR, 
tumour necrosis factor receptor. 
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another. This polymorphic reaction pattern was found for all three species with the cytokine 
receptor mAb panel, and for the rhesus macaques and squirrel monkeys also for the T cell 
surface marker panel. The observed intraspecies variation might reflect differences in 
activation levels between individual animals, possibly due to health status or polymorphism 
in the epitopes. Our findings agree with earlier studies in which polymorphic epitopes were 
demonstrated in T lymphocytes from other New World species, i.e., the spider monkey 
(Atelus fusciceps) and the owl monkey (Aotus trivirgatus) [5, 10]. Also, the finding that 
certain epitopes may be polymorphic in one species but monomorphic in another agrees with 
earlier studies [10].  
 In this study, we did not activate the cells prior to determination of mAb reactivity. 
Therefore, the lack of reactivity of the mAb with the known activation markers Cdw109, 
CD30L, and CD40L in chimpanzees should be treated with caution. The reactivity of these 
mAb with PBMC from rhesus macaques and squirrel monkeys might be due to aspecific 
binding or reflect the presence of circulating activated cells due to infections, although the 
reactivity of these antibodies was similar in the SIV-infected and non-infected rhesus 
macaques. Although it was not the objective of our study, we noticed that in the SlV-infected 
rhesus macaque the reactivity with all gpl30-specific mAb was less than in the uninfected 
monkeys. For all other mAb tested, we have no indication that there are major differences 
between infected and non-infected animals (data not shown). 
 Some of the mAb against the IL-2Rα and β and the IL-6R have been described before 
with respect to their reactivity with PBMC from rhesus macaques [16]. The data from the 
present study in general agrees with the earlier data, with the exception that some IL-6R-
specific mAb that reacted weakly with rhesus PBMC in our study (M91, M164, M182, B-
N12, BFI9, and PMI) were not reactive in the earlier study. One of the possible explanations 
for this discrepancy might be the use of PE-conjugated secondary antibodies in the present 
study, as opposed to FITC-conjugated antibodies in the earlier study since, in general, PE-
conjugated antibodies give a stronger signal than FITC-conjugated antibodies. 
 Antibodies that reacted with PBMC from one species but not with PBMC from the other 
species were detected in this study. These antibodies could be used to study species-specific 
variation in the expression of epitopes they determine. In the present study, a large number of 
mAb that may be useful in immunological studies that use nonhuman primates have been 
identified. Presently, we are further characterising the reactivity of these mAb to determine 
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their value in the analysis of specific immunological processes in experiments using various 
nonhuman primate models. 
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ABSTRACT 
 Our studies have previously shown that in vitro transfected P. knowlesi express bioactive 
rhesus IFN-γ. Preliminary safety and efficacy studies for these parasites were undertaken by 
infecting ("vaccinating") rhesus monkeys in vivo and measuring safety parameters and 
immune responses. In addition, immune response parameters were also measured in the 
monkeys after challenge with virulent P. knowlesi parasites. In total, four monkeys received 
IFN-γ expressing P. knowlesi and another five were inoculated with control parasites. All the 
animals developed patent parasitaemia; this peaked significantly earlier in vaccinated 
monkeys compared to the controls. Clinical chemistry and haematology data from these 
monkeys during the vaccination phase showed no abnormalities. This indicated that IFN-γ 
expressing parasites were safe and well tolerated in rhesus monkeys. Analysis of cellular 
changes revealed a significant increase in γδT cells in vaccinated animals compared to the 
controls, indirectly showing that IFN-γ released by parasites was bioactive in vivo. 
Subsequently, all animals were challenged with virulent P. knowlesi parasites. This resulted 
in a longer pre-patent infection period in vaccinated animals compared to the controls. This 
indicated that IFN-γ expressing P. knowlesi partially protected rhesus monkeys against 
virulent infection after a single vaccination. Analysis of cellular immune responses showed 
that peripheral blood cells from vaccinated monkeys showed higher levels of proliferation 
against crude parasite antigen than the controls. However, as the parasitaemia increased in 
these animals, the cellular responses waned.  
 
INTRODUCTION 
 More than one quarter of the world population is at risk from malaria and between 1 and 
2.7 million of them die annually [1]. Rapid spreading of parasite resistance to drugs of choice 
in the absence of a vaccine has made it difficult to combat the disease. New strategies, 
especially vaccines (being the most cost-effective way to prevent a disease) are urgently 
needed. Two observations suggest that a live malaria vaccine may be achievable. First, 
immunisation with attenuated sporozoites induces sterile protection in mice and humans[2, 
3], mediated via IFN-γ dependent mechanisms and we have recently published data [4] 
showing that chimpanzees can be protected. Hence a vaccine based upon attenuated parasites 
is feasible. Second, adults in areas endemic for malaria develop variable levels of clinical 
immunity [5].  
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 Studies have shown that pathogens expressing host cytokines in vivo become 
immunopotentiated, subsequently manipulating host-pathogen interaction and stimulating 
protective host responses [6-8]. We reasoned that parasites expressing immunomodulatory 
cytokines such as IFN-γ may become immunopotentiated and induce protective host 
responses better than normal parasites. P. knowlesi, a natural parasite of macaques [9], is an 
attractive experimental system to use in testing this assumption because it has potential use in 
humans (it is known to infect humans and recently an outbreak of infections has been 
reported in Asia) and it is closely related to human malaria parasites [10]. Recently P. 
knowlesi blood stage parasites were adapted to long term in vitro culture [11]. In contrasts to 
in vivo passaged parasites, the long term in vitro cultured P. knowlesi parasites tended to 
induce chronic parasitaemia in rhesus monkeys, characterised by low-level peak parasitaemia 
(0.2 to 1%). These parasites were used to generate P. knowlesi that expresses rhesus IFN-γ. 
Analysis of these parasites in vitro has shown that they release bioactive rhesus IFN-γ [12]. 
 Repeated exposure to P. knowlesi infection is required to generate protective immune 
responses in monkeys [13], therefore under normal circumstances, animals are not protected 
after a single infection. Cytokine releasing parasites could potentially prime the host to 
destroy the parasites and develop protective responses after a single infection. The 
development of immunopotentiated malaria parasites that protect the host against a virulent 
infection could have far-reaching implications in terms of developing a live malaria vaccine. 
 In rodent and human malaria models, IFN-γ has been shown to play a role in protection 
against malaria blood stages when either endogenously produced [14-16] or exogenously 
administered [17-19]. In addition, administration of exogenous IFN-γ is safe and 
immunogenic in rhesus monkeys when administered in short term [20-23] and when 
expressed by simian immunodeficiency virus [7]. However, exogenously produced cytokines 
could be toxic to the host [24, 25]. Therefore, it is critical to evaluate the in vivo safety of 
IFN-γ expressing parasites. 
 In this report, we evaluated the safety and efficacy of IFN-γ expressing P. knowlesi blood 
stage parasites in vivo by vaccinating rhesus monkeys and measuring parasite development 
and host responses during vaccination and after challenge with virulent parasites.  
 
MATERIALS AND METHODS 
 Animals. Ten adult intact malaria-free Macaca mulatta of either sex and weighing six 
kilos and above were used in the study. Each animal was housed individually in single cages 
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to avoid blood contact that could lead to cross infection. All experimental animal work in 
these studies was carried out under protocols approved by the independent Institutional 
Animal Care and Use Committee and performed according to Dutch and European laws. 
 Parasites. In vitro episomal transfected P. knowlesi H strain parasites used during 
vaccination were generated as described in Ozwara et al., [12]. Parasites from on going 
cultures were used to inoculate the monkeys. Wild type P. knowlesi H strain [26] parasites 
clone Pk1(A+) [27] for challenge infection were retrieved from liquid nitrogen followed by 
overnight in vitro culture. 
 Vaccination. Vaccinations were done in two independent experiments.  Experiment 1 
comprised 2 test and 2 control monkeys. The second experiment had 6 animals, 3 vaccinated 
and 3 control monkeys. Each vaccinated monkey was i.v. injected with 5×108 genetically 
modified blood stage P. knowlesi parasites in 1 ml of RPMI 1640 medium. Control monkeys 
were injected with P. knowlesi genetically modified with a similar plasmid but without the 
rhesus IFN-γ gene. Parasites used in inoculating both vaccinated and control animals were 
cultured under identical conditions. The time between parasite inoculation of the first and last 
animal (randomly divided over the two groups) was 1 h. Peripheral blood was obtained from 
each animal prior to parasite inoculation and used to determine pre-infection values for 
cytokine and cell surface maker levels, peripheral blood mononuclear cell (PBMC) isolation, 
antibody responses and clinical chemistry and haematology analysis. Thereafter, blood was 
obtained from each animal on a weekly basis to determine responses during infection. The 
general health status of the animals was monitored by regularly determining body 
temperature, weight, appetite and general behaviour. Body temperature and weight of animals 
was measured on a sedated animal at the time points of bleeding. Appetite was evaluated by 
closely monitoring the feeding habits of the animals. Finger prick blood was regularly taken 
from all animals for analysis of parasitaemia. Parasitaemia was determined in thin smears by 
separate enumeration of infected and total erythrocytes. Pyrimethamine (1 mg/kg body 
weight) was orally administered on a daily basis to maintain episomes in the parasites. 
Animals were radically cured when the level of parasitaemia reached 5% or higher, by 
injection of chloroquine sulphate (Rhone-Poulenc Rorer, Paris, France) at a dosage of 5 
mg/kg daily for three days. At three weeks post-vaccination all untreated animals were 
radically cured with chloroquine sulphate. 
 Challenge infection. At five weeks post vaccination, all vaccinated and control monkeys 
in both vaccination experiments were challenged by i.v. injection of 1×105 virulent blood 
stage P. knowlesi parasites (in 1 ml of RPMI 1640 medium). Challenged animals were bled 
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immediately prior to parasite inoculation to determine pre-challenge immune, clinical 
chemistry and haematology values. Subsequently, blood was obtained from each animal on a 
weekly basis to determine responses during challenge infection. Finger prick blood was 
obtained from challenged animals on a daily basis starting five days post challenge infection 
and continued until the end-point. Animals were radically cured when the level of 
parasitaemia reached over 5%, by injection of chloroquine sulphate. Otherwise, experiments 
were stopped at two weeks post-challenge by treating the animals with chloroquine sulphate. 
 Clinical Chemistry and Haematology. Peripheral EDTA blood was obtained from all 
monkeys as described above, and analysed in a Sysmex R500 (Sysmex, Kobe, Japan) to 
determine reticulocyte changes. A Sysmex SF 3000 (Sysmex, Kobe, Japan) was used to 
analyse for changes in haematocrit and red blood cells, haemoglobin, and leukocytes. To 
determine kidney and liver functions, serum was processed from part of peripheral blood and 
analysed in a COBAS INTEGRA 400 (Roche, Schweitz, Germany) to measure albumin, liver 
enzymes AST, ALT and lactate dehydrogenase, creatinine, total bilirubin, and urea. The data 
were compared with normal values obtained from over 500 naïve rhesus monkeys of different 
ages and sexes.  
 Lymphocyte proliferation assays. Lymphocyte proliferative responses were determined 
in both vaccinated and control monkeys. Previously isolated PBMC were cultured in 
triplicate in 96-well microtitre plates. The cells were stimulated with crude P. knowlesi H 
strain whole parasite antigen for 72h. Cultures were then pulsed with [3H]thymidine and 
cultured for 18h at 37°C prior to harvest and counting in a Top Count NXT Microplate 
Scintillation and Luminescence Counter (Perkin Elmer). 
 FACS analysis. Rhesus monkey peripheral blood was obtained as described above and 
100 µl was lysed with FACS lysis solution (BD, Heidelberg, Germany). Lysed blood was 
stained with cross-reactive antibodies against human CD3, CD20, CD64, MHC class II DR, 
CD14 and pan γδT cell receptor surface markers (BD). These markers stained for T and B 
cells, γδT cells and activated monocytes. The stained cells were analysed for cell surface 
marker expression by fluorescence activated cell sorting (FACS) as previously described 
[28], except that 1×105 cells were scanned and analysed. 
 Statistical analysis. Parasitaemia curves for several days were compared by two-way 
repeated-measures analysis of variance. Comparison between two groups was made by using 
a two-tailed Student's t test. All statistical calculations were performed with SPSS, version 
7.5 for windows (SPSS, Inc., Chicago, and Ill). 
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RESULTS 
 Vaccinated and control monkeys develop different parasitaemia profiles during 
the vaccination phase. Two studies, each comprising experimental and control animals were 
conducted six months apart under identical conditions.  In one study one animal had to be 
removed from the experimental group for technical reasons unrelated to the experiment. The 
results from these experiments are pooled in what follows to yield data from a total of 4 
experimental and 5 control animals (Table 1).  
  
Table 1. Selected parameters of parasitaemia in monkeys infected with P. knowlesi 
 
 
Animal 
 
Group 
Peak parasitaemiaa 
vaccination 
Pre-patent periodb 
challenge 
  % Parasitaemia Day Day 
C117 Experimentalc 1.4 9 11 
C019 Experimental 0.4 6 9 
C097 Experimental 0.7 9 11 
C017 Experimental 0.6 6 9 
     
C149 Control 0.3 14 NOd 
C143 Control 0.1 16 5 
C151 Control 0.1 16 5 
C039 Control 0.8 14 6 
C096 Control 0.6 14 6 
 
a The highest level of parasitaemia detected in the 21 days that vaccinated monkeys  
   were observed for peripheral parasitaemia. 
b Period from day of challenge to when the day parasites were first detected in peripheral  
   circulation by thin smear method. 
c Experimental monkeys were infected (vaccinated) with IFN- γ expressing P. knowlesi. 
d Peripheral parasitaemia was not detected in the animal during the entire challenge period of 14    
days. 
 
 
 Monkeys in both experiments were vaccinated with 5×108 transfected parasites containing 
either empty expression plasmids (controls) or plasmids allowing the expression of rhesus 
IFN-γ in late stage schizogony. Both IFN-γ expressing and control parasites had similar 
growth rates in vitro prior to vaccination (data not shown). All plasmids contained the 
pyrimethamine resistance cassette and were maintained in the parasite population by treating 
the monkeys with pyrimethamine.  After exposure for 3 weeks these genetically modified 
parasites were removed by chloroquine treatment.  A short period of rest was then allowed 
for washout of chloroquin before vaccinated and control animals were challenged with 1 x 
105 wild-type H strain P. knowlesi parasites (Fig. 1).  
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 All monkeys during the vaccination phase developed patent parasitaemia by day 6 post-
inoculation that developed into a low-level self-regulating parasitaemia (Fig. 2A). When 
compared with controls, vaccinated animals had significantly higher parasitaemias  between 
days 6 to 10 (P<0.007), (Fig. 2A). The peak parasitaemia  was achieved significantly earlier 
(day 8 against day 15, P<0.001) (Table 1). The parasitemia in control monkeys developed in 
similar fashion to that seen in rhesus monkeys inoculated with wild-type culture-adapted P. 
knowlesi H strain, a profile distinct from in vivo passaged parasites ([11] and our unpublished 
data). Animals vaccinated with IFN-γ parasites had a higher cumulative exposure to parasites 
than control animals (Fig 2B).  
 Changes in cellular immune responses were also monitored by FACS analysis of 
peripheral blood. Changes in B-cell, monocyte and most T-cell populations were comparable 
in experimental and control animals (not shown). However there was a significant (2-5 fold) 
increase in γδ T cells in experimental animals as compared to a 1-2 fold increase in controls 
(Fig. 3).  
In blood taken at days 0, 7, 14 and 21 PBMC proliferative responses to crude P. knowlesi 
H strain antigen remained within background levels. Serum IgG levels were comparable 
between the two groups, suggesting that exposure to IFN-γ had not significantly enhanced 
humoral responses.  
 To determine whether animals had been exposed to parasites of the expected phenotype, 
blood obtained from each monkey immediately prior to chloroquine cure was cultured and 
supernatants analysed by ELISA for IFN-γ expression. Rhesus IFN-γ was detected in cultures 
of parasites derived from each of the experimental animals but was not detected in blood 
from control animals (data not shown).  
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Figure 1. Vaccination and challenge schedule for rhesus monkeys infected with IFN-γ 
expressing and control P. knowlesi parasites. "Vaccination phase lasted 21 days and challenge 
infection followed 2 weeks later. Pyrimethamine treatment (1 mg/kg body weight) during vaccination 
was started less than 24 h post-inoculation. Monkeys were cured with chloroquine at the end of each 
phase. CQ, Chloroquine. 
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Figure 2. Individual monkey (A) and cumulative (B) parasitaemia profile in vaccinated and 
control monkeys 
 
 Host responses during vaccination. To determine whether exposure to IFN-γ expressing 
parasites was well-tolerated, blood samples from vaccinated animals collected on days 0, 7, 
14 and 21 were assessed for haematological and clinical chemistry criteria. Haematological 
values, and clinical chemistry indicators of liver and kidney function remained within normal 
ranges in all the animals (not shown). In addition, the animals were observed for appetite, 
body weight and temperature changes. There were no significant changes in body 
temperature, weight and appetite during the course of vaccination (not shown). 
 Vaccinated rhesus monkeys show a modified course of challenge infection. The 
parasite challenge dose administered at week 5 had previously been infective to all naïve 
animals tested, producing patent infection within 7 days of inoculation ([11] and unpublished 
data). A parasitaemia of over 5% was radically drug cured because above this level, a 
fulminating infection normally develops in the monkeys.  
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 As can be seen in Table 1 and Fig. 4A, three of the five control animals developed a 
fulminating parasitemia requiring treatment.  Unexpectedly, two of the five control animals 
controled the parasitemia to undetectable levels (C149) or to low chronic levels (C143). This 
could be the result of extended exposure to the control in vitro adapted parasites during the 
vaccination phase of the study.  By contrast, four of the four vaccinated animals had a 
significant delay in the onset of parasite development of 4 days (P<0.001). One animal 
(C017) had a peak parasitaemia at day 11, and subsequently controlled the parasitaemia.  All 
other experimental animals required drug treatment but at time points significantly later than 
the controls. Pooled cumulative parasitaemia graphs for challenge infection (Fig. 4B) further 
demonstrate the difference between the two groups. 
 Host responses during challenge infection. Analysis was performed on blood samples 
collected from all monkeys prior to challenge infection, and on a weekly basis thereafter. 
Haematological values remained comparable in both experimental and control groups. 
Clinical chemistry values for liver  and kidney functions were increased in monkeys with 
acute infection (data not shown). Cellular immune responses as determined by FACS analysis 
of peripheral blood changes in T cells, B cells and monocytes were similar in experimental 
animals compared to the controls (data not shown). 
 
 
 
 
 
 
Figure 3. Average percentage of γ δT cells during the vaccination phase. Dark line graphs 
represent percentage of cells in monkeys inoculated with parasites transfected with control plasmids 
and grey lines in monkeys infected with IFN- γ expressing parasites. Procedure for cell staining and 
FACS analysis is described in Materials and Methods. Error bars are standard deviations 
 
 
Sampling day
0
6
12
18
24
0 7 14 21
Vaccinated
Control
%
 C
D
3+
 g
am
m
a 
de
lta
 
Chapter 6 
84 
 At one week post-challenge, in vitro PBMC proliferative responses to crude P. knowlesi H 
strain antigen were generally higher in vaccinated monkeys than in controls (Table 2). The 
proliferation indices were significant for three out of four vaccinated monkeys and for one 
out of four measured control monkeys. However, these responses had partially waned at the 
end of the experiment following development of acute parasitaemia (Fig. 4A and Table 2). 
Serum IgG levels were comparable between the two groups throughout, suggesting that 
vaccination had not primed for enhanced antibody responses. 
 
Table 2. Stimulation of rhesus monkey PBMC with P. knowlesi total parasite antigen 
 
Group Pre-challengeϑ 
(Day 0) 
Challenge 
(Day 7) 
End Pont challenge 
(Day 14) 
Vaccinated       
C019   1.18+  5.36‡  2.13 
C097  1.25  2.53  1.23 
C117 
C017 
 1.35 
1.10 
 8.49 
0.70 
 2.01 
2.60 
Control       
C143  1.29  1.5  1.62 
C149  0.79  3.76  5.37 
C151 
C096 
C039 
 1.40 
0.90 
0.50 
 1.47 
ND 
0.9 
 1.42 
1.20 
1.20 
 
ϑ Pre-challenge day was 35 days post-vaccination. Samples were obtained immediately prior to 
inoculation of challenge parasites. 
+ Values are stimulation indices, calculated as readings from stimulated samples divided 
by background level values. ND = not done 
‡ Boldface figures are samples scored as having proliferated upon stimulation 
 
 
 
DISCUSSION 
 These preliminary experiments were designed to establish the safety of the genetically 
modified parasites and to assess whether there was any indication that exposure to parasites 
expressing IFN-γ would modulate the immune response and modify the course of subsequent 
infections.  We have previously shown that malaria parasites are able to express host cytokine 
genes, and because of the ease of manipulation and the ready availability of suitable assays, 
IFN-γ was selected as the first cytokine with which to show proof of principle. 
 We demonstrate that IFN-γ expressing P. knowlesi is well tolerated in rhesus monkeys. 
The in vitro adapted parasites induced as expected [12] a low level self-regulating infection 
that did not disturb important kidney and liver functions and did not induce significant 
changes in body temperature, weight and appetite during the course of vaccination. IFN-γ  
expressing P. knowlesi parasites induced an increase in γδT cells, and evoked responses 
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Figure 4. Individual monkey (A) and cumulative (B) parasitaemia profile in vaccinated and 
control monkeys during the challenge phase. 
 
 
 (presumably immune) that caused a delay in the development of infection in four out of four 
rhesus monkeys challenged with bloodstage parasites. Two out of five control monkeys also 
managed to control parasitemia, possibly caused by extended exposure to control in vitro 
adapted parasites during the vaccination phase. These data suggest that parasite-produced 
IFN-γ possibly enhanced anti-P. knowlesi immune responses evoked by exposure to in vitro 
adapted parasites. 
 The main measurable difference in immune response between the experimental and 
control animals during vaccination was at the cellular level.  Expansion of γδT cells during 
the vaccination period was significantly greater in the experimental group.  This may simply 
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be due to the higher parasite load experienced in the experimental group (Fig 2B). However, 
there were no differences in the expansion of γδT cells during asexual blood stage challenge, 
despite the control animals having been exposed to a much higher parasite load between 8 
and 12 days post challenge infection. It seems therefore more likely that the increase in γδT 
cells observed during the vaccination phase was largely due to IFN-γ release by P. knowlesi. 
Gamma delta T cells are known to proliferate and expand early during malaria infection [29, 
30] and can secrete IFN-γ within a day of exposure to parasitised erythrocytes in vitro [31, 
32]. Parasite produced IFN-γ is likely to have stimulated the γδT cells to proliferate and to 
release IFN-γ, leading to a positive feedback in IFN-γ production.  
The role of γδT cells in malaria infection is not yet clear.  Some studies have suggested 
that an increase in γδT cells could lead to an increase in parasitaemia (reviewed in [33]). 
Other studies have shown that γδT cells may also protect against malaria infection [34, 35]. It 
is tempting to attribute the observed increase in parasitaemia during vaccination with IFN-γ 
producing parasites to the effect of γδ T cells.  However, there are no sufficient sampling data 
points to confirm this. In addition, care should be taken when interpreting the data because 
the findings are a single observation using only four animals. 
 Total proliferative cellular responses were generally higher in vaccinated animals than in 
controls. Total antibody responses were similar in both groups during vaccination and after 
challenge.  The delay in parasitaemia observed after challenge in vaccinated animals may 
therefore have been mediated by cellular responses. This is surprising because protection 
against malaria blood stage infection is generally thought to be mediated by antibody 
dependent mechanisms [36]. Recent studies have, however, demonstrated that cell mediated 
mechanisms can mediate protection independent of antibody [37], especially at low parasite 
densities. A combination of exposure to low parasite density along with IFN-γ production 
may have stimulated a cellular response that is indeed able to control parasite development, 
albeit only for a short period. 
 Proliferative responses in experimental monkeys partially waned in the second week of 
challenge infection at the same time as high levels of parasitaemia emerged. The reasons for 
this are not clear, but may be related to the fact that excessive antigenic stimulation decreases 
T cell function and survival [38]. Malaria infected erythrocytes have also been reported to 
inhibit protective T cell responses [39, 40].  
 A more comprehensive analysis of host responses to IFN-γ expressing P. knowlesi and 
protection after challenge is now warranted. Nevertheless, this study has already 
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demonstrated that the parasites are well tolerated in vivo and that the IFN-γ produced by the 
parasites is bioactive in vivo. It is noteworthy that IFN-γ expressing P. knowlesi can mediate 
partial protection (a significant delay in peak parasitaemia) against challenge infection and 
this after only one vaccination episode. Studies in humans and animal models have shown 
that IFN-γ is intimately involved in protection during liver stage development of malaria 
parasites [41-43].  As far as we are aware, this is the first study to suggest that it may play an 
important role in the emergence of immune responses that control the development of asexual 
blood stage parasites.    
 Protection against asexual blood stage infection in monkeys can be induced by repeated 
exposure to parasites [13], a situation that is similar to the emergence of protection in human 
populations (reviewed in [44]). Our study suggests that by genetic manipulation with host 
immune response modifying genes, malaria parasites may be able to induce such protective 
responses in an accelerated manner. Nevertheless, although IFN-γ expressing parasites were 
immunopotentiated, they did not provide complete protection against challenge infection in 
rhesus monkeys, suggesting either that the expression of IFN-γ alone is insufficient to 
generate fully immunopotentiated parasites, or that multiple exposures to IFN-γ expressing 
parasites will be required to induce complete protection.  
 A vaccine for malaria is urgently required.  A variety of approaches based on presentation 
of one or a few selected  parasite components to the immune system are currently being 
developed.  While these approaches have great promise, there are concerns as to whether the 
immune response can be stimulated for a sufficiently long period of time and whether the 
polymorphism displayed by most of the parasite target antigens represents an insurmountable 
problem.  The induction of immune responses to whole parasites may have some advantage, 
in that responses to a broad range of host targets are induced, lessening the impact of 
polymorphism at any one locus. It is known that even individuals immune to the clinical 
effects of malaria lose this immunity after a relatively short period living outside the endemic 
area (and therefore no longer exposed to repeated sub-clinical boosting of immunity).   It may 
be possible, with judicious use of host immune modulator genes, to induce more long lived 
responses against the parasite. 
 This approach of immunopotentiation of parasites, when combined with strategies to 
attenuate parasites (such as genetically programmed decreases metabolic capabilities) may 
provide an attractive and cheap alternative to sub-unit vaccines.  Attenuated vaccines have 
been very successful against other diseases, and the possibility of such developments for 
malaria should not be ruled out. It will be important to continue this work and expand the 
Chapter 6 
88 
range of immune modulator genes being evaluated.  A further study is warranted to confirm 
these results, and to allow a deeper analysis of the immune responses evoked by vaccination 
with immunopotentiated malaria parasites. 
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ABSTRACT 
 Experimental systems that model some of the complex interactions between parasite and 
host can be extremely valuable in identifying and developing new prophylactics and 
therapeutics against human diseases. Because primates have similar immune systems to 
humans, we have characterised a baboon model for understanding host response to 
Plasmodium knowlesi. Ten intact olive baboons (Papio anubis) of either sex were 
experimentally infected with P. knowlesi H strain erythrocytic parasites. The infection in 
these baboons was either acute or chronic. Animals with acute infection developed multiple 
system organ dysfunction and cerebral involvement. In chronically infected animals, only the 
spleen was moderately enlarged. The P. knowlesi parasitaemia profile in baboons and rhesus 
monkeys was comparable. However, some clinical symptoms of the baboons and P. 
falciparum-infected humans were similar. These studies demonstrate for the first time that P. 
anubis is a suitable host for P. knowlesi for studying clinical symptoms and pathology. 
 
 
INTRODUCTION 
 The evaluation of new therapeutics and prophylactics for use in humans often requires 
testing in animal models that develop a disease comparable to that in humans. In certain basic 
and applied studies, primates are the only animal models susceptible to the human disease 
under study [1, 2]. Similarities in biologic mechanisms between humans and nonhuman 
primates underlie the value of nonhuman primates as the final system for evaluating the 
safety and efficacy of drugs and vaccines developed in studies with other laboratory animals 
and systems [3-5]. Nonhuman primates are widely used in malaria drug and vaccine 
development [5-7]. 
 The two major human malaria parasites (Plasmodium falciparum and P. vivax) have a 
very restricted host range,[8] which limits research on parasite biology especially at the host-
parasite interface. However, experimental systems have been used to model some of the 
complex interactions between parasite and host. There are three Plasmodium groups that are 
mainly used in experimental studies on host-parasite interactions, i.e., rodent, avian, and 
primate. Rodent malaria parasites are used to study parasite biology [9]. However, these 
parasites are phylogenetically distant from human Plasmodium [10] and do not easily allow 
investigations of natural host-parasite interactions. Although P. gallinaceum and P. lophurae, 
the most widely used avian malaria parasites are closely related to P. falciparum [11] their 
development in nucleated cells and the wide phylogenetic distance between birds and humans 
limits their applicability to study important questions on host-parasite interaction relevant to 
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human malarias. Simian Plasmodium such as P. knowlesi have a comparable phylogeny and 
host-parasite relationships to human malaria parasites [l0, 12]. The parasites are used to 
identify, develop, and evaluate vaccine and drug candidates [7, 13, 14] and to characterize 
host responses [15-17]. 
 Plasmodium knowlesi malaria infection has been described in Macaca fascicularis (natural 
host), as well as experimentally induced in a number of other nonhuman primates such as M. 
mulatta, M. radiata, M. assamensis, Presbytis entellus, Callithrix jacchus, Aotus trivigatus, 
Saimiri sciureus, and baboons [8, 12, 18, 22]. In baboons, the infection has been induced in 
Papio cynocepahalus, P. doguera, P. jubileaus, and P. papio [12]. The parasite also infects 
humans [12, 23] and clusters phylogenetically with P. vivax [24]. In most experimental 
models, P. knowlesi infection is acute, whereas in their natural host M. fascicularis, it 
generally induces a chronic infection [6, 12]. The availability of both natural and artificial 
hosts combined with the close relationship between primates and man make P. knowlesi 
infection in nonhuman primates attractive to study host-parasite interaction in detail. 
 We have recently developed protocols for long term in vitro culture and genetic 
modification of P. knowlesi [25, 26]. These are powerful tools for understanding parasite 
biology, especially gene function. This has been facilitated further by the recent sequencing 
of its genome (http://www.sanger.ac.uk/Projects/ Protozoa/) and that of P. falciparum [27]. 
The function(s) of attractive drug and vaccine candidates can be determined using 
homologous P. knowlesi genes. However, versatile in vivo systems are required to determine 
host-parasite interaction of the genetically modified parasites. The baboon is attractive 
because it is a well characterised and frequently used primate in biomedical research [4 ]. At 
the moment, the patterns and mechanisms of P. knowlesi infection in baboons are relatively 
unknown. 
 In this study, we determined the disease profile and pathology of the P. knowlesi H strain 
infection in the olive baboon as an experimental host system for understanding parasite 
biology of P. knowlesi, especially host-parasite interaction. 
 
 
MATERIALS AND METHODS 
 Parasites. Plasmodium knowlesi H strain [23] parasites for inducing baboon infection 
were retrieved from liquid nitrogen and cultured overnight. The original parasite inoculum 
was clone Pkl(A+),  previously cloned by micromanipulation and passaged in rhesus 
monkeys [28]. 
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 Animals. Adult Papio anubis (weight range = 11-21 kg) of either sex and originating from 
the Kajiado district of Kenya were used. Prior to the experiment, all animals were screened 
and determined to be free of infection with Plasmodium by a Giemsa-stained thick blood 
smear film. Ten baboons were inoculated intravenously with 1 x 104 to 1 x 106 P. knowlesi 
blood stage parasites. As controls for clinical symptoms, four uninfected animals were 
housed under similar conditions. All the animals were fed on a standard diet for baboons and 
water was provided ad libitum. The Institutional Animal Care and Use and the Scientific 
Review Committees of the Institute of Primate Research approved the baboon experiments. 
All experiments were performed in a biocontainment facility. 
For comparative purposes, historical data were collected from six rhesus monkeys that had 
been infected with 1 x 105 P. knowlesi H strain parasites of the same stock. These 
experiments were done at the Biomedical Primate Research Center after approval by the 
Institutional Animal Care and Use Committee (the DEC). 
 Animal observation and sampling. Baboon health was monitored on a daily basis. 
Animals were assessed for 1) general agility, 2) playing habit, and 3) appetite (by weighing 
leftover food). Agility and playing habits of the monkeys were assessed by an attendant 
familiar with normal behaviour of the particular animals. Animals were weighed on a weekly 
basis. Parasitaemia was determined microscopically on finger prick thin blood smears stained 
with Giemsa and plotted as the number of infected cells in 1 x 104 erythrocytes. 
 Clinical chemistry and haematology. Venous EDTA blood was obtained from infected 
baboons after sedation with ketamine. Blood was analysed in a Coulter counter (Beckman 
Coulter, Mijdrecht, The Netherlands) to determine haematocrit and haemoglobin changes. 
Serum was collected before and during peak infection, and used to analyse blood creatinine, 
bilirubin and urea. Commercial kits for Creatinine (Biotech Laboratories, Ipswich, United 
Kingdom), total bilirubin (Biotech Laboratories), and urea (Randox Laboratories, Antrim, 
United Kingdom) were used according to manufacture's instructions. 
 Pathology. After the duty veterinarian had certified baboons with severe malaria as 
lethargic or comatose, they were humanely killed and autopsies performed immediately. Two 
animals died unexpectedly and were immediately presented for necropsy. Animals with 
chronic infection were killed at four weeks post-infection. Gross organ and pathophysiologic 
derangements were observed during necropsy. Brain, liver, lung, kidney, spleen, and lymph 
node specimens were collected and immediately fixed in formalin. Sections of 5-µm 
thickness were prepared from paraffin-embedded specimens, stained in haematoxylin and 
eosin and analysed for pathologic changes. Erythrocyte aggregation in the brain was 
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quantified by examining 100 small blood vessels and expressed as percentages, as described 
by Pongponratn and others [29]. 
 
RESULTS 
 Parasitaemia. All baboons inoculated with P. knowlesi H strain developed patent 
parasitaemia by day five post-inoculation (Figure lA). Seven animals had acute parasitaemia 
that systematically increased to greater than 500 parasites per 1 x 104 erythrocytes, reaching 
as high as 4,950 parasites per 1 x 104 erythrocytes at the time of killing. All baboons with 
acute infection had become lethargic by day 12 post-infection (Table 1). The remaining three 
animals developed chronic parasitaemia (Table 1) with peak levels of less than 300 parasites 
per 1 x 104 erythrocytes by day 16, which thereafter decreased to less than 50 parasites per 1 
x 104 erythrocytes (Figure lA). At low parasitaemia, i.e., less than 300 parasites per 1 x 104 
erythrocytes schizont parasite stages were rarely observed in the peripheral circulation, 
suggesting sequestration. At higher parasitaemia, as observed in animals with severe malaria, 
the number of schizont stages in the peripheral circulation increased slightly, indicating 
reduced sequestration. The inoculum size and in vivo passage of parasites used to inoculate 
all the baboons did not determine the parasitaemia and disease profile (Table 1). 
 Historical data on patterns of parasitaemia were collected from rhesus monkeys previously 
infected with the same parasites as the baboons. All rhesus monkeys had developed patent 
parasitaemia by day six post-inoculation (Figure 1B). The parasitaemia profile in three of the 
monkeys (Rh2T, Rh 4086, and Rh9154) was characterised as chronic (Figure 1B), with peak 
parasitaemia less than 700 parasites per 1 x 104 erythrocytes and thereafter decreasing (Figure 
1B). The other three animals (Rh C029, Rh 3015, and Rh 3337) developed acute 
parasitaemia, i.e., levels greater than 700 parasites per 1 x 104 erythrocytes (Figure 1B). 
  Clinical symptoms. Onset of patent parasitaemia was followed by loss of appetite in all 
animals as measured by decreased food intake (Figure 2A) and marginal weight losses. 
Baboons with acute parasitaemia developed severe clinical symptoms and were characterised 
as having severe malaria. These symptoms included a significant increase in body 
temperature as the infection progressed (Figure 2C) and remaining in a sitting position in the 
cage (apathy) with raised fur. In addition, they progressively became lethargic, developed 
dyspnoea, and produced dark coloured urine suggesting cholestasis. There was reduced 
ocular tension and skin turgor indicating dehydration. Haematocrit and haemoglobin levels 
showed moderate to low decreases (Figures 2B and 2D). 
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Figure 1. Parasitaemia profile of A. baboons and B. rhesus monkeys infected with Plasmodium 
knowlesi H strain. RBC - red blood cells. 
 
Analysis of serum for bilirubin, creatinine, and urea to determine liver and kidney functions 
showed that in animals with severe malaria, there was a four-fold increase in total bilirubin 
(Table 2) and an increase in creatinine and blood urea, suggestive of severe haemolysis and 
dysfunctional kidneys (Table 2). By day 12 post-inoculation, all the baboons with severe 
malaria were either lethargic or comatose. Animals with chronic parasitaemia were classified 
as having mild malaria; they showed moderate to low level of the clinical symptoms observed 
in severely infected animals (Figure 2).  
  
Table 1. Parameters of baboons infected with the Plasmodium knowlesi H strain 
 
Baboon  Infection profile Inoculum passage in 
number Inoculum Profile Day post-infection* baboons** 
Pan 1996 2 x 105 Acute 12 1 
Pan 2525 2 x 105 Acute 10 1 
Pan 2531 1 x 106 Acute 12 1 
Pan 2497 1 x 106 Chronic 16 1 
Pan 2048 1 x 106 Acute 12 2 
Pan 2055 2 x 104 Chronic 16 3 
Pan 2509 1 x 104 Acute 11 4 
Pan 2635 1 x 104 Chronic 12 4 
Pan 2550 1 x 104 Acute 6 4 
Pan 2451 1 x 104 Acute 6 4 
 
*Day post-infection when the animal profile was scored as acute or chronic. 
**Parasite inoculum for the first passage was derived from rhesus monkeys and used to infect 
baboons after overnight in vitro culture. 
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However, they had a significant decrease in haematocrit and haemoglobin at peak 
parasitaemia (Figure 2). There was a marginal increase in total bilirubin, creatinine and blood 
urea (Table 2). After day 16 post-inoculation, the behaviour of these monkeys was similar to 
the uninfected and healthy control group. 
 
Table 2. Analysis of liver and kidney functions in baboons experimentally infected with 
Plasmodium knowlesi H strain* 
 
Group Creatinine (mg/dl) Total bilirubin (mg/dl) Blood urea (mg/dl) 
 Pre-infected Infected Pre-infected Infected Pre-infected         Infected 
Chronic (n=2) 1.66±0.19 2.80±0.36 0.78±0.16 1.07±0.20 30.25±7.35       45.53±8.61 
Acute (n=7) 1.86±0.27 4,05±1.25 0.58±0.15 2.35±0.40 34.29±13.07     120.0±38.37 
 
Samples from infected animals were collected at peak infection. Values are the mean ± SD. 
 
Gross pathology. At necropsy, baboons with severe malaria were remarkably similar in the 
quality of gross appearance, varying only in the degree of manifestation of pathologic 
changes. As a general feature, all tissues, particularly the mesentery, were of yellow-tan 
appearance. Intramural vascular deposition of malaria pigment was a widespread finding. 
These animals presented with severe acute haemolytic anaemia, severe diffuse pre-hepatic 
jaundice, hydropericardium, hydroperitoneum and hydrothorax. 
Baboons with mild malaria had no comparable alterations indicating severe acute 
haemolytic crisis. However, mucous membranes were pale with yellowish tinge but not 
extended to the mesentery.  
In all infected baboons, the spleen was highly friable, hemorrhagic, and pronouncedly 
enlarged with cut surfaces bulging out. Lungs from animals with severe malaria were 
distended with patchy consolidations and oedematous. In animals with mild malaria, lungs 
had patchy consolidation and diffuse hyperaemia. The liver of animals with severe malaria 
was enlarged, firm, and hyperaemic. The lobes were distinct with rounded edges and the gall 
bladder was distended. Animals with mild malaria had a slightly enlarged liver with whitish 
streaks. Kidneys showed diffuse hyperaemia and adherence of capsule in animals with severe 
malaria while kidneys of animals with mild malaria were without alterations. The brain of 
animals with severe malaria was oedematous, congested on the external surfaces, and blood 
vessels were prominent. No pathologic changes were observed in the brain of animals with 
mild infection. 
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Figure 2. Changes in A, appetite, B, haemoglobin, C, body temperature, and D, haematocrit in 
Plasmodium knowlesi-infected olive baboons with severe () and less severe (QQ) 
clinical symptoms. before = before infection; after = during peak infection. 
 
 
Histopathology. Histopathology showed that in animals with severe malaria, as expected 
from the high peripheral parasitaemia, blood vessels of all diameters down to the capillaries 
of all tissues studied were interspersed with parasitised erythrocytes. 
The brains of animals with severe malaria showed pronounced oedema, multifocal neuronal 
degenerations, and mild gliosis (Figures 3A and C), in addition to widespread intravascular 
schizont-infected erythrocytes in microvessels (Figure 3C). More than 70% of brain 
microvessels of these animals were filled with aggregates of infected and non-infected 
erythrocytes which might represent sequestration (Table 3). Infiltrations of lymphocytes and 
phagocytic cells between endothelial cells of brain blood vessels, as observed in murine 
cerebral malaria [30] were not encountered in baboons. The brain of baboons with mild 
malaria was normal (Figure 3B).  
In baboons with severe malaria, alveolar septa were increased in diameter due to multifocal 
to diffuse mononuclear cell infiltration, segmental neutrophil infiltration and interstitial 
oedema (Figure 4A). Pigment laden desquamated alveolar macrophages were commonly 
observed. In addition, multifocal neutrophilic granulocytes were found within alveolar 
lumina. Animals with mild infection showed low congestion of the lung. 
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The liver of animals with severe malaria showed cloudy to hydropic swelling of 
hepatocytes (Figure 4B), centrilobular dissociation, and necrosis of hepatocytes. Spaces of 
Disse were increased in diameter. Presence of hypertrophy pigment laden kupffer cells and 
pigment laden sinus lining endothelial cells was a common feature in animals with severe 
malaria but less pronounced in animals mild malaria. 
Kidneys from animals with severe malaria were characterised by multifocal interstitial 
nephritis with infiltration of mononuclear cells (Figure 4C). Glomeruli often showed 
segmental or diffuse increase in volume of mesangial matrix. Atrophic glomeruli were an 
occasional finding. No lesions were observed in animals with mild malaria. In all baboons, 
spleens were characterised by the presence of reactive germinal centres with mantle zones 
and showed pronounced pigment depositions. Compared with animals with mild malaria, 
thickening of lienal capsules and trabeculae appeared more pronounced in animals with 
severe malaria. 
 
Table 3. Erythrocyte aggregation in blood microvessels of Plasmodium knowlesi-infected 
baboon brain 
   
Animal PAN 1996 PAN 2525 PAN 2497 
Parasitaemia profile Acute Acute Chronic 
Peripheral parasitaemia* 4,950 1,710 20 
Blood microvessels containing**    
Parasitised erythrocytes 86 87 1 
Aggregated erythrocytes 80 70 2 
 
 *Peripheral parasitaemia was determined as the animal was presented for necropsy. Values 
are the number of parasitised erythrocytes in 1 x 104 peripheral circulation erythrocytes. 
 **For each baboon, 100 blood micro vessels in the brain were randomly evaluated. Values 
are percentages of brain micro vessels. 
 
 
 
DISCUSSION 
 
 In this report, the clinical spectrum and pathology of experimental P. knowlesi infection in 
P. anubis is presented for the first time. The disease profile was either severe or mild. 
Baboons with severe malaria developed multiple system organ dysfunction with cerebral 
involvement. 
 In baboons with severe P. knowlesi infection, the brain showed considerable pathology 
including congestion, oedema, neuronal degeneration, prominence of blood vessels, mild 
gliosis and aggregation of infected and uninfected erythrocytes in cerebral microvessels. 
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 Figure 3. A, Overview of the brain of a Plasmodium
knowlesi-infected olive baboon with severe malaria
showing cerebral oedema, micro-vacuolisation
around nuclei (black arrows), and vacuolisation
around blood vessels (white arrows) (magnification
x 200). B, Overview of the brain of P. knowlesi-
infected olive baboon with mild malaria. Black
arrows = micro-vacuolisation around nuclei: white
arrows = vacuolisation around blood vessels
(magnification x 200). C. Parasitised (black arrows)
and non-parasitised erythrocytes in a blood
microvessel from the brain of P. knowlesi infected
olive baboon with severe malaria (magnification x
600). (Haematoxylin and eosin stained.) 
 
 
Figure 4. A, Lungs of a Plasmodium knowlesi-
infected olive baboon with severe malaria showing
increased cellular infiltration resulting in thickened
width of alveolar septa. B, Liver of a P. knowlesi-
infected baboon with severe malaria showing
hydropic swelling of hepatocytes, widespread
pigment deposition (dark spots) and oedema of the
space of Disse. C. Kidney of P. knowlesi-infected
baboon with severe malaria showing multifocal
interstitial nephritis with infiltration of mononuclear
cells. (Haematoxylin and eosin stained,
magnification x 400) 
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The presence of aggregated erythrocytes in the brain of baboons with severe malaria suggests 
blockade of cerebral capillaries, which is associated with cerebral malaria in humans [31, 32]. 
 Cerebral malaria is a serious neurologic condition that can lead to coma and death. It is 
defined as an altered consciousness in a patient who has malaria parasites in the blood and in 
whom no other cause of altered consciousness can be found [33]. Blockade of brain blood 
microvessels in P. falciparum-infected humans and P. coatneyi- or P. fragile-infected 
macaques is mediated through sequestration of knob-forming, mature, parasite-infected 
erythrocytes [31, 32, 34, 35]. Although knob-formation has not been defined in P. knowlesi 
[36, 37] sequestration of P. knowlesi infected erythrocytes might be mediated by schizont-
infected cell agglutination variant antigens [38-40]. Further studies to elucidate cerebral 
phenomena in the brain of P. knowlesi infected baboons are required. 
 In the brain microvessels of baboons with severe malaria, many parasitised erythrocytes 
were present, but no lymphocytes and phagocytic cells were observed in contact with 
parasite-infected erythrocytes. This is similar to human cerebral malaria [29, 31, 32]. In 
contrast, numerous phagocytic cells are encountered in brain microvessels of rhesus monkeys 
infected with P. knowlesi and in rodent cerebral malaria [30, 36]. Together, our data suggest 
that the cerebral involvement in P. knowlesi-infected baboons resembles several aspects of 
human cerebral malaria. 
 Papio anubis developed either severe malaria or controlled the parasitaemia, resulting in a 
mild infection. This is also seen in rhesus monkeys [36, 37, 41-44]. The mechanisms that 
predispose P. knowlesi-infected monkeys to developing either severe or mild infection are 
unknown. In general, P. knowlesi produces a chronic self-regulating infection in the natural 
host M. fascicularis. However, Schmidt and others [45] showed that the course of P. knowlesi 
infection can differ in M. fascicularis from different geographic origins. In our study, animals 
originated from the same area, excluding monkey origin as a factor involved in the different 
infection outcomes. Our study also shows that inoculum size, age, and sex were not 
indicative of infection outcome. In humans, basal cytokine levels at the time of infection and 
host genetic factors are most likely involved in determining P. falciparum infection outcome 
[46, 47]. The precise mechanism that predisposes a dual outcome during malaria warrants 
further investigation and P. knowlesi-infected baboons might be helpful in this. 
 Our report shows that P. anubis is fully susceptible to experimental P. knowlesi H strain 
infection since all infected animals developed patent parasitaemia. The parasitaemia profile 
observed in the baboons was comparable to those in rhesus monkeys following infection with 
the same parasites [26] indicating that the virulence of this strain is similar in both monkeys, 
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although studies were not done in parallel. In contrast to rhesus monkeys, P. knowlesi-
infected baboons develop clinical symptoms at onset of patent parasitaemia. Plasmodium 
knowlesi-infected rhesus monkeys frequently show minor clinical symptoms until they 
suddenly collapse due to massive parasitaemia [6, 12, 37, 4l-43] (Langermans JAM and 
others, unpublished data). One possible explanation is that rhesus monkeys are relatively 
resistant to endotoxin-like characteristics mediated by malaria parasites [6, 48, 49]. Humans 
infected with P. falciparum also frequently develop clinical symptoms at onset of 
parasitaemia [8, 33, 46]. 
 Papio anubis was successfully infected with an inoculum size of 1 x 104 P. knowlesi 
parasites. This suggests that the infection can be initiated by mosquito bite since a single 
hepatocyte infected with Plasmodium could contain 1 x 104 merozoites. Sporozoite induced 
infection is necessary if the olive baboon is to be used to study P. knowlesi liver stage 
analyses. Moreover, we observed that P. knowlesi continued to produce gametocytes after 
four passages in baboons. The viability of the gametocytes has not yet been characterised. 
 Infection of olive baboons with P. knowlesi provides an additional malaria model that 
allows for in vivo analysis of mechanisms of host response during severe and mild malaria. 
The use of baboons to study P. knowlesi will specifically find relevance in facilities that are 
not home to other hosts of P. knowlesi. These include baboon source countries and primate 
research facilities with access to baboons. Baboons can also be used to analyse host-parasite 
interaction of transfected P. knowlesi (Ozwara H and others, unpublished data), which is an 
important tool for converting genome sequence information to medical use. Overall, our 
findings show that P. anubis infected with P. knowlesi show various clinical characteristics 
that are also seen in human malaria including cerebral involvement. 
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General discussion 
 Transfection technology for blood stage malaria parasites offers new tools for direct 
correlation of genotype to phenotype, thus enhancing further understanding of parasite 
biology. Most of the existing malaria transfection systems rely upon artificial host-parasite 
combinations with limited capacity for investigating natural host-parasite interaction. 
Because both natural and experimental hosts for P. knowlesi are available, van der Wel and 
co-workers [1] developed an in vivo transfection system for the parasite (Fig. 1). The work 
described in this thesis was aimed at further development and application of the P. knowlesi 
transfection system. A long term in vitro culture protocol for P. knowlesi blood stages was 
developed to facilitate in vitro transfection and expand experimental possibilities of the 
system; an in vitro transfection protocol was developed; integration, transient and stable 
episomal transfection of the parasite was achieved; in vitro transfection technology was 
successfully applied to generate bioactive rhesus IFN-γ expressing P. knowlesi, a new 
approach to generating immunopotentiated malaria parasites and finally, reagents for 
characterising host responses and a new experimental host were identified, to facilitate in vivo 
phenotypic analysis of transfected parasites. These studies have shown that the P. knowlesi 
transfection system is unique in providing fast and simple in vitro genetic manipulations with 
the opportunity to perform in vivo studies in systems highly predictable of the human 
situation.  
 In section 1 of this chapter, the impact of long term in vitro culture on P. knowlesi 
research is discussed. The second section deliberates on the status of P. knowlesi transfection 
system and section 3 is devoted to technical aspects of the system. Sections 4 and 5 consider 
transgene expression in P. knowlesi and some perspectives on the studies reported in this 
thesis.  
 
1. Long term in vitro culture of P. knowlesi.  
 Continuous and mass in vitro culture of P. knowlesi is required to reduce the need for 
resourceful monkeys for simple propagation of parasites for transfection and analysis. In 
chapter 2, blood stage parasites of two P. knowlesi strains, nuri and H, were adapted to long 
term in vitro growth using a simplified protocol. This was done in standard closed-cap culture 
flasks, under gas conditions of 5% CO2, 5% O2 and 90% N2 and haematocrit of 2.5%. Culture 
medium was completely changed every other day and fresh erythrocytes were added at a 
minimum of once a week. These cultures were continuously maintained for over 18 months 
General discussion 
 107
without observable changes in parasite morphology and multiplication rates. Culture adapted 
parasites were originally maintained in medium with rhesus serum, but conditions were 
improved further to allow the use of human serum and 5% haematocrit. A 200 ml roller bottle 
culture yielded as high as 1×1010 parasites and a 50% parasitaemia was feasible. For the first 
time, cloning of P. knowlesi by limiting dilution was achieved in a 96 well plate. In vitro 
culture adapted parasites were regularly cryopreserved and retrieved for further culturing 
using a standard protocol [2].  
 The simplified long term in vitro culture system for P. knowlesi is in some aspects similar 
to the P. falciparum system [3] because (i) cloning by limiting dilution is feasible in a 96 well 
plate; (ii) parasite morphology and multiplication rates do not deteriorate after prolonged 
culturing; (iii) small scale culturing does not require specialised apparatus; (iv) adding fresh 
culture medium and erythrocytes depends on culture haematocrit, parasitaemia and volume; 
(v) cultures are readily expanded to provide enough material for transfection (chapter 2) and 
analysis; (vi) culture medium is supplemented with human serum. Previous protocols for long 
term in vitro culture of P. knowlesi blood stage parasites either achieved low parasitaemia in 
the range of 0.92% and 3.6% [4] or the parasites became morphologically abnormal [5]. 
Culturing was done using the petri-dish candle jar method [4] and a sophisticated semi-
automated tipping culture apparatus [5]. In addition, cloning by limiting dilution was not 
done. Compared to our procedure, these culturing conditions are insufficient for generating 
large amounts of parasites for analysis.  
 Long term in vitro cultured P. knowlesi parasites were transferred into rhesus monkeys in 
order to determine their in vivo characteristics. Normal parasitaemia profiles were regained 
after a single passage through an intact rhesus monkey (chapter 2). In addition, parasites from 
first to third passage in vivo retained in vitro growth characteristics upon re-introduction into 
culture, allowing the possibility of generating shuttle parasites for in vitro to in vivo work. 
These features offer an opportunity to analyse adaptations that the parasites may have 
undergone following adaptation to in vitro growth conditions. This is important because one 
of the potential risks in using parasites maintained in vitro is that they may change from the 
original isolate in both phenotype and genotype. It can be difficult to compensate for the 
possible impact of these changes on individual host-parasite interaction studies. Prolonged in 
vitro culturing of P. knowlesi might lead to alteration of sicavar genes [6] leading to loss of 
sequestration capacity and consequently to reduced virulence in intact monkeys [7].  
 Adaptation of P. knowlesi to long term in vitro culture greatly enhances the experimental 
possibilities of the system. Culture adapted parasites are readily transfected, drug selected and 
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cloned in vitro to provide a homogenous parasite population for molecular analysis (chapters 
2 and 3). This has obviated the need for monkeys as parasite donors and recipients of 
parasites for genetic modification (Fig. 1). Furthermore, in vivo cloning of parasites is 
ethically complex because a large number of monkeys would be required (Fig. 1). Finally, 
long term in vitro drug screening is now possible using culture adapted P. knowlesi unlike in 
the rodent parasite P. berghei where long term in vitro drug screening is not readily achieved 
[8]; this approach is currently used for characterising new selectable markers for the P. 
knowlesi transfection system [9]. 
 The current status of the P. knowlesi system shows that it is now feasible to culture 
parasites, use them for transfection and selection, clone the heterogeneously transfected 
parasites, determine the genotype of the resultant clone and characterise host-parasite 
interaction in monkeys. As further optimisation of the system takes place, it will be possible 
to infect mosquitoes (Anopheles dirus/An. stephensi) using cultured parasites and sporozoites 
used to infect hepatocyte cell cultures, which mature to yield invasive merozoites [10]. This 
requires generation of high gametocyte producing in vitro culture adapted parasite lines 
which is still ongoing. However, the entire life cycle of P. knowlesi can be maintained in 
principle in the laboratory without the need for primates (Fig. 2).  
 
2. Transfection of P. knowlesi.  
 Transfection technology was originally developed in P. knowlesi through stable episomal 
expression of selectable marker genes in a rhesus monkey [1]. Constructs for transfection of 
P. berghei and P. falciparum were transfected into P. knowlesi to express dihydrofolate 
reductase-thymidylate synthase (dhfr-ts) genes from Toxoplasma gondii and P. berghei. 
Studies described in this thesis (chapters 2-4) expanded the system by developing protocols 
for stable episomal, transient, and site-specific DNA targeting forms of transfection. 
 
2.1. Stable episomal transfection of P. knowlesi. 
 Stable episomal transfection (chapter 1) was achieved in P. knowlesi using P. berghei and 
P. falciparum transfection plasmids [1]. These plasmids were designed for expression of the 
T. gondii and P. berghei dhfr-ts selectable markers under control of dhfr-ts  and histidine rich 
proteins 2 and 3 (hrp2/hrp3) promoter regions from P. berghei and P. falciparum 
respectively [11, 12]. In chapter 3, plasmids for selection and expression of green fluorescent 
protein (GFP) were used to develop an in vitro stable episomal transfection protocol in P. 
knowlesi [8, 13]. In these experiments, GFP was expressed under control of the heterologous 
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pbama-1 and pbdhfr-ts UTRs. In order to maintain the plasmids in transfected parasites, drug 
pressure was continuously applied. These and earlier experiments [1] showed that plasmids 
for stable episomal transfection can be shuttled between P. knowlesi and other malaria 
parasites. Shuttle plasmids are suitable for comparing the biology of identical genetic 
components in different parasite/host backgrounds. Thus, the biology of genetic components 
from P. berghei and/or P. falciparum can be analysed in P. knowlesi. Because stable 
episomal transfection allows for long-term overexpression of genes [14], P. falciparum 
vaccine candidates can be overexpressed in P. knowlesi using shuttle plasmids and the 
vaccine potential of the candidates tested in monkeys. This would enhance the use of P. 
knowlesi as an adjunct system for testing vaccine candidates. 
 Recently (Beetsma A., unpublished), constructs were engineered for site-specific gene 
targeting of P. falciparumcsp in P. knowlesi under the control of P. knowlesi regulatory DNA 
sequences. The constructs were transfected in P. knowlesi as circular plasmids, and 
expression of the transgenes successfully characterised. Unlike in the P. falciparum 
transfection system [12], the circular plasmids did not integrate into the genome after 
prolonged culture under drug pressure. Therefore, based on analogy, the mechanisms for 
plasmid replication and segregation in P. knowlesi is similar to P. berghei [15], i.e., plasmids 
are maintained in monomeric form (chapter 3) and do not integrate into the genome. 
 
2.2. Transient transfection of P. knowlesi. 
 In chapter 3, transient transfection technology was developed for blood stages of P. 
knowlesi using episomes designed for the P. berghei system [16]. The technology was used to 
characterise heterologous promoter activity of the pbama-1 and pbef-1α  5' regulatory DNA 
sequences and to optimise transfection conditions for P. knowlesi. Using the promoters, 
expression of luciferase (an exogenous reporter) was achieved within 24h. This shows that it 
is now possible to ascertain rapidly expression of transgenes and activity of new heterologous 
regulatory DNA sequences in P. knowlesi. Although there are some differences in transient 
transfection methodologies between the various Plasmodium systems, the DNA constructs 
used have the same configuration (chapter 3; [14]).  
 Very little is known about how gene expression is developmentally controlled in malaria 
parasites. Transient transfection provides the opportunity to identify genetic elements that 
control gene expression in P. knowlesi, as was done for P. falciparum and P. chabaudi  [17, 
18].  
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FIGURE 1.  In vitro and in vivo transfection of P. knowlesi. In order to develop an in vivo
transfection protocol for P. knowlesi blood stages [1], cryopreserved parasites were retrieved and
used to infect a donor rhesus monkey. Blood was collected from the monkey when erythrocytes were
infected with mature schizonts. The schizonts were mixed with transfection DNA and electroporated.
The electroporated mixture was injected into a recipient monkey. Pyrimethamine was orally applied
to the monkey for selecting drug resistant (transfected) parasites. In vivo cloning of transfected
parasites would require an unacceptably high number of monkeys and was not persued.  In order to
develop an in vitro transfection protocol (the right half of the diagram), cryo-preserved blood stage
parasites were retrieved and adapted to long term in vitro culture as described in chapter 2. Mature
schizonts were harvested, mixed with transfection DNA and electroporated. These were transferred
into in vitro culture system for overnight culture. Pyrimethamine was added to the culture for
selection of drug resistant parasites. Where necessary, transfected parasites were cloned in a 96
well plate by limiting dilution to obtain parasites with the correct genotype. This enables further
analysis of selected clones in the monkey. ,, stages that were successfully done during in vivo
transfection.
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These studies showed that different regions of Plasmodium promoters were associated with 
controlling varying levels of expression, reminiscent of regulatory elements in other 
eukaryotes. Transient transfections can also be used to temporarily (over)express genes that 
are otherwise toxic to Plasmodium [14]. 
 
2.3. Site-specific DNA targeting in P. knowlesi. 
 Site-specific DNA targeting (gene targeting) relies on the homologous recombination 
between two copies of a sequence, one present in the genome (target DNA sequence) and the 
other in the incoming DNA (targeting construct) [19]. Gene targeting was originally achieved 
Viable 
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Figure 2. Complete primate free life cycle of P. knowlesi. In principle, the entire life cycle of P.
knowlesi can be maintained in the laboratory without the need for primates. It is now feasible to
culture, transfect and select drug resistant parasites in vitro. Once high gametocyte producing parasite
lines have been established, feeder systems can be used to infect mosquitoes (Anopheles dirus/An.
stephensi) with transfected parasites. Mature sporozoites would then be isolated and used to infect
hepatocyte cultures in vitro.  Exo-erythrocytic stages would develop in the hepatocytes, ultimately
yielding merozoites to continue the cycle. Apart from transfection, this system can also be used to
generate viable free merozoites for studying basic parasite cell biology mechanisms such as cell-cell
interactions.
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in P. knowlesi (chapter 2) using a replacement type of construct (see section 3 below). The 
construct comprised 1 kb of the 5’ and 3' homologous csp gene sequences disrupted by 
tgdhfr-ts selectable marker expression cassette, to allow for integration by double crossover 
mechanisms (chapter 2). In vitro transfection using the linearised construct generated CSP 
knockout parasites (chapter 2).  In these experiments and similar ones that followed (Table 
1), non homologous DNA recombination was not detected in P. knowlesi, suggesting that 
gene targeting in this parasite occurs only by homologous recombination (chapters 3 and 5). 
Evidently, non homologous recombination is uncommon in Plasmodium [14, 20]. 
 Recently, integration into the P. knowlesi genome was achieved by single crossover 
mechanisms, using an insertion type plasmid ([9]; section 3 below). The plasmid was 
restriction digested in the target sequence prior to transfection, similar to the P. berghei 
transfection system [14]. Gene targeting experiments in P. knowlesi show that the 
transfection construct and selection procedures are identical to the P. berghei system (chapter 
2;[14]). In P. falciparum both replacement and insertional constructs are transfected as 
circular plasmids [17, 21]. Furthermore, the procedure for integrating replacement constructs 
into P. falciparum requires both negative and positive selectable markers [21]. These studies 
show that the mechanisms for DNA integration into the P. knowlesi and P. berghei genomes 
are similar, but different from P. falciparum.  
 
3. Parameters for P. knowlesi transfection. 
 The application of a transfection procedure is significantly influenced by the type of 
transfection construct, the regulatory DNA sequences driving gene expression and the nature 
of selectable marker(s) used. New construct designs, regulatory DNA sequences and 
selectable markers are continuously being identified and incorporated into malaria 
transfection systems. The status of these parameters in the P. knowlesi transfection system is 
elaborated in this section. 
  
Transfection Constructs  
 Vectors for the transfection of P. knowlesi are based on a bacterial plasmid backbone for 
propagation in Escherichia coli. They are assembled in a cassette-like structure so that DNA 
sequences can be exchanged easily (chapters 3-5; [8]).   
 Different DNA constructs are used in genetically modifying P. knowlesi, depending on the 
type of transfection. Expression cassettes for transient transfection constructs (chapter 3), 
consist of the gene to be expressed flanked by 5' and 3' UTRs of Plasmodium origin. The 
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cassette is cloned into a high copy number plasmid for cloning in E. coli. Transient 
transfection constructs are electroporated into P. knowlesi as circular plasmids. The design of 
constructs for transient transfection is remarkably similar in all Plasmodium systems [14].  
 DNA constructs for stable episomal transfection of P. knowlesi contain a selection cassette 
and an adjacent expression cassette cloned either in a head to head or a head to tail 
orientation. The expression cassette contains the gene of interest. The genes in both cassettes 
are flanked by UTRs of Plasmodium origin (chapters 4, and 5; [1]). Circular constructs are 
used for stable episomal transfection of P. knowlesi (chapters 4-5; [1]), similar to other 
transfection systems [14, 22].  
 Replacement DNA constructs are based on vectors for selection and integration. They 
consist of homologous DNA targeting sequences disrupted by a selection cassette. In 
addition, an expression cassette can be cloned immediately downstream or upstream to the 
selection cassette. These constructs are designed for site-specific integration by double 
crossover mechanism (chapters 3 and 5). In P. knowlesi, the minimum size of homologous 
DNA target sequence used was 0.6 kb. The gene for TRAP was knocked out using 1 kb and 
0.6 kb 5’ and 3' homologous DNA target sequences respectively (Ozwara et al., 
unpublished). Current replacement constructs contain 1 kb of 5’ and 3’ of homologous DNA 
targeting sequences as the standard sizes for site-specific recombination in P. knowlesi. Prior 
to electroporation, replacement constructs are linearised at two sites to extract bacterial DNA 
sequences (chapters 2 and 5), similar to P. berghei [19]. However, in P. falciparum, circular 
constructs are used [21].  
 Insertional DNA constructs are used for site-specific integration of DNA into P. knowlesi 
by single crossover mechanism [9]. The constructs are similar to replacement constructs, 
except that they have a single internal site-specific homologous DNA segment for gene 
targeting [14]. The construct is linearised within the targeting sequence, prior to transfection 
[9]. The structure and processing of constructs for integrating DNA into P. knowlesi, P. 
berghei and P. yoelii by single cross-over mechanism are similar [9, 14, 22]). Thus far, the 
structure of P. knowlesi and P. berghei transfection constructs is identical. 
 
Selectable markers 
 Transfection was first achieved in P. knowlesi using constructs containing P. berghei and 
T. gondii dhfr-ts (tgdhfr-ts) selectable marker genes [1]. These experiments showed that when 
P. knowlesi parasites were co-transfected with both constructs, the tgdhfr-ts  construct was 
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preferentially selected in vivo [1]. Subsequently, tgdhfr-ts was used as the selectable marker 
in all stable transfection studies reported in this thesis (chapters 2 to 4). 
 Although the haploid genome of blood stage P. knowlesi parasites has enabled the use of a 
single selectable marker for stable transfection, additional selectable markers would be 
required for further genetic manipulation of the same parasite. This may be required to target 
more than one gene in the same parasite, and to complement knockout parasites. Long term 
in  vitro drug screening is now possible using culture adapted P. knowlesi, facilitating the 
screening of new selectable markers for the P. knowlesi system.  Consequently, development 
of new selectable markers for stable transfection of P. knowlesi is underway (Table 1). 
Already, a new marker based on dhfr-ts genes from human (hudhfr-ts [24], flanked by P. 
berghei regulatory DNA sequences  has been identified [9]. Other recently identified markers 
include basticidine S deaminase (bsd) from Aspergillus terreus, neomycin phosphotransferase 
II (neo) from transposon Tn 5, and viral thymidine kinase [9, 21, 24]. 
 
Regulatory DNA sequences 
 Regulatory DNA sequences for P. knowlesi transfection (Table 1) comprises the 5' region 
that provides both the promoter and the 5'  UTR and the 3' region containing the 3' UTR and 
the transcriptional stop signals. Initial transfection of P. knowlesi was achieved using 
regulatory DNA sequences from P. falciparum and P. berghei [1]. This study provided the 
first evidence of heterologous promoter (regulatory DNA sequence) activity in P. knowlesi. 
The use of heterologous regulatory DNA sequences offers advantages for site-specific gene 
targeting. Integration into the locus of the regulatory sequence might be reduced, and in the 
process improve gene targeting into the desired loci. In addition, using heterologous 
regulatory DNA sequences in transfection vectors facilitates generation of shuttle vectors for 
use across Plasmodium. 
 The experiments in chapter 3 showed that the pbef-1α 5' UTR can function in P. knowlesi. 
The ef-1α 5' UTR consistently yielded high luciferase activity, suggesting that it is suitable 
for driving over-expression of genes in P. knowlesi. Furthermore, the pbef-1α intergenic 
region has promoter activity in two directions [25], hence it can also be used to drive 
simultaneous expression of two genes, for instance the gene for the selectable marker, and the 
gene under study. This could have a significant improvement in the design of constructs for 
stable transfection of P. berghei and P. knowlesi, by reducing the size of the constructs. 
 The pbama-1, a stage specific promoter, was shown to work in the same way in P. 
knowlesi as in the homologous system (chapter 2). This indicated for the first time that the 
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activity of P. berghei regulatory DNA sequences in P. knowlesi is similar to the homologous 
system.  
4. Transgene expression in P. knowlesi. 
 Transgene expression is a means by which critical aspects of Plasmodium biology such as 
mechanisms underlying drug resistance [26] can be investigated. Stable and transient 
transfection protocols for P. knowlesi have provided the fundamental tools for transgene 
expression. The two procedures have been used to express four categories of transgenes in P. 
knowlesi (Table 1). These are IFN-γ (chapters 4 and 6), reporter molecules (chapter 3), 
selectable markers (chapters 2 to 4; [9]) and P. falciparum antigen (PFCSP) (A. Beetsma et 
al., unpublished). The categories will be elaborated below, except selectable markers, which 
were covered in section 3. 
 
Table 1. Parameters for transfection of P. knowlesi 
Parameter DNA sequences References 
5' UTRs pbdhfr-ts 
pbama-1 
pbef-1α 
pfhrp3 
pfhsp86 
pfcam 
tgdhfr 
[1] 
Chapter 3 
Chapter 3 
[1] 
[9] 
[9] 
[1] 
 
3'UTRs pbdhfr-ts 
pbs21 
pfhrp2 
tgdhfr 
[1] 
A. van der Wel et al., unpublished 
[1] 
[1] 
 
Positive selectable markers tgdhfr-ts 
neo 
bsd 
hudhfr-ts 
pbdhfr-ts 
 
[1] 
[9] 
[9] 
[9] 
[1] 
 
Negative selectable markers Thymidine kinase [9] 
Disrupted loci csp 
trap 
140 kD  
172 kD 
ssu 
Chapter 2 
H. Ozwara et al., unpublished 
Chapter 4 
A. van der Wel et al., unpublished 
[9]  
 
Transgene expression Rhesus IFN-γ 
Mouse IFN-γ 
PfAMA-1 
PfCSP 
Chapter 4 
H. Ozwara, unpublished 
A. van der Wel et al., unpublished 
A. Beetsma et al., unpublished 
 
Reporter gene expression GFP 
Luciferase 
Chapter 3 
Chapter 3 
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 Stable transfection procedures for P. knowlesi (chapter 2) enabled us to test expression of 
host cytokines in malaria parasites by generating rhesus IFN-γ-expressing parasites (chapters 
4 and 6). Immunoassays demonstrated that transfected P. knowlesi released bioactive rhesus 
IFN-γ. A similar strategy was also used to express mouse IFN-γ in P. berghei and P. knowlesi 
(H. Ozwara et al., unpublished). These experiments showed for the first time that malaria 
parasites have the capacity to process higher mammalian proteins correctly. This offers 
possibilities for investigating the expression of other host  immunomodulatory molecules in 
order to define those that sufficiently immunopotentiate malaria parasites.  
 In chapter 3, luciferase and GFP reporter molecules were expressed in P. knowlesi. 
Expression of reporters provides an effective means to study both gene expression and 
protein trafficking in tagging experiments [27, 28]. For instance, parasite molecules can be 
fused to GFP for elucidating trafficking pathways and their signals [8]. In addition, the ability 
to easily harvest GFP expressing parasites by fluorescence activated cell sorting as described 
for P. berghei [29] and P. yoelii [22] could be adapted to P. knowlesi for harvesting specific 
parasite stages for further analysis. 
 Transfection of malaria parasites provides a powerful tool for determining gene functions, 
thus enhancing understanding of parasite biology. Understanding the function of genes of 
malaria parasite vaccine candidate molecules will facilitate rational design of new vaccines. 
In recent experiments, A. Beetsma et al., (unpublished) successfully expressed P. falciparum 
CSP in P. knowlesi sporozoites. This indicates that P. knowlesi homologues of vaccine 
candidate molecules can be knocked out and complemented with molecules from clinically 
relevant Plasmodium species. Phenotypic analysis of the transgenic parasites would enhance 
the understanding of the function of the vaccine candidate molecule. Furthermore, in the P. 
knowlesi/primate system, host responses to the transgenic vaccine candidate molecule can be 
determined under natural-chronic and acute-experimental host-parasite interface (chapter 7), 
which enhances understanding of the vaccine potential of the molecule.  
 In chapter 3, the pbama-1 and pbef-1α heterologous promoters were identified to function 
in P. knowlesi. The pbef-1α promoter drives expression in all parasite blood stages except 
mature schizonts and the pbama-1 is only active in mature schizonts [25, 30]. This indicates 
that the two promoters combined can be used to express transgenes virtually in all blood 
stages of P. knowlesi. Therefore, in principle, genes of stage specific malaria vaccine 
candidates such as the AMA-1 can be episomally expressed under the pbef-1α promoter in all 
blood stages. If successful, this would over-express the vaccine candidate, possibly 
generating immunopotentiated  parasites. 
General discussion 
 117
5. Perspectives. 
 Studies reported in this thesis have significantly developed P. knowlesi as a versatile 
transfection system. In outlook, certain questions that are relevant to the  objectives of the 
thesis need to be studied. This section outlines some of the issues.  
 The advent of a simple long term in vitro culture system  for blood stages has expanded 
experimental possibilities of the system (chapter 2). However, three aspects of the culture 
system require further optimisation. Monkeys are still required as erythrocyte-donors for P. 
knowlesi culturing. Adaptation to culturing in human erythrocytes would be more ideal. 
Failure to achieve this, the parasites will only be maintained in facilities accessible to monkey 
erythrocytes. Secondly, conditions for inducing in vitro gametocyte production are still sub-
optimal because long term cultured parasites show a significant decline in gametocyte 
production. Gametocytes are required for transmission to mosquitoes.  In the presence of 
infectious gametocytes, sporozoites from mosquitoes fed on culture adapted parasites can be 
used to infect rhesus or human hepatocytes in vitro [31], thereby entirely completing the P. 
knowlesi cycle in the laboratory without the need for monkeys (Fig. 2). Finally, although it is 
possible to adapt P. knowlesi to culture in serum free medium (H. Ozwara, unpublished), the 
potential of this system has not been fully achieved. Using serum free medium would 
significantly reduce the cost of culturing P. knowlesi. 
 The transfection efficiency of the system is estimated at 1 in 106 (Ozwara et al., 
unpublished). Higher transfection efficiencies are required for developing a more robust 
transfection system. New mechanisms for delivering DNA into the parasites must be tested to 
identify those that enhance transfection efficiency. One possible approach involves the use of 
polyamidoamine dendrimers [32]. Using this procedure, the efficiency for transfecting P. 
falciparum  was estimated at 1 in 10. Conditions for intracellular transfection of P. knowlesi 
have also not been optimised. These transfection conditions would  deliver DNA into all 
blood developmental  stages thus improving transfection efficiency in P. knowlesi.  
 Although the genome of P. knowlesi has been sequenced [33], the sequence requires 
assembling and annotation. This would facilitate DNA microarray studies to identify 
molecules of interest for isolation of drug and vaccine candidate molecules. The current 
status of P. knowlesi transfection system requires more tools to facilitate identification of 
more genes of interest from the P. knowlesi genome. For example, random insertional 
mutagenesis system has not been developed for P. knowlesi transfection system. The 
technique can be used to tag the P. knowlesi genome. In this manner, the genes whose 
inactivation can be specifically selected for can be isolated and identified. Transposable 
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elements such as mariner from Drosophila [34] which shows a simple requirement for TA 
dinucleotide at its target site could be used in developing an insertional mutagenesis system 
for P. knowlesi.  
 In vivo studies (chapter 6)  show that although ‘vaccination’ with IFN-γ expressing P. 
knowlesi mediates a  delay in the onset of challenge P. knowlesi infection, it does not prevent 
development of a fulminant infection. Other studies [35, 36], showing that more than one 
cytokine is necessary for protection against malaria. It is necessary to screen for a 
combination of cytokines  that generate immunopotentiated malaria parasites in vivo. A 
combination of cytokines that enhance antigen presentation combined with those that 
generate TH1 responses is attractive because studies have shown that malaria infection 
modulates antigen presenting cell functions [37]. 
 
CONCLUSION 
 As a result of the studies described in this thesis, the P. knowlesi transfection system is 
now a more versatile resource for understanding parasite biology. The parasite is 
phylogenetically close to P. vivax and a number of protein homologues exist between the two 
parasites, allowing determination of function by analogy. Long term in vitro cultured 
parasites expand experimental possibilities for transfection and general understanding of 
parasite cell biology. In vitro and in vivo transfection  protocols minimise the use of monkeys 
for the simple process of generating parasites, while retaining the possibility of using either 
of the protocols as need arises. The natural chronic and experimental acute vertebrate hosts of 
P. knowlesi ensure that host responses to transfected parasites can be determined either to 
understand mechanisms of protection in a chronic host, or to determine the vaccine potential 
of a transfection approach in an acute host. Expression of host cytokines such as IFN-γ offers 
possibilities for using transfection as a tool for developing attenuated and immunopotentiated 
malaria vaccines. The genome of P. knowlesi has been sequenced, indicating that genes for 
all possible drug and vaccine candidates are accessible. Transfection should play a role in 
deciphering the function of these molecules and by analogy, similar molecules could be 
isolated from human malaria parasites and expressed in P. knowlesi using shuttle vectors. 
Subsequently, the drug and/or vaccine potential of selected candidates can be determined 
using in vitro and in vivo systems.  As a parasite of primates that also infects humans, P. 
knowlesi currently is the only malaria experimental and transfection system available to 
malaria researchers that combines the benefits of a simple long term in vitro culture system 
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and analysis of host-parasite interaction in natural and experimental host systems similar to 
human. 
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 Malaria is een ziekte die voornamelijk voorkomt bij mensen die leven in 
ontwikkelingslanden in de tropische en sub-tropische gebieden van de wereld. Malaria 
infecties worden in het algemeen behandeld met geneesmiddelen als chloroquine. De snelle 
verspreiding van chloroquine resistentie en het ontbreken van nieuw ontwikkelde goedkope 
anti-malaria medicijnen onderstreept de noodzaak voor een malaria vaccin. Vaccinatie is de 
meest kost effectieve manier om malaria te voorkomen, een ziekte die overwegend voorkomt 
in landen waar budgetten voor gezondheidsbewaking zeer minimaal zijn. Tot nu toe waren er 
slechts beperkte mogelijkheden tot het uitvoerig bestuderen van structuur/funktie relaties van 
malaria vaccin kandidaten om inzicht te krijgen in het funktioneren van kandidaat moleculen, 
een noodzaak voor een rationeel ontwerp van vaccins. Met de komst van transfectie 
technologieën voor malaria bloedstadium parasieten, zijn er betere methoden beschikbaar 
gekomen om de funktie van moleculen te bepalen, door parasieten te genereren die het eiwit 
van onderzoek niet tot expressie brengen, of die gewijzigde vormen van het eiwit tot 
expressie brengen, en het fenotype van deze parasieten te bestuderen. Bovendien is het 
mogelijk om immuno-modulerende eiwitten die reaktiviteit van het immuunsysteem 
bevorderen tot expressie te brengen. Het is dan ook misschien wel mogelijk om uiteindelijk 
geattenueerde parasieten te ontwikkelen die sterk beschermende afweerreakties induceren en 
als zodanig gebruikt kunnen worden als levend vaccin. Deze strategie is wellicht veel 
effectiever dan de subunit vaccin strategie die tot op heden wordt gevolgd. In de studies 
beschreven in dit proefschrift, zijn protocollen ontwikkeld voor het genereren van malaria 
parasieten die bepaalde eiwitten niet meer tot expressie brengen, die veranderde vormen van 
die eiwitten van andere origine tot expressie brengen, en wordt het fenotype van deze 
mutante parasieten bestudeerd.  
 
Hoofdstuk 1: Inleiding 
 Malaria transfectie is een robuust genetisch hulpmiddel voor onderzoek naar de funktie 
van genen. Transfectie systemen zijn ontwikkeld voor de knaagdier malaria parasieten P. 
berghei en P. yoelii, de humane malaria parasiet P. falciparum en de primaten malaria 
parasietsoorten P. cynomolgi en P. knowlesi. Transfectie systemen voor P. berghei en P. 
falciparum zijn verder ontwikkeld dan voor de andere malaria transfectie systemen. Het P. 
knowlesi/primaten model is echter het enige experimentele malaria systeem dat de 
mogelijkheid biedt tot het bestuderen van gastheer-parasiet interacties in de experimentele en 
natuurlijke gastheer. Om deze reden is verdere ontwikkeling van het P. knowlesi systeem 
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belangrijk. In de introductie van dit proefschrift wordt het malaria probleem beschreven, de 
verschillende modellen voor transfectie van malaria en het P. knowlesi malaria model.  
 
Hoofdstuk 2: In vitro en in vivo transfectie systeem voor P. knowlesi 
 Om de basis biologie van een parasiet en interactie tussen gastheer en parasiet te kunnen 
bestuderen is een combinatie van in vitro en in vivo studies van groot belang. In dit hoofdstuk 
wordt de ontwikkeling van langlopende in vitro kweeksystemen voor P. knowlesi beschreven. 
Bloedstadium parasieten werden aan kweek geadapteerd. In vitro geadapteerde parasieten 
konden weer gemakkelijk in vivo groeien en hadden na een enkele passage in een intacte 
resus aap wildtype karakteristieken terug verkregen. Protocollen voor in vitro transfectie en 
transfectie waarbij het ingebrachte DNA integreert in het genoom van de parasiet werden 
ontwikkeld gebruik makend van in vivo verkregen of in vitro geadapteerde P. knowlesi 
parasieten. P. knowlesi circumsporozoite eiwit (CSP) knockout parasieten werden 
gegenereerd door dubbel crossover mechanismen. In vitro getransfecteerde en gekloneerde 
CSP knockout parasieten werden binnen 18 dagen verkregen. Microscopische evaluatie van 
zich ontwikkelende oocysten in muskieten die CSP knockout parasieten hadden opgenomen 
bevestigden de afwezigheid van de vorming van sporozoiten, zoals eerder was geobserveerd 
in P. berghei knockout parasieten. Op dit moment is het P. knowlesi model het enige malaria 
systeem dat snelle en precieze dubbel crossover genetische manipulatie procedures 
combineert met complete in vitro en in vivo mogelijkheden. Dit biedt de mogelijkheid tot 
volledige analyse van P. knowlesi genotype-fenotype relaties en gastheer-parasiet interacties 
in een systeem dat nauw is verwant aan de mens.  
 
Hoofdstuk 3: Heterologe promoter activiteit en transiënte transfectie in P. knowlesi 
 De transiënte transfectie voor malaria parasieten biedt de mogelijkheid tot precieze en 
snelle bestudering van de controle van genexpressie, een aanpak die cruciaal is om te kunnen 
begrijpen hoe genexpressie plaatsvindt tijdens de ontwikkeling van Plasmodium parasieten. 
Het doel van de studie zoals beschreven in hoofdstuk 3 was om heterologe promoter aktiviteit 
te karakteriseren na transiënte en stabiele transfectie van de apen malaria parasiet P. 
knowlesi. Het gebruik van heterologe promoters voor de transfectie van Plasmodium heeft het 
voordeel dat tijdens integratie experimenten gerichte integratie van het construct in de locus 
van interesse vergemakkelijkt wordt. Expressie van luciferase en green fluorescent protein 
(GFP), reporter moleculen die hun nut bewezen hebben als markers voor genexpressie, werd 
ook getest in P. knowlesi. Expressie van luciferase werd bereikt in P. knowlesi door gebruik 
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te maken van de stadium specifieke promoter van P. berghei apical membrane antigen-1 
(pbama-1) en de constitutieve promoters van P. berghei elongation factor-1 alpha (pbef-1α) 
and P. berghei dihydrofolate reductase-thymidylate synthase (pbdhfr-ts). Het is van belang 
regulatie van genexpressie onder controle van heterologe promoter gebieden te analyseren 
om te bepalen of de regulatie door heterologe promoters op dezelfde manier plaatsvindt als 
expressie in het homologe systeem. Stabiele integratie experimenten waarbij GFP tot 
expressie werd gebracht lieten zien dat de pbama-1 promoter strikt stadium-specifieke 
regulatie van expressie in P. knowlesi behoudt, op dezelfde wijze als in het homologe 
systeem. Deze studie heeft bovendien de pbef-1α promoter geïdentificeerd als een sterke 
heterologe promoter die goed geschikt is voor integratie en over-expressie van transgenen in 
P. knowlesi bloedstadium parasieten. De hulpmiddelen hier beschreven zullen gebruikt 
worden om het P. knowlesi systeem verder te ontwikkelen om de voordelen verbonden aan 
dit veelzijdige transfectie systeem ten volle te kunnen benutten. 
  
Hoofdstuk 4: Getransfecteerde P. knowlesi parasieten produceren bio-actief gastheer 
IFN-γ 
 Het is aangetoond dat recombinant pathogene micro-organismen die gastheer cytokines als 
IFN-γ tot expressie brengen immuunresponsen kunnen moduleren. Deze immunomodulatie 
leidde tot een verhoogde mate van bescherming. De expressie van gastheer cytokines door 
malaria parasieten is echter nog niet bestudeerd. De ontwikkeling van transfectie technologie 
voor malaria parasieten biedt nu de mogelijkheid tot het tot expressie brengen van gastheer 
eiwitten zoals cytokines in Plasmodium. Indien het mogelijk blijkt gastheer cytokines tot 
expressie te brengen in malaria parasieten, zou dit de mogelijkheid bieden het vaccin 
potentieel van een immunomodulerende aanpak te onderzoeken door parasieten te maken die 
een versterkende werking hebben op het afweersysteem van de gastheer. In dit hoofdstuk 
wordt het recentelijk ontwikkelde transfectie protocol voor P. knowlesi toegepast om de 
mogelijkheden voor het tot expressie brengen van gastheer cytokines in malaria parasieten te 
onderzoeken. Langlopende, aan in vitro kweek aangepaste P. knowlesi bloedstadium 
parasieten werden getransfecteerd met DNA constructen voor het tot expressie brengen van 
resusaap (Macaca mulatta) IFN-γ onder controle van de pbama-1 promoter. De 
getransfecteerde parasieten bleken IFN-γ te produceren. In vitro analyse via inhibitie van het 
celdodend effect van virussen en activatie van M. mulatta perifere blood cellen liet zien dat 
het door de parasiet geproduceerde IFN-γ bio-actief was. Dit is de eerste keer dat aangetoond 
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is dat het mogelijk is om malaria parasieten te genereren die bio-actieve immunomodulerende 
gastheer cytokines tot expressie brengen. De expressie van gastheer cytokines door malaria 
parasieten, zoals in deze studie is aangetoond, biedt een nieuw perspectief om onderzoek te 
doen naar de mogelijkheid levend geattenueerde malaria vaccins te ontwikkelen die mogelijk 
een betere afweerreaktie teweeg brengen dan een natuurlijke infectie.  
 
Hoofdstuk 5: Humane monoklonale antilichamen kruisreaktief met primaten antigenen 
 P. knowlesi is een apen malaria parasiet. Omdat humane en primaten afweersystemen 
grotendeels vergelijkbaar zijn, reageert een aanzienlijk deel van monoklonale antilichamen, 
gericht tegen eiwitten van het humane immuunsysteem met gelijkwaardige primaten eiwitten. 
Er zijn echter slechts weinig van dergelijke monoklonale antilichamen gekarakteriseerd voor 
hun toepasbaarheid in studies naar het afweer systeem van diverse niet-humane primaten. 
Hoofdstuk 5 heeft als doel de lijst van antilichamen, beschikbaar voor de karkterisering van 
het immuunsysteem van de chimpanzee, de resusaap en het doodshoofdaapje, uit te breiden. 
In totaal 161 monoklonale antilichamen tegen humane T-cel antigenen en cytokine 
receptoren werden met behulp van FACS getest op perifere bloed mononucleaire cellen van 
de chimpanzee, de resusaap en het doodshoofdaapje. Deze primaten worden regelmatig 
gebruikt als experimentele gastheer van malaria. Onze studies identificeerden 105, 73 en 68 
nieuwe monoklonale antilichamen die kruisreageerden met de immuunsystemen van 
respectievelijk chimpanzee, de resusaap en het doodshoofdaapje. De monoklonale 
antilichamen tegen het systeem van de resusaap zijn een aanvulling op reeds beschikbare 
antilichamen voor het definiëren van gastheer responsen in de resusapen na infectie met P. 
knowlesi.  
Hoofdstuk 6: De respons van resusapen op expressie van IFN-γ door P. knowlesi 
 Het P. knowlesi transfectie systeem biedt de mogelijkheid tot analyse van gastheer-
parasiet interacties van getransfecteerde parasieten in niet-humane primaten. In hoofdstuk 6 
worden gastheer responsen tegen de in hoofdstuk 4 beschreven parasieten die IFN-γ tot 
expressie brengen gekarakteriseerd. Deze experimenten werden ontworpen om met metingen 
aan klinische en immuunsysteem parameters de veiligheid en efficacy van infecties met 
parasieten die cytokine tot expressie brengen in resusapen te bepalen. Bovendien kon de 
bioaktiviteit van door parasieten geproduceerd IFN-γ worden bepaald. Alle geïnfecteerde 
dieren ontwikkelden een milde parasitaemie waarvan de piek significant vroeger plaatsvond 
dan in de controle dieren. Analyse van de klinische chemie en haematologische data van deze 
apen lieten geen abnormaliteiten aan vitale orgaanfunkties zien. Dit suggereert dat de 
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hoeveelheid IFN-γ die door de parasiet werd uitgescheiden goed getolereerd werd en dat deze 
parasieten de veiligheid van de aap niet in gevaar hadden gebracht. Immunologische analyse 
liet een tweeëneenhalf tot vijfvoudige toename in γδT-cellen zien in dieren die waren 
geinfecteerd met P. knowlesi parasieten die IFN-γ tot expressie brachten in vergelijking met 
een één tot tweevoudige toename in de controle dieren, suggererend dat de IFN-γ die 
uitgescheiden werd door de parasieten bioaktief was in resusapen. Alle dieren werden 
genezen met medicijnen en twee weken later geïnfecteerd met virulente P. knowlesi 
bloedstadium parasieten. Na infectie was er een vijf tot zes dagen langere pre-patente periode 
in experimentele dieren in vergelijking met controle dieren. Dit suggereert dat P. knowlesi 
parasieten die IFN-γ tot expressie brachten resusapen gedeeltelijk beschermden tegen infectie 
met homologe parasieten. Bovendien was de in vitro proliferatie reaktiviteit van T-cellen één 
week na infectie significant groter in experimentele apen. Eén week later waren deze 
responsen echter significant verlaagd, een fenomeen dat samenviel met een toename in 
parasitaemie. Deze resultaten laten zien dat P. knowlesi parasieten die IFN-γ tot expressie 
brengen even veilig in resusapen zijn als wildtype parasieten en gedeeltelijk een wildtype 
infectie met behulp van het afweersysteem kunnen moduleren. Bovendien laten deze 
experimenten zien dat het wellicht mogelijk is om door op de juiste wijze malaria parasieten 
te genereren die cytokinen tot expressie brengen, het immuunsysteem op een effective manier 
tot reaktiviteit kan worden aangezet.  
 
 
 
Hoofdstuk 7: Het bavianenmodel voor experimentele P. knowlesi infectie 
 Het doel van dit hoofdstuk was om een bavianen (Papio anubis) model op te zetten voor 
de studie naar de reaktie van de gastheer op Plasmodium knowlesi. Omdat de baviaan één van 
de meest gebruikte primaten voor biomedisch onderzoek is, is dit dier aantrekkelijk als 
experimentele gastheer om gastheer-parasiet interacties van P. knowlesi te kunnen 
onderzoeken. Het gebruik van bavianen in landen waar bavianen van nature voorkomen en in 
faciliteiten zonder toegang tot andere P. knowlesi gastheren, zou de import van resusapen 
voor P. knowlesi onderzoek onnodig maken. Bovendien zijn reagentia voor analyse van het 
bavianen afweersysteem commercieel verkrijgbaar. Voor deze studie werden bavianen 
experimenteel geïnfecteerd met P. knowlesi bloedstadium parasieten. Alle dieren 
ontwikkelden of een ernstige dodelijke ziekte die gepaard ging met een bepaalde mate van 
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funktieverlies van diverse organen en cerebrale malaria, of een milde infectie die werd 
gekarakteriseerd door een laag niveau van parasieten en vergroting van de milt. Het patroon 
van parasitaemie dat werd gevonden was vergelijkbaar met dat van resusapen die uit dezelfde 
parasieten voorraad waren ingespoten. Enkele klinische symptomen in bavianen die waren 
geïnfecteerd met P. knowlesi waren echter vergelijkbaar met infecties van P. falciparum in 
mensen. Deze resultaten hebben voor de eerste keer laten zien dat P. anubis volledig gevoelig 
is voor experimentele infectie met P. knowlesi en een geschikt model vormt voor de studie 
naar gastheer responsen tegen de parasiet.  
Experimentele systemen die als model kunnen fungeren voor enige van de complexe 
interacties die plaatsvinden tussen malaria parasiet en de gastheer, zoals P. knowlesi in de 
baviaan, kunnen van groot belang zijn voor de identificatie en ontwikkeling van nieuwe 
profylactische geneesmiddelen en geneesmiddelen tegen de ziekte in de mens. Bovendien is 
de DNA-sequentie bepaald van het genoom van P. knowlesi, zodat genen voor alle mogelijke 
geneesmiddel en vaccin kandidaat moleculen toegankelijk zijn. Gebruik van transfectie 
technologie zal nuttig zijn voor het bepalen van de funktie van kandidaat moleculen. Ons 
doel is om bavianen als in vivo gastheren te gebruiken om de geschiktheid van geselekteerde 
kandidaten als geneesmiddel en/of vaccin te bepalen.  
 
Hoofdstuk 8: Algemene discussie 
 In dit hoofdstuk wordt de huidige staat van P. knowlesi transfectie besproken. Protocollen 
voor langdurige in vitro kweek werden ontwikkeld waardoor de mogelijkheden voor 
transfectie-experimenten vergroot worden. Met de ontwikkelde protocollen voor in vitro en in 
vivo transfectie is het mogelijk geworden om het gebruik van apen alleen maar om parsieten 
te genereren te minimaliseren. In vivo experimenten zijn nu alleen nog noodzakelijk in het 
kader van studies aan parasiet-gastheer interacties. De expressie van gastheer cytokinen zoals 
IFN-γ biedt nieuwe mogelijkheden voor de ontwikkeling van geattenueerde en 
immunoreactive malaria vaccins. De DNA-sequentie van het genoom van P. knowlesi is 
bepaald, zodat de genen voor alle mogelijke geneesmiddel en vaccin kandidaat moleculen 
bekend zijn. Transfectie kan nu een bijdrage leveren aan het ontrafelen van de funktie van 
deze moleculen. Zo kunnen bijvoorbeeld homologe moleculen worden geïsoleerd uit de 
humane malaria parasieten en tot expressie worden gebracht in P. knowlesi. Vervolgens kan 
het potentieel van de geselecteerde kandidaten als geneesmiddel of vaccin worden bepaald 
met behulp van in vitro en in vivo systemen. Als een primaten parasiet die ook mensen kan 
infecteren, is P. knowlesi momenteel het enige malaria transfectie systeem dat de voordelen 
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van een eenvoudig langdurig kweeksysteem combineert met de analyse van gastheer-parasiet 
interacties in natuurlijke en experimentele gastheer systemen die sterk lijken op die van de 
mens.  
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